{
  "questions": [
    {
      "body": "Which genes are known to be involved in Diamond-Blackfan anemia?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23812780", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23257444", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22706301", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22689679"
      ], 
      "type": "list", 
      "id": "550312b4e9bde6963400001c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 645, 
          "text": "Diamond-Blackfan anemia (DBA) is an inherited red blood cell aplasia that usually presents during the first year of life. The main features of the disease are normochromic and macrocytic anemia, reticulocytopenia, and nearly absent erythroid progenitors in the bone marrow. The patients also present with growth retardation and craniofacial, upper limb, heart and urinary system congenital malformations in ~30-50 % of cases. The disease has been associated with point mutations and large deletions in ten ribosomal protein (RP) genes RPS19, RPS24, RPS17, RPL35A, RPL5, RPL11, RPS7, RPS10, RPS26, and RPL26 and GATA1 in about 60-65 % of patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23812780", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 344, 
          "text": "This study was aimed to explore the mutations of ribosomal protein (RP) genes in patients with Diamond Blackfan anemia (DBA). Twenty-one cases of DBA admitted in our hospital from Dec 2008 to Aug 2012 were screened by PCR for mutations in the nine known genes associated with DBA: RPS19, RPS24, RPS17, RPL5, RPL11, RPS7, RPL35a, RPS10 and RPS26", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23257444", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 346, 
          "offsetInEndSection": 602, 
          "text": "The results found that 8 patients (38.1%) with DBA had mutations in the genes coding for ribosomal protein, in which RPS19 mutation was identified in 3 patients, RPS24, RPS7, RPL5, RPL11 and RPL35A mutations were identified respectively in 1 of the patient", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23257444", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 379, 
          "text": "Diamond-Blackfan anemia (DBA) is a hypoplastic anemia characterized by impaired production of red blood cells, with approximately half of all cases attributed to ribosomal protein gene mutations. We performed exome sequencing on two siblings who had no known pathogenic mutations for DBA and identified a mutation in the gene encoding the hematopoietic transcription factor GATA1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22706301", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 352, 
          "offsetInEndSection": 679, 
          "text": "As a proof of concept, we designed a multiplex ligation-dependent probe amplification assay targeted to screen the six genes that are most frequently mutated in Diamond-Blackfan anemia patients: RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35A. Using this assay we showed that deletions represent approximately 20% of all mutations", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22689679", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which gene is most commonly associated with severe congenital and cyclic neutropenia?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23463630", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20582973", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19415009", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19057199", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17761833"
      ], 
      "type": "factoid", 
      "id": "5503133ae9bde6963400001d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 151, 
          "text": "Neutrophil elastase gene (ELANE) mutations are responsible for the majority of cases of severe congenital neutropenia (CN) and cyclic neutropenia (CyN)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23463630", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 153, 
          "offsetInEndSection": 430, 
          "text": "We screened CN (n\u00a0=\u00a0395) or CyN (n\u00a0=\u00a092) patients for ELANE mutations and investigated the impact of mutations on mRNA expression, protein expression, and activity. We found 116 different mutations in 162 (41%) CN patients and 26 in 51 (55%) CyN patients, 69 of them were novel", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23463630", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Cyclic neutropenia and severe congenital neutropenia in patients with a shared ELANE mutation and paternal haplotype", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20582973", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 356, 
          "text": "Cyclic neutropenia (CN) and severe congenital neutropenia (SCN) are disorders of neutrophil production that differ markedly in disease severity. Mutations of the ELANE gene (the symbol recently replacing ELA2) are considered largely responsible for most cases of CN and SCN, but specific mutations are typically associated with one or the other", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20582973", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 531, 
          "offsetInEndSection": 624, 
          "text": "One patient with CN had the same S97L ELANE mutation as seven patients with the SCN phenotype", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20582973", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 202, 
          "text": "Three familial cases of each of severe congenital neutropenia (SCN) and cyclic neutropenia (CN) in addition to 3 sporadic cases of SCN were analyzed for neutrophil elastase (Ela2) gene mutation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19415009", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 658, 
          "offsetInEndSection": 836, 
          "text": "Three cases of familial SCN (P13L, R52P, and S97L), 2 of familial CN (W212stop and P110L), and 1 of sporadic SCN (V72M) were shown to have heterozygous mutations in the Ela2 gene", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19415009", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 469, 
          "offsetInEndSection": 689, 
          "text": "Recent studies have elucidated a role for the unfolded protein response in mediating the pathogenic effects of ELA2 mutations, the most common mutation in severe congenital neutropenia (SCN) as well as cyclic neutropenia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19057199", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 252, 
          "text": "Severe congenital neutropenia (SCN) is an inborn disorder of granulopoiesis. Mutations of the ELA2 gene encoding neutrophil elastase (NE) are responsible for most cases of SCN and cyclic neutropenia (CN), a related but milder disorder of granulopoiesis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17761833", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which treatment leads to an increase in neutrophil counts in severe congenital neutropenia?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16822461", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7529539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1705835", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1689595"
      ], 
      "type": "summary", 
      "id": "550313aae9bde6963400001f", 
      "snippets": [
        {
          "offsetInBeginSection": 173, 
          "offsetInEndSection": 441, 
          "text": "This chapter focuses on cyclic and congenital neutropenia, two very interesting and rare hematological conditions causing severe chronic neutropenia. Both disorders respond well to treatment with the myeloid growth factor, granulocyte colony-stimulating factor (G-CSF)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21052952", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1176, 
          "offsetInEndSection": 1474, 
          "text": "Data on more than 600 patients with CN collected by the Severe Chronic Neutropenia International Registry (SCNIR) demonstrate that, regardless of the particular CN subtype, more than 95% of these patients respond to recombinant human (rHu)G-CSF with ANCs that can be maintained above 1.0 x 10(9)/L.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16822461", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 153, 
          "text": "Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7529539", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 121, 
          "offsetInEndSection": 380, 
          "text": "In phase I/II/III studies in patients with severe congenital and cyclic neutropenia, treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) resulted in a rise in the absolute neutrophil counts (ANC) and a reduction in infections", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7529539", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 541, 
          "offsetInEndSection": 660, 
          "text": "A sustained ANC response was seen in 40/44 severe congenital neutropenia patients and 10/10 cyclic neutropenia patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7529539", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 200, 
          "offsetInEndSection": 433, 
          "text": "We examined peripheral blood mononuclear cells (PBMC) of SCN patients who demonstrated normalization of their blood neutrophil counts in a phase II clinical study with recombinant human granulocyte colony-stimulating factor (rhG-CSF)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1705835", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 166, 
          "text": "Severe congenital neutropenia (SCN) is a disorder of myelopoiesis characterized by severe neutropenia secondary to a maturational arrest at the level of promyelocytes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1689595", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 942, 
          "offsetInEndSection": 1170, 
          "text": "In contrast to rhGM-CSF treatment, all five patients responded to rhG-CSF during the first 6 weeks of treatment with an increase in the ANC to above 1,000/microL. The level of ANC could be maintained during maintenance treatment", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1689595", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the risk in G-CSF treatment for severe congenital neutropenia?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22371884", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21052952", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20456363", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15642668"
      ], 
      "type": "summary", 
      "id": "55031406e9bde69634000021", 
      "snippets": [
        {
          "offsetInBeginSection": 211, 
          "offsetInEndSection": 1301, 
          "text": "We obtained serial hematopoietic samples from an SCN patient who developed AML 17 years after the initiation of G-CSF treatment. Next- generation sequencing was performed to identify mutations during disease progression. In the AML phase, we found 12 acquired nonsynonymous mutations. Three of these, in CSF3R, LLGL2, and ZC3H18, co-occurred in a subpopulation of progenitor cells already in the early SCN phase. This population expanded over time, whereas clones harboring only CSF3R mutations disappeared from the BM. The other 9 mutations were only apparent in the AML cells and affected known AML-associated genes (RUNX1 and ASXL1) and chromatin remodelers (SUZ12 and EP300). In addition, a novel CSF3R mutation that conferred autonomous proliferation to myeloid progenitors was found. We conclude that progression from SCN to AML is a multistep process, with distinct mutations arising early during the SCN phase and others later in AML development. The sequential gain of 2 CSF3R mutations implicates abnormal G-CSF signaling as a driver of leukemic transformation in this case of SCN", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22371884", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 173, 
          "offsetInEndSection": 441, 
          "text": "This chapter focuses on cyclic and congenital neutropenia, two very interesting and rare hematological conditions causing severe chronic neutropenia. Both disorders respond well to treatment with the myeloid growth factor, granulocyte colony-stimulating factor (G-CSF)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21052952", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1688, 
          "offsetInEndSection": 1957, 
          "text": "Treatment with G-CSF is usually effective, but the dose of G-CSF required to normalize blood neutrophils varies greatly. Ten to thirty percent of severe congenital neutropenia patients evolve to develop acute myeloid leukemia, necessitating careful clinical monitoring.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21052952", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 248, 
          "text": "In severe congenital neutropenia (SCN), long-term therapy with granulocyte colony-stimulating factor (G-CSF) has reduced mortality from sepsis, revealing an underlying predisposition to myelodysplastic syndrome and acute myeloid leukaemia (MDS/AML)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20456363", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 145, 
          "offsetInEndSection": 332, 
          "text": "Granulocyte colony-stimulating factor (G-CSF) therapy has significantly reduced the frequency and severity of infections, but its possible influence on the risk of malignancy is not known", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15642668", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1054, 
          "offsetInEndSection": 1238, 
          "text": "No septic deaths occurred during G-CSF therapy. Thirteen cases of MDS/AL were recorded. The cumulative incidence of MDS/AL was 2.7% (SD 1.3%) at 10 years and 8.1% (SD 2.7%) at 20 years", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15642668", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1488, 
          "offsetInEndSection": 1706, 
          "text": "Owing to their particular susceptibility to infections, patients with severe congenital neutropenia had the strongest exposure to G-CSF; the risk of leukemia increased with the degree of G-CSF exposure in this subgroup", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15642668", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "How many different subtypes of thyroid cancer exist?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24163390", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21553140", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21272686", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17985985", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8608779"
      ], 
      "type": "list", 
      "id": "5503145ee9bde69634000022", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 458, 
          "text": "Thyroid cancer is the most common cancer of the endocrine system and is responsible for the majority of deaths from endocrine malignancies. Although a large proportion of thyroid cancers belong to well differentiated histologic subtypes, which in general show a good prognosis after surgery and radioiodine ablation, the treatment of radio-resistant papillary-type, of undifferentiated anaplastic, and of medullary-type thyroid cancers remains unsatisfactory", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163390", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 966, 
          "offsetInEndSection": 1090, 
          "text": "Supervised hierarchical cluster analysis demonstrated grouping of 2 histologies (papillary and follicular thyroid carcinoma)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21553140", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 747, 
          "offsetInEndSection": 1199, 
          "text": "FDG-PET/CT is also useful in the initial (post thyroidectomy) staging of high-risk patients with less differentiated (and thus less iodine-avid and clinically more aggressive) subtypes, such as tall cell variant and H\u00fcrthle cell carcinoma, but in particular poorly differentiated and anaplastic carcinoma. FDG-PET/CT may help in defining the extent of disease in some patients with medullary thyroid carcinoma and rising postoperative calcitonin levels", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21272686", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 268, 
          "offsetInEndSection": 399, 
          "text": "Histologic subtypes included papillary (41%), follicular (22%), anaplastic (19%), medullary (15%), and H\u00fcrthle cell carcinomas (4%)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17985985", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 80, 
          "text": "Follicular thyroid cancer is the second most common thyroid malignancy after PTC", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8608779", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which neuroendocrine tumors are associated with specific tumor syndromes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23010473", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22041710", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21181474", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19708762", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14685672"
      ], 
      "type": "list", 
      "id": "55031628e9bde69634000024", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 150, 
          "text": "Pheochromocytomas are neuroendocrine tumors of the adrenal medulla which can occur either sporadically or in the context of hereditary tumor syndromes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23010473", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 237, 
          "text": "Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare neuroendocrine tumors of the adrenal glands and the sympathetic and parasympathetic paraganglia. They can occur sporadically or as a part of different hereditary tumor syndromes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22041710", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 184, 
          "text": "Pancreatic neuroendocrine tumors (PNETs) are a characteristic feature of the tumor syndromes multiple endocrine neoplasia type 1 (MEN-1) and von Hippel-Lindau disease (VHL)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21181474", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1297, 
          "offsetInEndSection": 1804, 
          "text": "This review focuses on hereditary syndromes with neuroendocrine tumors, including multiple endocrine neoplasia types 1 and 2, Von Hippel-Lindau disease, neurofibromatosis type 1, Carney complex, pheochromocytoma-paraganglioma syndrome, and familial nonmedullary thyroid carcinoma. In addition, several individual neuroendocrine tumors are described, such as medullary thyroid carcinoma, gastroenteropancreatic tumors, pheochromocytoma, and paraganglioma, emphasizing specific histopathologic characteristics", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19708762", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 168, 
          "text": "Neuroendocrine tumors (NETs) are a heterogeneous group of benign and malignant neoplasias, detectable in the context of hereditary tumor syndromes in up to 30% of cases", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14685672", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1110, 
          "offsetInEndSection": 1218, 
          "text": "RET gene analysis can identify individuals with a very high risk to develop familial medullary cancer (MEN2)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14685672", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is PTEN involved in follicular thyroid carcinoma?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21417916", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18055323", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9832031"
      ], 
      "type": "yesno", 
      "id": "55031650e9bde69634000026", 
      "snippets": [
        {
          "offsetInBeginSection": 986, 
          "offsetInEndSection": 1221, 
          "text": "Two of the 259 patients (0.8%), with both follicular thyroid carcinoma and macrocephaly, were found to carry a germline mutation in the PTEN gene. The PTEN mutation frequency in unselected cases of follicular thyroid carcinoma was 4.8%", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21417916", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1235, 
          "offsetInEndSection": 1422, 
          "text": "The frequency of germline pathogenic PTEN mutations in an unselected series of patients with DTC is relatively low, but it is enriched by considering follicular histology and macrocephaly", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21417916", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 354, 
          "offsetInEndSection": 594, 
          "text": "Similarly, there is increasing evidence demonstrating that mutations leading to activation of the phosphatidylinositol 3- kinase (PI3K)/AKT effectors -PTEN and PI3KCa- are essential for the pathogenesis of follicular thyroid carcinoma (FTC)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18055323", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1351, 
          "offsetInEndSection": 1489, 
          "text": "A single male with follicular thyroid carcinoma from one of these 64 (2%) CS-like families harboured a germline point mutation, c.209T-->C", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9832031", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "How thyrocyte destruction is induced in autoimmune thyroiditis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11321234", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11101869", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9886394", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9020075"
      ], 
      "type": "summary", 
      "id": "5503167be9bde69634000028", 
      "snippets": [
        {
          "offsetInBeginSection": 208, 
          "offsetInEndSection": 537, 
          "text": "These morphological findings suggested that autoreactive T-cell clones were responsible for thyrocyte destruction and hypothyroidism through effector-target cytotoxic recognition. Later, autonomous interaction between thyrocyte Fas and FasL has been proposed as a major mechanism of thyrocyte depletion in Hashimoto's thyroiditis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11321234", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 539, 
          "offsetInEndSection": 763, 
          "text": "Here, we analyze the possible role of Fas and FasL in the pathogenesis of Hashimoto's thyroiditis. We suggest that the Fas-FasL system dictates the outcome of the autoimmune response by acting on both immune and target cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11321234", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "After autoimmune inflammation, interactions between CD95 and its ligand (CD95L) mediate thyrocyte destruction in Hashimoto's thyroiditis (HT)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11101869", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 826, 
          "offsetInEndSection": 943, 
          "text": "modulation of apoptosis-related proteins by TH1 and TH2 cytokines controls thyrocyte survival in thyroid autoimmunity", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11101869", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 110, 
          "text": "Hashimoto's thyroiditis (HT) is a chronic autoimmune disease resulting from Fas-mediated thyrocyte destruction", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886394", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 112, 
          "offsetInEndSection": 324, 
          "text": "Although autocrine/paracrine Fas-Fas ligand (FasL) interaction is responsible for thyrocyte cell death during the active phases of HT, the role of infiltrating T lymphocytes (ITL) in this process is still unknown", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886394", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 405, 
          "offsetInEndSection": 744, 
          "text": "All ITL expressed high levels of Fas and CD69, an early marker of T cell activation associated with functional Fas expression in T cells in vivo. In contrast to thyrocytes that were found to produce high levels of FasL, ITL did not express significant amounts of FasL, suggesting that ITL are not directly involved in thyrocyte destruction", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886394", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1448, 
          "offsetInEndSection": 1654, 
          "text": "These data demonstrate that ITL are not directly involved in thyrocyte cell death during HT, suggesting that autocrine/paracrine Fas-FasL interaction is a major mechanism in autoimmune thyrocyte destruction", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886394", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 108, 
          "offsetInEndSection": 798, 
          "text": "Thyrocytes from HT glands, but not from nonautoimmune thyroids, expressed Fas. Interleukin-1beta (IL-1beta), abundantly produced in HT glands, induced Fas expression in normal thyrocytes, and cross-linking of Fas resulted in massive thyrocyte apoptosis. The ligand for Fas (FasL) was shown to be constitutively expressed both in normal and HT thyrocytes and was able to kill Fas-sensitive targets. Exposure to IL-1beta induced thyrocyte apoptosis, which was prevented by antibodies that block Fas, suggesting that IL-1beta-induced Fas expression serves as a limiting factor for thyrocyte destruction. Thus, Fas-FasL interactions among HT thyrocytes may contribute to clinical hypothyroidism", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9020075", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which diseases have been associated with the PTPN22 620W allele?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22237046", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16320352", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16277672", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15790351", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15719322"
      ], 
      "type": "list", 
      "id": "550316a6e9bde69634000029", 
      "snippets": [
        {
          "offsetInBeginSection": 667, 
          "offsetInEndSection": 1045, 
          "text": "The frequency of the minor allele (620W) was significantly higher in GPA patients than in controls [P\u2009=\u20090.005, \u03c7(2\u2009)=\u20097.858, odds ratio (OR)\u2009=\u20091.91], while no statistically significant association was found with MPA or CSS. Among GPA patients, the 620W allele was particularly enriched in ANCA-positive patients as compared with controls (P\u2009=\u20090.00012, \u03c7(2\u2009)=   14.73, OR\u2009=\u20092.31)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22237046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1302, 
          "offsetInEndSection": 1443, 
          "text": "The PTPN22 620W allele confers susceptibility to the development of GPA (but not of MPA or CSS), and particularly of its ANCA-positive subset", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22237046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 68, 
          "text": "The PTPN22 620W allele is a risk factor for Wegener's granulomatosis", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16320352", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 415, 
          "text": "Analyses of families with multiple autoimmune disorders have revealed a functional polymorphism, 620W, in the intracellular tyrosine phosphatase gene PTPN22 as a predisposing factor for type 1 diabetes, seropositive rheumatoid arthritis, systemic lupus erythematosus, and Hashimoto thyroiditis, and the presence of the PTPN22 protein appears to herald the development of autoantibodies in these disorders", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16320352", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 790, 
          "offsetInEndSection": 948, 
          "text": "The PTPN22 620W allele frequency was significantly increased in antineutrophil cytoplasmic antibody (ANCA)-positive WG patients compared with healthy controls", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16320352", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1129, 
          "offsetInEndSection": 1246, 
          "text": "The PTPN22 620W allele appears to be involved in the pathogenesis of WG, and ANCA positivity seems to be the hallmark", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16320352", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "Rheumatoid arthritis seropositive for the rheumatoid factor is linked to the protein tyrosine phosphatase nonreceptor 22-620W allele", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16277672", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 357, 
          "text": "The protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene encodes for lymphoid tyrosine phosphatase LYP, involved in the negative regulation of early T-cell activation. An association has recently been reported between the PTPN22-620W functional allele and rheumatoid factor-positive (RF+) rheumatoid arthritis (RA), among other autoimmune diseases", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16277672", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 439, 
          "offsetInEndSection": 666, 
          "text": "A functional variant (R620W) of the intracellular protein tyrosine phosphatase N22 (PTPN22) has now been conclusively shown to confer approximately two-fold risk for seropositive RA as well as several other autoimmune disorders", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15790351", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 96, 
          "offsetInEndSection": 165, 
          "text": "the PTPN22 620W allele associates with multiple autoimmune phenotypes", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15719322", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 964, 
          "offsetInEndSection": 1231, 
          "text": "We report that a recently described functional single-nucleotide polymorphism (rs2476601, encoding R620W) in the intracellular tyrosine phosphatase (PTPN22) confers risk of four separate autoimmune phenotypes in these families: T1D, RA, SLE, and Hashimoto thyroiditis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15719322", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is desmin an intermediate filament protein involved in Dilated Cardiomyopathy (DCM)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17325244", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16890305", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15699919", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15572040", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15475165", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14734054", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12025381", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11515275", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11374497", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10974018", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10904833", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7774871"
      ], 
      "type": "yesno", 
      "id": "55031963e9bde6963400002a", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 377, 
          "text": "Desmin-related myofibrillar myopathy (DRM) is a cardiac and skeletal muscle disease caused by mutations in the desmin (DES) gene. Mutations in the central 2B domain of DES cause skeletal muscle disease that typically precedes cardiac involvement. However, the prevalence of DES mutations in dilated cardiomyopathy (DCM) without skeletal muscle disease is not known.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17325244", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1492, 
          "offsetInEndSection": 1699, 
          "text": "The lack of severe disruption of cytoskeletal desmin network formation seen with mutations in the 1A and tail domains suggests that dysfunction of seemingly intact desmin networks is sufficient to cause DCM.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17325244", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 292, 
          "text": "According to the predominant view, desmin mutations cause dilated cardiomyopathy (DCM). We evaluated a family with restrictive cardiomyopathy (RCM) associated with a novel desmin mutation and reviewed recent reports regarding the frequency of RCM in patients with desmin myopathy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16890305", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 716, 
          "text": "Dilated cardiomyopathy (DCM) is characterized by enlargement and dilation of all heart compartments associated with serious decrease of its contractile function. DCM hallmark is the combination of dystrophic and hypertrophic alterations of cardiomyocytes. Since the power output of cardiac cells is directly related to remodeling of their contractile machinery we investigated expression of selected contractile and cytoskeletal proteins in the left ventricle of DCM patients using immunoblotting. The content of the recognized protein markers of cardiomyocyte hypertrophy such as tubulin, desmin and slow skeletal myosin heavy chain isoform, MHCbeta, was significantly elevated in DCM compared to normal myocardium.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15699919", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1311, 
          "offsetInEndSection": 1857, 
          "text": "In contrast, overexpression of desmin filaments by itself is not detrimental to the heart. Although loss-of-function studies have been more limited, ablation of the desmin gene causes mitochondrial dysfunction and apoptosis, resulting in cardiomyopathy in mice. From function studies, abnormal desmin aggregation and disruption of the desmin networks resulting from expression of either mutant desmin or mutant CryAB have been shown to remodel the heart and compromise cardiac function, suggesting their synergistic roles in disease pathogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15572040", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 187, 
          "offsetInEndSection": 261, 
          "text": "A missense mutation in the desmin gene (DES) causes DCM in a human family.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15475165", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 440, 
          "text": "Mice deficient in desmin, the muscle-specific member of the intermediate filament gene family, display defects in all muscle types and particularly in the myocardium. Desmin null hearts develop cardiomyocyte hypertrophy and dilated cardiomyopathy (DCM) characterized by extensive myocyte cell death, calcific fibrosis and multiple ultrastructural defects. Several lines of evidence suggest impaired vascular function in desmin null animals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14734054", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 400, 
          "offsetInEndSection": 796, 
          "text": "Familial DCM is commonly inherited as autosomal dominant trait; less frequently it is autosomal recessive, X-linked or matrilinear. The disease is clinically and genetically heterogeneous. Genes causally linked to this phenotype include dystrophin, dystrophin-associated glycoproteins, actin, desmin, beta-miosin heavy chain, cardiac troponin T, and mitochondrial DNA genes, mostly transfer RNAs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12025381", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1094, 
          "offsetInEndSection": 1309, 
          "text": "Examination of families has identified so far eight disease genes, namely the dystrophin, tafazzin, cardiac actin, desmin, lamin A/C, delta- sarcoglycan, cardiac beta-myosin heavy chain, and cardiac troponin T gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11515275", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1789, 
          "offsetInEndSection": 2001, 
          "text": "Mutations of the desmin,   delta-sarcoglycan, the cardiac actin and beta-myosin heavy chain as well as the troponin T gene are known to cause autosomal dominant-dilated cardiomyopathy without other abnormalities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11515275", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 354, 
          "offsetInEndSection": 605, 
          "text": "Autosomal dominant DCM is the most frequent form (56% of our cases), and several candidate disease loci have been identified by linkage analysis. Three disease genes are presently known: the cardiac actin gene, the desmin gene, and the lamin A/C gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11374497", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 241, 
          "text": "Dilated cardiomyopathy (DCM) is a major cause of morbidity and mortality. Two genes have been identified for the X-linked forms (dystrophin and tafazzin), whereas three other genes (actin, lamin A/C, and desmin) cause autosomal dominant DCM;", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10974018", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1658, 
          "offsetInEndSection": 1740, 
          "text": "Desmin defects were also recently identified in 1 familial dilated cardiomyopathy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10904833", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1904, 
          "offsetInEndSection": 2043, 
          "text": "By candidate gene screening, the molecular diagnosis can be provided for dystrophin, DAG, mitochondrial DNA, actin and desmin gene defects.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10904833", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1698, 
          "offsetInEndSection": 1939, 
          "text": "Desmin (z-bands) are partly destroyed in DCM. Anti-desmin antibody titers as indicators of a possible secondary immune response are found high in patients with acute myocarditis declining during reconvalescence and are also elevated in DCM. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7774871", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the association between adiponectin and migraine?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24250893", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23489216", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22823862", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19882941", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19845784", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19556389", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18474846", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17515549", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17448181"
      ], 
      "type": "summary", 
      "id": "55031d82e9bde6963400002c", 
      "snippets": [
        {
          "offsetInBeginSection": 65, 
          "offsetInEndSection": 253, 
          "text": "Increase in body fat, especially in gluteofemoral region, elevates adiponectin and leptin secretion which in turn impair inflammatory processes that could be contributing to migraine risk.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24250893", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2064, 
          "offsetInEndSection": 2350, 
          "text": "CONCLUSION: In this pilot study of women episodic migraineurs, the HMW\u2009:\u2009LMW ADP ratio level was associated with migraine severity and predictive of acute treatment response. ADP and the HMW\u2009:\u2009LMW ratio of ADP represent potential novel biomarkers and drug targets for episodic migraine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23489216", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 652, 
          "offsetInEndSection": 842, 
          "text": "Specifically, neurotransmittors such as serotonin, peptides such as orexin, and adipocytokines such as adiponectin and leptin have been suggested to have roles in both feeding and migraine. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22823862", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 774, 
          "offsetInEndSection": 1158, 
          "text": "Obesity can be considered as a proinflammatory state in which increased inflammatory mediators, vascular hyperreactivity, plasma calcitonin gene-related peptide (CGRP) concentrations and decreased adiponectin concentrations are observed. These alterations can cause an increase in the frequency of migraine attacks developed of central sensitization, and thereafter, chronic migraine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882941", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 492, 
          "offsetInEndSection": 682, 
          "text": "Specifically, neurotransmittors such as serotonin, peptides such as orexin, and adipocytokines such as adiponectin and leptin have been suggested to have roles in both feeding and migraine. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19845784", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 181, 
          "offsetInEndSection": 507, 
          "text": "Several adipocytokines appear to play an integral role in feeding and obesity--and have also been linked to pain. Among these proteins are adiponectin and leptin. The author reviews the regulation of adipose tissue and feeding and provides an in-depth examination of adiponectin and leptin and their association with migraine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19556389", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1621, 
          "offsetInEndSection": 1720, 
          "text": "CONCLUSION: Serum adiponectin levels are increased in women chronic daily headache (CDH) sufferers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18474846", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1440, 
          "offsetInEndSection": 1741, 
          "text": "n this review we discuss the basic science of adiponectin and its potential connection to the pathophysiology of migraine. Future research may focus on how adiponectin levels are potentially altered during migraine attacks, and how that information can be potentially translated into migraine therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17448181", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List symptoms of 4H leukodystrophy.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24190003", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23307887", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23242285", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22855961", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22451160", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21855841", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18671210"
      ], 
      "type": "list", 
      "id": "550320cbe9bde6963400002d", 
      "snippets": [
        {
          "offsetInBeginSection": 161, 
          "offsetInEndSection": 426, 
          "text": " MRI demonstrated diffuse cerebral hypomyelination, cerebellar atrophy, and thin corpus callosum; X-ray revealed persistent milk teeth and hypoplastic crowns and roots (figure), indicative of 4H syndrome (hypomyelination, hypodontia, hypogonadotropic hypogonadism).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24190003", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "4H syndrome is a rare and distinct leukodystrophy characterized by hypomyelination, hypogonadotropic hypogonadism, and hypodontia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23307887", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "The 4H syndrome (hypomyelination, hypodontia, hypogonadotropic hypogonadism) is a newly recognized leukodystrophy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23242285", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 456, 
          "offsetInEndSection": 887, 
          "text": " The five overlapping clinical phenotypes (described as distinct entities before their molecular basis was known) include: Hypomyelination, hypodontia, hypogonadotropic hypogonadism (4H syndrome); Ataxia, delayed dentition, and hypomyelination (ADDH); Tremor-ataxia with central hypomyelination (TACH); Leukodystrophy with oligodontia (LO); and Hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum (HCAHC).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22855961", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 236, 
          "text": "OBJECTIVE: To report a novel clinical and genetic presentation of a patient with 4H syndrome, which is a recently described leukodystrophy syndrome characterized by ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22451160", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 596, 
          "offsetInEndSection": 905, 
          "text": "Because these families were mapped to the same locus as leukodystrophy with oligodontia (LO) and presented clinical and radiological overlap with individuals with hypomyelination, hypodontia and hypogonadotropic hypogonadism (4H) syndrome, we sequenced this gene in nine individuals with 4H and eight with LO.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21855841", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "AIM: To report one patient with slowly progressive encephalopathy, ataxia, central hypomyelination, hypodontia and hypogonadotropic hypogonadism, the 4H syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18671210", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are BBS mutations involved in syndromic Hirschsprung disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19666486"
      ], 
      "type": "yesno", 
      "id": "55032179e9bde6963400002e", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 111, 
          "text": "Epistasis between RET and BBS mutations modulates enteric innervation and causes syndromic Hirschsprung disease", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19666486", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 341, 
          "offsetInEndSection": 656, 
          "text": "Here, we report 3 families with BBS and HSCR with concomitant mutations in BBS genes and regulatory RET elements, whose functionality is tested in physiologically relevant assays. Our data suggest that BBS mutations can potentiate HSCR predisposing RET alleles, which by themselves are insufficient to cause disease", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19666486", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the association between personality trait of neuroticism and risk for Alzheimer's disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23706517", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23567438", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23079898", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23040035", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22040898", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21905097", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21835104", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21427641", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20973606", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20438208", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18694539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18590355", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18079420", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17244848", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16974109", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16314587", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16252381", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15358438", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12767492", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10718200", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10679843", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9924832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7493597"
      ], 
      "type": "summary", 
      "id": "550324d7e9bde6963400002f", 
      "snippets": [
        {
          "offsetInBeginSection": 415, 
          "offsetInEndSection": 685, 
          "text": "RESULTS: Individuals with scores in the top quartile of neuroticism (hazard ratio = 3.1; 95% confidence interval = 1.6-6.0) or the lowest quartile of conscientiousness (hazard ratio = 3.3; 95% confidence interval = 1.4-7.4) had a threefold increased risk of incident AD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23706517", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 674, 
          "offsetInEndSection": 967, 
          "text": "Five of nine studies found that higher neuroticism was associated with greater dementia risk (pooled hazard ratio [HR] per unit increase on neuroticism score, HR\u00a0= 1.13, 95% confidence interval [CI]\u00a0= 1.08-1.18, z\u00a0= 5.11, p\u00a0<0.001, N\u00a0= 3,285), and two studies showed it increased risk of MCI. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567438", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1519, 
          "offsetInEndSection": 1609, 
          "text": "CONCLUSIONS: Neuroticism increased risk for dementia, and conscientiousness reduced risk. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567438", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 691, 
          "offsetInEndSection": 1194, 
          "text": "RESULTS: Fully adjusted multivariate analyses showed that the association between the presence of APOE [Latin Small Letter Open E]-4 allele(s) and both outcomes was evident among individuals with high levels of neuroticism and extraversion but not among persons with low levels of these traits. CONCLUSIONS: Phenotypic personality dimensions, primarily neuroticism and extraversion, moderate the relationship between APOE [Latin Small Letter Open E]-4 genotype and cognitive outcomes among older adults.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23079898", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 497, 
          "offsetInEndSection": 1181, 
          "text": " Individuals with higher baseline scores on vulnerability to stress, anxiety, and depression (neuroticism: odds ratio, 2.0; 95% confidence interval, 1.2-3.5), or lower scores on order and competence (conscientiousness: odds ratio, 0.4; 95% confidence interval, 0.2-0.9) were less likely to remain asymptomatic in the presence of AD neuropathology. Neuroticism (r = 0.26), low agreeableness (r = -0.34), and some facets were also significantly associated with advanced stages of neurofibrillary tangles, but the associations between personality traits and risk of clinical dementia were mostly unchanged by controlling for the extent of neurofibrillary tangles and A\u03b2 neuritic plaques.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23040035", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 211, 
          "offsetInEndSection": 518, 
          "text": "Using mixed models adjusted for age, sex, education, race, social network size, depression, chronic conditions, disability, neuroticism, extraversion, cognitive activity, and physical activity, more social activity was associated with less cognitive decline during average follow-up of 5.2 years (SD = 2.7).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22040898", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 700, 
          "offsetInEndSection": 1007, 
          "text": "RESULTS: After controlling for age, the Alzheimer disease group presented significantly higher scores than normal control subjects on current neuroticism, and significantly lower scores on current extraversion, openness, and conscientiousness, while no significant difference was observed on agreeableness. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21835104", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 934, 
          "offsetInEndSection": 1458, 
          "text": " In analyses of specific cognitive systems, neuroticism subscales were related to decline in episodic memory, working memory, and perceptual speed, but not in semantic memory or visuospatial ability. No component of neuroticism was related to the neuropathologic lesions most commonly associated with late-life dementia. CONCLUSIONS: Neuroticism's association with late-life dementia mainly reflects vulnerability to stress and anxiety and their correlation with decline in the ability to process and retain new information.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21427641", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 800, 
          "offsetInEndSection": 993, 
          "text": "The finding that AD risk is associated with elevated Neuroticism and lower Conscientiousness can be added to the accumulating literature documenting the pathogenic effects of these two traits. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20973606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1124, 
          "offsetInEndSection": 1315, 
          "text": "tau was also correlated with the psychometric measures of episodic/semantic memory, working memory, and processing speed, and with the personality traits of neuroticism and conscientiousness.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20438208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 140, 
          "offsetInEndSection": 300, 
          "text": "The pre-morbid personality domain of Neuroticism constituted an interesting and theoretically plausible, yet uninvestigated, candidate for such an association. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18694539", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 945, 
          "offsetInEndSection": 1042, 
          "text": "RESULTS: Midlife Neuroticism predicted younger age of dementia onset in females but not in males.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18694539", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 284, 
          "offsetInEndSection": 497, 
          "text": "Preliminary research suggests that cognitively impaired MS patients exhibit elevation in Neuroticism, and diminution in Extraversion, Agreeableness, and Conscientiousness, as do patients with Alzheimer's disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18590355", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 425, 
          "offsetInEndSection": 694, 
          "text": "On the basis of both self-report and informant report, there was an increase in neuroticism and a decrease in conscientiousness in persons with very mild DAT relative to healthy individuals without it, and in persons with mild DAT relative to those with very mild DAT. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18079420", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1264, 
          "offsetInEndSection": 1481, 
          "text": "CONCLUSIONS: As subjective cognitive complaints in the AACD group were related to neuroticism and gender rather than to cognitive performance, their inclusion in diagnostic concepts such as AACD should be revaluated. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16252381", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 342, 
          "text": "Multiple studies of individuals with Alzheimer disease have substantiated significant levels of informant-rated change in several domains and facets of the Neuroticism-Extraversion-Openness Personality Inventory, including increases in Neuroticism and decreases in Extraversion and Conscientiousness relative to premorbid personality traits. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10718200", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 468, 
          "offsetInEndSection": 556, 
          "text": "RESULTS: The AD patients showed higher neuroticism than the controls with PD (p=0.013). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10679843", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 741, 
          "offsetInEndSection": 880, 
          "text": "CONCLUSION: Our results support the assumption of specific premorbid characteristics in AD patients, ie increased neuroticism and rigidity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10679843", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 335, 
          "offsetInEndSection": 535, 
          "text": "Personality change in DAT was consistent with previous reports of increased neuroticism, decreased extraversion, and decreased conscientiousness, with smaller decreases in openness and agreeableness. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7493597", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List three major features of the CCFDN syndrome.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19070320", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17578274", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17195938", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16939648", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15234148", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14517542", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14512967", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11805249", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10442556", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10439962", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10360766"
      ], 
      "type": "list", 
      "id": "5503263fe9bde69634000030", 
      "snippets": [
        {
          "offsetInBeginSection": 1028, 
          "offsetInEndSection": 1468, 
          "text": "Because of our experience in neuromuscular disorders, we choose six, frequent, autosomal recessive disorders for these clinical and genetic studies: hereditary motor and sensory neuropathy type Lom (HMSNL), hereditary motor and sensory neuropathy type Russe (HMSNR), congenital cataracts facial dysmorphism syndrome (CCFDN), limb-girdle muscular dystrophy 2C (LGMD2C), congenital myasthenic syndrome (CMS) and spinal muscular atrophy (SMA).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070320", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 154, 
          "text": "The congenital cataracts facial dysmorphism neuropathy (CCFDN) syndrome (OMIM 604168) is a recently described autosomal recessive developmental disorder. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17578274", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 280, 
          "text": "Congenital cataracts-facial dysmorphism-neuropathy syndrome (CCFDN, MIM: 604168), is a recently delineated neurogenetic disease causing recurrent episodes of rhabdomyolysis; prevention and early diagnosis of rhabdomyolysis should be part of the clinical management of the disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17195938", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 140, 
          "text": "Congenital Cataracts Facial Dysmorphism Neuropathy (CCFDN) syndrome is a complex developmental disorder of autosomal recessive inheritance. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16939648", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 195, 
          "text": "OBJECTIVE: To determine the nature and course of ophthalmologic abnormalities in congenital cataracts facial dysmorphism neuropathy (CCFDN) syndrome in a genetically verified group of 9 patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15234148", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 201, 
          "text": "Congenital cataracts facial dysmorphism neuropathy (CCFDN) syndrome (OMIM 604168) is an autosomal recessive developmental disorder that occurs in an endogamous group of Vlax Roma (Gypsies; refs. 1-3). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14517542", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 415, 
          "offsetInEndSection": 587, 
          "text": "The major differential diagnosis of MSS is the syndrome defined by congenital cataracts, facial dysmorphism and peripheral neuropathy (CCFDN), which is localised to 18qter.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14512967", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 269, 
          "offsetInEndSection": 599, 
          "text": "The CCFDN syndrome is a complex phenotype involving multiple systems, characterized by facial dysmorphism, congenital cataracts, microcorneae, delayed early motor and intellectual development, hypogonadotrop hypogonadism, hypomyelination of the peripheral nervous system, and serious complications related to general anaesthesia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17578274", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 269, 
          "offsetInEndSection": 623, 
          "text": "Developmental abnormalities include congenital cataracts and microcorneae, primary hypomyelination of the peripheral nervous system, impaired physical growth, delayed early motor and intellectual development, mild facial dysmorphism and hypogonadism. Para-infectious rhabdomyolysis is a serious complication reported in an increasing number of patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16939648", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1755, 
          "offsetInEndSection": 1972, 
          "text": "CONCLUSIONS: Early-onset congenital cataracts associated with microcornea, microphthalmos, and micropupil are essential ocular features of the CCFDN syndrome and are the first recognizable signs during early infancy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15234148", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1051, 
          "offsetInEndSection": 1427, 
          "text": "All patients showed a peripheral, demyelinating neuropathy and varying degrees of ataxia. In the older patients, muscular atrophy in distal muscles and facial dysmorphism was evident. Early-onset bilateral congenital cataracts associated with microcornea, microphthalmos, and micropupil could be found in all patients. All children had floppy eyelid syndrome and pseudoptosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15234148", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1532, 
          "offsetInEndSection": 1754, 
          "text": "All patients had syndrome-associated nystagmus and congenital esotropia. Distant visual acuity could be classified as severe to moderate impairment, whereas near visual acuity was much better (mild to moderate impairment).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15234148", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 202, 
          "offsetInEndSection": 577, 
          "text": "Because these families originated from the same genetically isolated founder population as did patients with congenital cataracts facial dysmorphism neuropathy (CCFDN) syndrome, and because the two syndromes have clinical manifestations in common, we hypothesized that the two related, albeit distinct, syndromes may represent clinical variants of a single genetic disorder. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11805249", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Peripheral nerve abnormalities in the congenital cataracts facial dysmorphism neuropathy (CCFDN) syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10442556", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "Congenital cataracts facial dysmorphism neuropathy (CCFDN) syndrome: a novel developmental disorder in Gypsies maps to 18qter.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10439962", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 196, 
          "offsetInEndSection": 295, 
          "text": "We propose to refer to the syndrome as congenital cataracts facial dysmorphism neuropathy (CCFDN). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10439962", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 221, 
          "offsetInEndSection": 357, 
          "text": "The disorder has been termed the congenital cataracts facial dysmorphism neuropathy (CCFDN) syndrome to emphasize its salient features. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10360766", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 901, 
          "offsetInEndSection": 1302, 
          "text": "Associated neurological features are a moderate nonprogressive cognitive deficit in most affected individuals together with pyramidal signs and mild chorea in some. Accompanying nonneurological features include short stature, characteristic facial dysmorphism, and hypogonadotrophic hypogonadism. Nerve conduction studies suggest a hypomyelinating/demyelinating neuropathy, confirmed by nerve biopsy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10360766", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Congenital cataracts facial dysmorphism neuropathy (CCFDN) syndrome: a rare cause of parainfectious rhabdomyolysis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17195938", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the association between NT-proBNP and cognitive function?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23579182", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23384944", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22973461", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22479261", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21683832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21526197", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20727348"
      ], 
      "type": "summary", 
      "id": "55032785e9bde69634000031", 
      "snippets": [
        {
          "offsetInBeginSection": 1027, 
          "offsetInEndSection": 1175, 
          "text": "RESULTS: Measures of cognitive decline were significantly associated with stroke, NT-proBNP, ABI, and cIMT, but not with nonstroke vascular events. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23579182", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 990, 
          "offsetInEndSection": 1185, 
          "text": "SCI was present at baseline more often in NYHA IV patients compared with NYHA II [odds ratio 2.94; 95% confidence interval (CI) 1.15-7.51, P = 0.025], but it was not related to NT-proBNP levels. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23384944", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1022, 
          "offsetInEndSection": 2049, 
          "text": "Comparing extreme quintiles of NT-proBNP, subjects in the highest quintile were more likely to have reduced cognitive ability (within the lowest tertile of 'g') and 'possible' depression (HADS depression \u22658) (OR 1.80; 95% CI: 1.20, 2.70; p\u200a=\u200a0.005 and OR 2.18; 95% CI: 1.28, 3.71; p\u200a=\u200a0.004, respectively). Associations persisted when pre-morbid ability was adjusted for, but as expected were no longer statistically significant following the adjustment for diabetes-related and vascular co-variates (\u03b2 -0.02, 95% CI -0.07 to 0.03, p>0.05 for 'g'; \u03b2 0.03, 95% CI -0.02 to 0.07, p>0.05 for depression scores). CONCLUSION: Raised plasma NT-proBNP was weakly but statistically significantly associated with poorer cognitive function and depression. The prospective phases of the ET2DS will help determine whether or not NT-proBNP can be considered a risk marker for subsequent cognitive impairment and incident depression and whether it provides additional information over and above traditional risk factors for these conditions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22973461", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 430, 
          "offsetInEndSection": 711, 
          "text": "RESULTS AND CONCLUSION: Patients with vascular disease and elevated serum NT-proBNP level had a lower cognition level, shorter survival time, lower renal function and a higher percentage of pathological brain imaging than patients with vascular disease and normal NT-proBNP level. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22479261", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 224, 
          "text": "BACKGROUND: Natriuretic peptides have prognostic value across a wide spectrum of cardiovascular diseases and may predict cognitive dysfunction in patients with cardiovascular disease, even in the absence of previous stroke. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21683832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1114, 
          "offsetInEndSection": 1711, 
          "text": "In unadjusted analyses, all 3 cognitive function test scores were significantly associated with NT-proBNP levels (P<.001). After adjusting for age, sex, education, hypertension, body mass index, exercise, alcohol use, smoking, low density lipoprotein cholesterol, creatinine clearance, and previous cardiovascular disease, elevated NT-proBNP levels remained independently associated with poor cognitive performance on MMSE (odds ratio [OR] 2.0; 95% confidence interval [CI], 1.1-3.6; P=.02) and Trails B (OR 1.7; 95% CI, 1.2-2.7; P=.01), but not Category Fluency (OR 1.4; 95% CI, 0.9-2.2; P=.19). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21683832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1798, 
          "offsetInEndSection": 1936, 
          "text": " CONCLUSIONS: NT-proBNP levels were strongly and independently associated with poor cognitive function in community-dwelling older adults.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21683832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 798, 
          "offsetInEndSection": 876, 
          "text": "However, NT-proBNP level did not predict cognition as assessed by MMSE score. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20727348", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is there an association between TERT promoter mutation and survival of glioblastoma patients?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23955565", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23393205"
      ], 
      "type": "yesno", 
      "id": "55032bbfe9bde69634000032", 
      "snippets": [
        {
          "offsetInBeginSection": 993, 
          "offsetInEndSection": 1734, 
          "text": "Glioblastoma patients with TERT mutations showed a shorter survival than those without TERT mutations in univariate analysis (median, 9.3 vs. 10.5 months; P = 0.015) and multivariate analysis after adjusting for age and gender (HR 1.38, 95 % CI 1.01-1.88, P = 0.041). However, TERT mutations had no significant impact on patients' survival in multivariate analysis after further adjusting for other genetic alterations, or when primary and secondary glioblastomas were separately analysed. These results suggest that the prognostic value of TERT mutations for poor survival is largely due to their inverse correlation with IDH1 mutations, which are a significant prognostic marker of better survival in patients with secondary glioblastomas.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955565", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1593, 
          "offsetInEndSection": 1825, 
          "text": "Patients with tumors lacking hTERT expression/TA showed a significant survival benefit (Kaplan-Meier test, both P < .01), which, however, was based exclusively on the younger patient subgroup (\u226460 y, both P < .005; >60 y, both ns). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23393205", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is myasthenia gravis associated with osteoporosis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23543381", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22840813", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22531999", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16690366", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15168159", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15003307", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11328209", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2237235"
      ], 
      "type": "yesno", 
      "id": "55032d8be9bde69634000033", 
      "snippets": [
        {
          "offsetInBeginSection": 508, 
          "offsetInEndSection": 615, 
          "text": "We performed PVP in 4 patients with generalized MG associated with recent steroid-induced symptomatic VFs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23543381", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 242, 
          "offsetInEndSection": 436, 
          "text": "In this case report, we used tacrolimus to successfully treat a 13-year-old boy with ocular MG who had suffered from severe steroid complications, including a failure of thrive and osteoporosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22840813", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 360, 
          "offsetInEndSection": 573, 
          "text": " INTRODUCTION: Myasthenia gravis (MG) is a neuromuscular disease which has been associated with an increased falls risk and glucocorticoid-induced osteoporosis, recognized determinants of increased fracture risk. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22531999", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 949, 
          "offsetInEndSection": 1462, 
          "text": "RESULTS: Compared to the control cohort, there was no statistically significant increased risk observed in patients with MG for any fracture (adjusted hazard ratio [AHR] 1.11; 95 % confidence interval [CI], 0.84-1.47) or osteoporotic fractures (AHR 0.98 [95 % CI 0.67-1.41]). Further, use of oral glucocorticoids up to a cumulative dose exceeding 5 g prednisolone equivalents did not increase risk of osteoporotic fracture (AHR 0.99 [95 % CI, 0.31-3.14]) compared with MG patients without glucocorticoid exposure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22531999", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1271, 
          "offsetInEndSection": 1405, 
          "text": "The RANKL/OPG ratio and indices of bone metabolisms are also not affected by THX, although THX increases the levels of IL-7 and RANKL.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16690366", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 83, 
          "offsetInEndSection": 575, 
          "text": "Both disorders had been controlled for around 15 years by oral prednisolone and a cholinesterase inhibitor following surgical removal of invasive thymoma and radiotherapy, but muscular weakness due to myalgia and an increase in serum levels of myogenic enzymes, mainly ascribable to the recurrence of PM, reappeared immediately after cessation of these drugs, which was done because the patient had multiple bone fractures and severe osteoporosis due to the long-term corticosteroid therapy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15168159", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 160, 
          "offsetInEndSection": 391, 
          "text": "We measured bone density in 36 patients (26 females and 10 males) who had undergone long-term prednisolone administration, and found a decrease in bone density in 31% of female patients and osteoporosis in only 11.5% (three cases).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15003307", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 533, 
          "offsetInEndSection": 681, 
          "text": "In conclusion, prednisolone-treated patients with myasthenia gravis have an acceptable risk of bone loss if prophylactic medication is administered.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15003307", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the characteristic feature of the Dyke-Davidoff-Masson syndrome.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23672850", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23591309", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23344879", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23189018", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22967682", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22681314", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21764333", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21559157", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20691943", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20236868", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19744394", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19204321", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19169186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19097769", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24257011", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19029569", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17250509", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15869006", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16100487", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15798614", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15158218", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12763349", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11814746", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10029885", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8997138", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7761171", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1547482", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7214933"
      ], 
      "type": "factoid", 
      "id": "55032e65e9bde69634000034", 
      "snippets": [
        {
          "offsetInBeginSection": 202, 
          "offsetInEndSection": 402, 
          "text": "Dyke-Davidoff-Masson syndrome is a rare condition characterized by cerebral hemiatrophy, calvarial thickening, skull and facial asymmetry, contralateral hemiparesis, cognitive impairment and seizures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23672850", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 155, 
          "text": "Dyke-Davidoff-Masson syndrome refers to atrophy of one cerebral hemisphere (hemiatrophy) due to an insult to the brain in fetal or early childhood period. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23591309", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "Acquired cerebral hemiatrophy: Dyke-Davidoff-Masson Syndrome - a case report.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23344879", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 620, 
          "offsetInEndSection": 730, 
          "text": "CT and MRI scan of the head showed hemiatrophic cerebral parenchyma with prominent sulci and encephalomalacia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23344879", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 163, 
          "offsetInEndSection": 298, 
          "text": "CT of the brain revealed characteristic features diagnostic of infantile type of cerebral hemiatrophy or Dyke-Davidoff-Masson syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23189018", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 510, 
          "offsetInEndSection": 728, 
          "text": "Magnetic resonance imaging (MRI) of brain revealed atrophic of left cerebral hemisphere with mildly ventricular dilatation, prominent paranasal and mastoid air cells, suggestive of Dyke-Davidoff-Masson syndrome (DDMS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22967682", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1158, 
          "offsetInEndSection": 1271, 
          "text": "Imaging showed resolution of the infection and features of Dyke-Davidoff-Masson syndrome (cerebral hemiatrophy). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22681314", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 265, 
          "text": "Dyke-Davidoff-Masson syndrome (DDMS) is a rare epilepsy syndrome that is characterized by cerebral hemiatrophy, homolateral skull hyperplasia, hyperpneumatization of the paranasal sinuses, seizures with or without mental retardation, and contralateral hemiparesis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764333", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 699, 
          "offsetInEndSection": 857, 
          "text": "Brain MRI showed prominent atrophy in the left frontal dorsal and lateral regions and mild atrophy of the left superior temporal gyrus and left parietal gyri.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764333", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "A 15-year-old female presented with seizures, right-sided hemiparesis, hemiatrophy of the right side of the body and mental retardation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21559157", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 308, 
          "text": "Described here is the case of a girl with a reticulated capillary malformation on the right side of her face, along with Dyke-Davidoff-Masson syndrome, as evidenced by microphthalmia and severe associated anomalies in the right eye, and right cerebral hemispheric atrophy and cerebral arteries malformations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20691943", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 178, 
          "text": "The purpose of this study was to retrospectively evaluate the cognitive and electroclinical characteristics of right cerebral hemiatrophy (Dyke-Davidoff-Masson syndrome [DDMS]). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236868", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 216, 
          "offsetInEndSection": 810, 
          "text": "The CHA of childhood or Dyke-Davidoff-Masson syndrome, is originated by intrauterine or perinatal insults that affect the perfusion of a single cerebral hemisphere, manifesting clinically by variable mental retardation, refractory epilepsy, facial asymmetry, hemiplegia/hemiparesis or abnormal movements of the contralateral extremities and by imaging studies, loss of volume in one cerebral hemisphere and ipsilateral compensatory cranial changes such as skull vault thickening, elevation of the orbital roof and petreous ridge, also hyperpneumatization of the frontal sinus and mastoid cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19744394", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 453, 
          "text": "Dyke-Davidoff-Masson syndrome is a disorder involving hemiatrophy or hypoplasia of 1 cerebral hemisphere secondary to an insult in the developing brain. Often this will manifest with seizures, hemiparesis, mental retardation, and facial changes. Associated with this pathology are the radiologically evident changes, such as thickening of the calvarium, hyperpneumatization of the sinuses, and dilation of the ipsilateral lateral ventricle among others.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19204321", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 235, 
          "text": "Dyke-Davidoff-Masson syndrome, or cerebral hemiatrophy, is a pre- or perinatally acquired entity characterized by predominantly neurologic symptoms, such as seizures, facial asymmetry, contralateral hemiplegia, and mental retardation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169186", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 267, 
          "text": "The Dyke-Davidoff-Masson syndrome is characterized by various symptoms related to hemiatrophy of the cerebrum and hypertrophy of the ipsilateral calvarium and paranasal sinuses. Clinical findings include hemiparesis or hemiplegia, seizures and/or mental retardation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19097769", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 356, 
          "offsetInEndSection": 572, 
          "text": "Asymmetry of cerebral hemispheric growth with atrophy on one side, ipsilateral osseous hypertrophy and hyper-pneumatization of sinuses with contralateral paresis are features of Dyke Davidoff Masson Syndrome (DDMS). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24257011", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 402, 
          "text": "Dyke Davidoff Masson syndrome (DDMS) is characterized by seizures, facial asymmetry, contralateral hemiplegia and mental retardation. The characteristic radiologic features are cerebral hemiatrophy with homolateral hypertrophy of the skull and sinuses. We report a case of DDMS in an 18-month-old girl who presented with right sided focal seizures, hemiparesis of the same side, and delayed milestones.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19029569", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "Cerebral hemiatrophy (Dyke-Davidoff-Masson syndrome) in childhood: clinicoradiological analysis of 19 cases.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17250509", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 290, 
          "text": "The so-called Dyke-Davidoff-Masson syndrome (DDMS) is a rare disorder of cerebral hemiatrophy. The clinical presentation may consist of facial asymmetry, contralateral atrophy (including the trunk, and the extremities) and hemiparesis, speech difficulties, mental retardation, and epilepsy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15869006", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 287, 
          "text": "Dyke-Davidoff-Masson syndrome is clinically characterized by hemiparesis, hemiplegia, seizures, mental retardation, and facial asymmetry secondary to congenital or early childhood vascular insult. A 21-year-old man with Dyke-Davidoff-Masson syndrome presented with uncontrolled seizures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16100487", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 153, 
          "text": "Dyke-Davidoff-Masson syndrome is a condition characterized by seizures, facial asymmetry, contralateral hemiplegia or hemiparesis and mental retardation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15798614", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 271, 
          "offsetInEndSection": 408, 
          "text": "Brain MRI showed unilateral loss of cerebral volume with hypertrophy and hyperpneumatization of the paranasal sinuses and mastoid cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15798614", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 188, 
          "text": "Although radiological findings of cerebral hemiatrophy (Dyke-Davidoff-Masson Syndrome) are well known, there is no systematic study about the gender and the affected side in this syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15158218", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 635, 
          "text": "The patient was a 19-year-old woman who presented with hemiatrophy and diminished superficial sensation on the left side of her body including her face. She had a past history of tonic-clonic seizures accompanied by left hemiparesis in late childhood. Brain CT demonstrated dilatation of the frontal sinus, calvarial thickening, cerebral hemiatrophy and dilatation of the lateral ventricle on the right side. Brain MRI showed atrophy of the right cerebrum and midbrain and dilatation of the lateral ventricle on T1-weighted images, as well as a high signal intensity area from the parietal to the occipital lobe on T2-weighted images. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12763349", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 179, 
          "text": "Cerebral hemiatrophy or Dyke-Davidoff-Masson syndrome is a condition characterized by seizures, facial asymmetry, contralateral hemiplegia or hemiparesis, and mental retardation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10029885", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 263, 
          "offsetInEndSection": 507, 
          "text": "The radiological features are unilateral loss of cerebral volume and associated compensatory bone alterations in the calvarium, like thickening, hyperpneumatization of the paranasal sinuses and mastoid cells and elevation of the petrous ridge. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10029885", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "We reported a 39-year-old man with Dyke-Davidoff-Masson syndrome presenting with total hemiatrophy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8997138", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 238, 
          "offsetInEndSection": 623, 
          "text": "This paper presents an 18-year-old mentally retarded patient with cerebral hemiatrophy (Dyke-Davidoff-Masson syndrome) associated with a growing skull fracture in the ipsilateral hemicranium, in whom not only a dural tear but also the ipsilaterally displaced and dilated lateral ventricle due to the original disease apparently contributed to the development of growing skull fracture.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7761171", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 264, 
          "text": "The magnetic resonance (MR) findings of three patients with cerebral hemiatrophy, the so-called Dyke-Davidoff-Masson syndrome, which is characterized by variable degrees of unilateral loss of cerebral volume and compensatory changes of the calvarium are presented.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1547482", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which receptor is targeted by telcagepant?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23975906", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23798725", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23196486", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22816019", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22512641", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22278333", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22221076", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22090312", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21631478", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21480950", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21457238", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21383046", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21350792", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21221171", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21110235", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21070230", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21070229", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21054362", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20974601", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20954694", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20937606", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20855369", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20826335", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20573757", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20433208", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20416945", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20188075", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20173082", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20164785", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20120204", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20099900", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20078608", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23480465", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19939188", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19914210", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19796656", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19795182", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19779958", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19770473", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19737844", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19579177", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19551474", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19469188", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19346171", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19219746", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19157980", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19084002", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18991732", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19036425", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18808506", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18799366", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18590336", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18217201", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18039958", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17929795", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17914062"
      ], 
      "type": "factoid", 
      "id": "55032efde9bde69634000035", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 184, 
          "text": "In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23975906", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23798725", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 684, 
          "offsetInEndSection": 963, 
          "text": "Olcegepant is the first selective CGRP receptor antagonist of proven efficacy in migraine. Olcegepant could only be administered intravenously and never taken beyond Phase II. Telcagepant is orally available and several completed Phase III trials have revealed positive results. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196486", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22816019", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 599, 
          "offsetInEndSection": 765, 
          "text": "Four chemically unrelated CGRP receptor (CGRP-R) antagonists (olcegepant, telcagepant, MK-3207 and BI 44370 TA) have displayed efficacy in the treatment of migraine. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22512641", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 122, 
          "text": "Telcagepant is a calcitonin gene-related peptide (CGRP) receptor antagonist being evaluated for acute migraine treatment. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22278333", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 106, 
          "offsetInEndSection": 328, 
          "text": "BACKGROUND: Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine treatment in patients with cardiovascular disease, a population for whom triptans are contraindicated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22221076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 493, 
          "offsetInEndSection": 683, 
          "text": "The calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096 BS), telcagepant (MK-0974), MK3207, and BI 44370 TA-are effective in treating acute migraine. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22090312", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 314, 
          "offsetInEndSection": 438, 
          "text": "Telcagepant, a calcitonin gene-related peptide receptor antagonist, is being developed for the acute treatment of migraine. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21631478", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 143, 
          "text": "The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21480950", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "AIMS: To assess the effect of the calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on the haemodynamic response to sublingual nitroglycerin (NTG). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21480950", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 158, 
          "offsetInEndSection": 307, 
          "text": "BACKGROUND: Telcagepant is an oral calcitonin gene-related peptide receptor antagonist which is being evaluated for the acute treatment of migraine. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21457238", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "BACKGROUND: The calcitonin gene-related peptide (CGRP) receptor antagonists olcegepant and telcagepant are very potent drugs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21383046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 841, 
          "offsetInEndSection": 995, 
          "text": "CONCLUSION: The apparently high doses of CGRP receptor antagonists, olcegepant and telcagepant needed for anti-migraine effect are not so high after all. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21383046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 207, 
          "text": "Dose-response curves for headaches relief and adverse events (AEs) are presented for five triptans: sumatriptan, zolmitriptan, naratriptan, almotriptan, and frovatriptan, and the CGRP antagonist telcagepant.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21350792", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 152, 
          "text": "INTRODUCTION: Telcagepant (MK-0974) is a novel, orally active and selective CGRP receptor antagonist being investigated for acute treatment of migraine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21221171", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1175, 
          "offsetInEndSection": 1469, 
          "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstrictor approach to treating acute migraine. Olcegepant (BIBN4096BS) and telcagepant (MK-0974) have been shown to be safe and effective in phase I, II, and (for telcagepant) phase III clinical trials. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21110235", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 119, 
          "offsetInEndSection": 263, 
          "text": "Background.- Telcagepant is a calcitonin gene-related peptide (CGRP) receptor antagonist being investigated for the acute treatment of migraine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21070230", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 216, 
          "text": "In 3 randomized clinical trials (n = 1585) the calcitonin gene-related peptide antagonist telcagepant 300 mg orally had an incidence of adverse events similar to placebo when used in the acute treatment of migraine. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21070229", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 99, 
          "offsetInEndSection": 246, 
          "text": "BACKGROUND: Telcagepant is an oral calcitonin gene-related peptide receptor antagonist with acute antimigraine efficacy comparable to oral triptans", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21054362", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 185, 
          "text": "METHODS: This study evaluated the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across four attacks.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20974601", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "A highly efficient, asymmetric synthesis of telcagepant (1), a CGRP receptor antagonist for the treatment of migraine, is described", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20954694", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "Asymmetric synthesis of telcagepant, a CGRP receptor antagonist for the treatment of migraine.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20954694", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 219, 
          "text": "Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20937606", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 289, 
          "offsetInEndSection": 623, 
          "text": "METHODS: The aim of this study was to evaluate new composite efficacy-plus-tolerability endpoints based on a post-hoc analysis of patient-level data from a previous randomized, placebo-controlled trial of the calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, and zolmitriptan in the acute treatment of migraine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20937606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 111, 
          "text": "Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20855369", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 182, 
          "offsetInEndSection": 375, 
          "text": "MATERIALS AND METHODS: We investigated the effect of the CGRP receptor antagonist, telcagepant, on CGRP-induced cranial vasodilatation in human isolated cerebral and middle meningeal arteries. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20855369", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1102, 
          "offsetInEndSection": 1328, 
          "text": "CONCLUSIONS: Our findings provide morphological and functional data on the presence of CGRP receptors in cerebral and meningeal arteries, which illustrates a possible site of action of telcagepant in the treatment of migraine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20855369", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20573757", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 287, 
          "offsetInEndSection": 585, 
          "text": "We therefore investigated the effects of the antimigraine CGRP receptor antagonist telcagepant (MK-0974) [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-yl)piperidine-1-carboxamide] on human isolated coronary arteries. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20573757", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1861, 
          "offsetInEndSection": 2060, 
          "text": "These findings in vitro support the cardiovascular safety of CGRP receptor antagonists and suggest that telcagepant is unlikely to induce coronary side effects under normal cardiovascular conditions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20573757", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1115, 
          "offsetInEndSection": 1482, 
          "text": "Towards this end, the non-peptide CGRP receptor antagonists olcegepant and telcagepant have been shown to be effective in the acute treatment of migraine. While telcagepant is being pursued as a frontline abortive migraine drug in a phase III clinical trial, an oral formulation of a novel CGRP receptor antagonist, BI 44370, is currently in phase II clinical trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20433208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 229, 
          "offsetInEndSection": 340, 
          "text": "Telcagepant represents a new class of antimigraine drug-the calcitonin gene-related peptide receptor blockers. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20416945", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 406, 
          "offsetInEndSection": 634, 
          "text": "The CGRP receptor antagonists telcagepant and olcegepant (BIBN4096BS) have demonstrated clinical efficacy in the treatment of migraine and there is now a need to better understand how these molecules interact with the receptor. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20188075", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 147, 
          "text": "Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20173082", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 176, 
          "text": "Telcagepant is a novel, orally active, and selective calcitonin gene-related peptide receptor antagonist being developed for acute treatment of migraine with and without aura. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20173082", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 249, 
          "text": "Studies were conducted in human isolated coronary arteries to explore the vascular effects of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant and to compare its coronary vasoconstrictive potential to that of zolmitriptan. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20164785", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 662, 
          "offsetInEndSection": 848, 
          "text": "Intravenous BIBN4096BS (olcegepant) and oral MK-0974 (telcagepant), two CGRP-receptor antagonists, were safe and effective in the treatment of migraine attacks in Phase I and II trials. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120204", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is  the clinical value of naltrexone in Parkinson's disease patients?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22426027", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7969211", 
        "http://www.ncbi.nlm.nih.gov/pubmed/152622"
      ], 
      "type": "summary", 
      "id": "55033064e9bde69634000036", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 93, 
          "text": "Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426027", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 535, 
          "offsetInEndSection": 685, 
          "text": "These patients responded poorly to serotonin reuptake inhibitors, whereas treatment with opioid antagonist naltrexone resulted in the remission of PG.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426027", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 843, 
          "offsetInEndSection": 948, 
          "text": "CONCLUSIONS: The opioid antagonist naltrexone could be an effective option for the treatment of PG in PD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426027", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 282, 
          "offsetInEndSection": 350, 
          "text": "No improvement in the clinical features of either disorder was noted", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/152622", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 415, 
          "offsetInEndSection": 529, 
          "text": "Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the role of venous angioplasty in multiple sclerosis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24255092", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23953830", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23948669", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23809937", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23781006", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23701076", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23691321", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23660636", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23563645", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23523158", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23493652", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23443168", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23419569", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23402260", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23301864", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23249660", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23235683", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23202144", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23034121", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22987234", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22951366", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22687168", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22648477", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22640501", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22577160", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22569567", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22496109", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22311713", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22155803", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22088659", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21876515", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21856578", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21839654", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21808631", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21803799", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21679067", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21487978", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21107001", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21106999", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21059535", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20373339", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20351675", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20351673", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19958985"
      ], 
      "type": "summary", 
      "id": "550331abe9bde69634000037", 
      "snippets": [
        {
          "offsetInBeginSection": 1850, 
          "offsetInEndSection": 1977, 
          "text": "Balloon angioplasty corrects blood pressure deviation in multiple sclerosis patients undergoing internal jugular vein dilation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255092", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 325, 
          "text": "PURPOSE: To investigate prevalence of extracranial abnormalities in azygos and internal jugular (IJ) veins using conventional venography and intravascular ultrasound (IVUS) in patients with multiple sclerosis (MS) being evaluated for chronic cerebrospinal venous insufficiency, a condition of vascular hemodynamic dysfunction", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23953830", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "Feasibility and safety of endovascular treatment for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23948669", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 2026, 
          "offsetInEndSection": 2099, 
          "text": "CONCLUSIONS: Endovascular treatment for CCSVI appears feasible and safe. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23948669", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 204, 
          "offsetInEndSection": 433, 
          "text": "This report presents the case of a 45-year-old man with known MS and suspected CCSVI who had undergone previous internal jugular angioplasty and stenting. The patient reported dramatic improvement of symptoms after intervention. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23809937", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 565, 
          "offsetInEndSection": 851, 
          "text": "Open venous reconstruction of the internal jugular vein was performed with a spiral graft from the saphenous vein. The patient's symptoms improved for several weeks until the venous reconstruction occluded. This case is the first reported open venous reconstruction for suspected CCSVI.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23809937", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency in people with multiple sclerosis: a summary of a Cochrane systematic review.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23781006", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 398, 
          "text": "BACKGROUND: It has been recently hypothesised that chronic cerebrospinal venous insufficiency (CCSVI) may be an important factor in the pathogenesis of multiple sclerosis (MS). The proposed treatment for CCSVI is percutaneous transluminal angioplasty, also known as the 'liberation procedure', which is claimed to improve the blood flow in the brain, thereby alleviating some of the symptoms of MS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23781006", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1081, 
          "offsetInEndSection": 1262, 
          "text": "CONCLUSIONS: There is currently no high level evidence to support or refute the efficacy or safety of percutaneous transluminal angioplasty for treatment of CCSVI in people with MS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23781006", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1813, 
          "offsetInEndSection": 2019, 
          "text": "CONCLUSION: The results of the current study suggest that endovascular evaluation and management of chronic cerebrospinal venous insufficiency is safe, with low morbidity and no procedure-related mortality.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23701076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 819, 
          "offsetInEndSection": 945, 
          "text": "There are clinical trials ongoing or planned to treat chronic cerebrospinal venous insufficiency (CCSVI) through angioplasty. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23691321", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 166, 
          "text": "Percutaneous transluminal angioplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis: dichotomy between subjective and objective outcome scores.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23660636", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 234, 
          "text": "Some multiple sclerosis (MS) patients reported an improvement after percutaneous transluminal angioplasty (PTA) for chronic cerebrospinal venous insufficiency (CCSVI), despite the lack of correspondence with objective outcome scores. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23660636", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1141, 
          "offsetInEndSection": 1300, 
          "text": " Spontaneously performed approach to CCSVI does not improve clinical and MRI parameters, despite frequent subjective perception of quality of life improvement.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23660636", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 174, 
          "text": "Percutaneous angioplasty of internal jugular and azygous veins in patients with chronic cerebrospinal venous insufficiency and multiple sclerosis: early and mid-term results.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23563645", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 151, 
          "text": "Purpose: To assess the safety of endovascular treatment of chronic cerebrospinal venous insufficiency (CCSVI) in patients with multiple sclerosis (MS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23563645", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1341, 
          "offsetInEndSection": 1831, 
          "text": ".Conclusion: Endovascular treatment of the IJV and azygous veins in patients with CCSVI and MS is a safe procedure with no post-procedural complications followed by significant improvement of IJV flow haemodynamic parameters and decrease in the EDSS score. Whether CCSVI percutaneous treatment might affect clinical improvement in patients suffering from MS is yet to be seen after completion of major multicentric clinical trials, still it seems like that this procedure is not negligible.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23563645", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1654, 
          "offsetInEndSection": 1810, 
          "text": " CONCLUSIONS: PTA in patients with MS with CCSVI increased CSF flow and decreased CSF velocity, which are indicative of improved venous parenchyma drainage.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523158", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 288, 
          "text": "BACKGROUND: It has been postulated that Multiple sclerosis (MS) stems from a narrowing in the veins that drain blood from the brain, known medically as chronic cerebrospinal venous insufficiency, or CCSVI. It has been proposed that balloon angioplasty should alleviate the symptoms of MS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23493652", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 517, 
          "offsetInEndSection": 688, 
          "text": " The revival of this concept has generated major interest in media and patient groups, mainly driven by the hope that endovascular treatment of 'CCSVI' could alleviate MS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23443168", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 822, 
          "offsetInEndSection": 1022, 
          "text": " The data obtained here do generally not support the 'CCSVI' concept. Moreover, there are no methodologically adequate studies to prove or disprove beneficial effects of endovascular treatment in MS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23443168", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 230, 
          "text": "RATIONALE: It is estimated that some hundreds of Canadian patients with multiple sclerosis (MS) have journeyed abroad to avail themselves of 'liberation therapy' (venoplasty) following the initial report by Zamboni et al in 2009. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23419569", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1235, 
          "offsetInEndSection": 1400, 
          "text": "CONCLUSION: No objective improvement was found at one year in thirty MS subjects who had undergone venoplasty, although many reported a degree of subjective benefit.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23419569", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 128, 
          "offsetInEndSection": 274, 
          "text": "Zamboni et al. reported significant improvement in neurological outcomes in MS patients who underwent percutaneous transluminal angioplasty (PTA).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23301864", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1515, 
          "offsetInEndSection": 1733, 
          "text": "CONCLUSION: The study revealed that PTA in relapsing remitting MS patients was not associated with any neurological improvement. However, there was an increase in disease activity irrespective of the adherence to DMTs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23301864", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 161, 
          "text": "Serious complication of percutaneous angioplasty with stent implantation in so called \"chronic cerebrospinal venous insufficiency\" in multiple sclerosis patient.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23249660", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 943, 
          "offsetInEndSection": 1082, 
          "text": "We           strongly ask for restriction of PTA procedure in so called CCSVI, which concept           was not proven to be relevant to MS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23249660", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23235683", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 682, 
          "offsetInEndSection": 903, 
          "text": "The proposed treatment for CCSVI is percutaneous transluminal angioplasty, also known as the 'liberation procedure', which is claimed to improve the blood flow in the brain thereby alleviating some of the symptoms of MS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23235683", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2031, 
          "offsetInEndSection": 2222, 
          "text": "AUTHORS' CONCLUSIONS: There is currently no high level evidence to support or refute the efficacy or safety of percutaneous transluminal angioplasty for treatment of CCSVI in people with MS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23235683", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 692, 
          "offsetInEndSection": 796, 
          "text": "Significant improvement of clinical disability in relapsing-remitting patients was (P < 0.001) achieved.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23202144", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 465, 
          "offsetInEndSection": 647, 
          "text": "Data from a few small case series suggest possible improvement of the clinical course and quality of life by performing percutaneous balloon angioplasty (PTA) of the stenotic veins. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034121", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1275, 
          "offsetInEndSection": 1422, 
          "text": "CONCLUSION: In the case presented, PTA of the IJV confluence resulted in haemodynamic improvement despite the presence of IJV external compression.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22987234", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1543, 
          "offsetInEndSection": 1685, 
          "text": "CONCLUSIONS: Endovascular treatment of CCSVI in patients with MS appears to be a safe procedure resulting in significant clinical improvement.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22951366", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1728, 
          "offsetInEndSection": 1905, 
          "text": "Endovascular treatment of concurrent CCSVI seems to be safe and repeatable and may reduce annual relapse rates and cumulative disability in patients with relapsing-remitting MS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22687168", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1355, 
          "offsetInEndSection": 1495, 
          "text": "Therefore, any potentially harmful interventional treatment such as transluminal angioplasty and/or stenting should be strongly discouraged.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22648477", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 898, 
          "offsetInEndSection": 1173, 
          "text": "The work of Dr. Zamboni, et al, who reported that treating the venous stenoses causing CCSVI with angioplasty resulting in significant improvement in the symptoms and quality of life of patients with MS (2) has led to further interest in this theory and potential treatment. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22640501", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 237, 
          "offsetInEndSection": 493, 
          "text": "Regardless of this continued uncertainty surrounding the safety and efficacy of this therapy, MS patients from Canada, and other jurisdictions, are traveling abroad to receive central venous angioplasty and, unfortunately, some also receive venous stents. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22577160", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 898, 
          "offsetInEndSection": 1150, 
          "text": "Finally, no proven (i.e., based on strict scientific methodology and on the rules of evidence-based medicine) therapeutic effect of the \"liberation\" procedure (unblocking the extracranial venous obstruction using angioplasty) has been shown up to date.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22569567", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 759, 
          "offsetInEndSection": 957, 
          "text": "The angiographic and hemodynamic improvement was associated with improvement in symptomatology, most particularly in cognitive and constitutional symptoms that may be related to cerebrovenous flow. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496109", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1072, 
          "offsetInEndSection": 1287, 
          "text": " In conclusion, in this series, endovascular intervention to correct venous stenosis associated with multiple sclerosis was associated with improvement in symptoms possibly related to disturbed venous hemodynamics. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496109", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 932, 
          "offsetInEndSection": 1385, 
          "text": "Some investigators have proceeded to unblinded nonrandomized angioplasty and stenting procedures in patients with CCSVI, with anecdotal reports of symptom improvement. Because of conflicting data on the presence of CCSVI and the absence of controlled trials of CCSVI intervention, the current standard of clinical care is neither to evaluate multiple sclerosis (MS) patients for CCSVI anomalies, nor to intervene with procedures to alter such anomalies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22311713", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 478, 
          "offsetInEndSection": 640, 
          "text": "Endovascular treatment (percutaneous transluminal angioplasty (PTA) with or without stenting) of CCSVI was reported to be feasible with a minor complication rate.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155803", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1180, 
          "offsetInEndSection": 1363, 
          "text": "PTA seems to be an effective treatment for patients with CCVI and multiple sclerosis, However, randomized studies are warranted to establish the efficacy of this new treatment for MS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155803", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1577, 
          "offsetInEndSection": 1687, 
          "text": "CONCLUSIONS: Endovascular treatment of CCSVI is a safe procedure; there is a 1.6% risk of major complications.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22088659", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1589, 
          "offsetInEndSection": 1837, 
          "text": "CONCLUSIONS: The endovascular treatment in patients with MS and concomitant CCSVI did not have an influence on the patient's neurological condition; however, in the mid-term follow-up, an improvement in some quality-of-life parameters was observed.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876515", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 338, 
          "offsetInEndSection": 678, 
          "text": "Although there is no methodologically rigorous evidence to support this hypothesis presently, a considerable number of MS patients have undergone endovascular CCSVI procedures. Such procedures include angioplasty or stent placement in jugular and azygous veins. The safety and efficacy of these procedures is unknown, but not without risk. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21856578", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1148, 
          "offsetInEndSection": 1352, 
          "text": "CONCLUSIONS: As the debate about CCSVI and its relationship to MS continues, the complications and risks associated with venous stenting and angioplasty in jugular and azygous veins are becoming clearer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21856578", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1246, 
          "offsetInEndSection": 1358, 
          "text": "CONCLUSIONS: This study further confirms the safety of PTA treatment in patients with CCSVI associated with MS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21839654", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 336, 
          "offsetInEndSection": 581, 
          "text": "This review aims to describe the proposed association between CCSVI and MS, summarize the current data, and discuss the role of endovascular therapy and the need for rigorous randomized clinical trials to evaluate this association and treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808631", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1451, 
          "offsetInEndSection": 1544, 
          "text": "CONCLUSION: Endovascular therapy appears to be a safe and reliable method for treating CCSVI.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21679067", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 800, 
          "offsetInEndSection": 999, 
          "text": "In particular, the potential shift in treatment concepts possibly leading to an interventional treatment approach including balloon angioplasty and venous stent placement is currently being debated. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21487978", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1494, 
          "offsetInEndSection": 1688, 
          "text": "In conclusion, the present conclusive data confuting the theory of CCSVI in MS should lead to reluctance with respect to the interventional treatment of possible venous anomalies in MS patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21487978", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 141, 
          "offsetInEndSection": 315, 
          "text": "Although balloon angioplasty and stenting seem to be safe procedures, there are currently no data on the treatment of a large group of patients with this vascular pathology. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21107001", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1315, 
          "offsetInEndSection": 1564, 
          "text": "CONCLUSIONS: The procedures appeared to be safe and well tolerated by the patients, regardless of the actual impact of the endovascular treatments for venous pathology on the clinical course of multiple sclerosis, which warrants long-term follow-up.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21107001", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1185, 
          "offsetInEndSection": 1408, 
          "text": "Two pilot studies demonstrated the safety and feasibility in Day Surgery of the endovascular treatment of CCSVI by means of balloon angioplasty (PTA). It determines a significant reduction of postoperative venous pressure. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21106999", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1486, 
          "offsetInEndSection": 1625, 
          "text": "However, PTA seems to positively influence clinical and QoL parameters of the associated MS and warrants further randomized control trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21106999", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 520, 
          "offsetInEndSection": 700, 
          "text": "Furthermore, they have obtained apparent clinical improvement or stabilization by endovascular ballooning of points of obstruction in the great veins in some, at least temporarily.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21059535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 341, 
          "offsetInEndSection": 579, 
          "text": "A potential shift in the treatment paradigm of MS involving endovascular balloon angioplasty or venous stent placement has been proposed as well as conducted in small patient series. In some cases, it may have resulted in serious injury. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20373339", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1052, 
          "offsetInEndSection": 1264, 
          "text": " At present, invasive and potentially dangerous endovascular procedures as therapy for patients with MS should be discouraged until such studies have been completed, analyzed, and debated in the scientific arena.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20373339", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 730, 
          "offsetInEndSection": 1125, 
          "text": "She underwent percutaneous balloon angioplasty of the associated chronic cerebrospinal venous insufficiency (CCSVI), due to membranous obstruction of the proximal azygous vein, with severe stenosis of the left internal jugular vein. Treatment of the associated CCSVI made a parallel improvement in both clinical and neurophysiological parameters, allowing us to avoid high dose steroid therapy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20351675", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2113, 
          "offsetInEndSection": 2352, 
          "text": "CONCLUSIONS: PTA of venous strictures in patients with CCSVI is safe, and especially in patients with RR, the clinical course positively influenced clinical and QOL parameters of the associated MS compared with the preoperative assessment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19958985", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the major symptom of the Doose syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23941843", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23159713", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22780699", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22322415", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22266062", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21396429", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21351810", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20722665", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20472190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20301494", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19049588", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18990309", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17105462", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12073789", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10768159", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9184597", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8753132", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8891396", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8214350", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8243377", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1396420", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2115971"
      ], 
      "type": "factoid", 
      "id": "550342a8f8aee20f27000002", 
      "snippets": [
        {
          "offsetInBeginSection": 816, 
          "offsetInEndSection": 1011, 
          "text": "KD is particularly effective in myoclonic astatic epilepsy (MAE; Doose Syndrome) and West syndrome with 100% and 81.25% of the patients having a greater than 50% seizure reduction, respectively. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23941843", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 80, 
          "text": "Myoclonic astatic epilepsy (Doose syndrome) - a lamotrigine responsive epilepsy?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23159713", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "PURPOSE: Myoclonic astatic epilepsy (MAE, Doose syndrome) is a difficult to treat idiopathic generalized epilepsy of early childhood.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23159713", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "Herman Doose first described the generalized childhood epilepsy syndrome of myoclonic astatic epilepsy (MAE) in 1970, attributing a genetic cause from this first description. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22780699", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 410, 
          "offsetInEndSection": 704, 
          "text": "RECENT FINDINGS: In the past several years, neurologists are finding new indications to use these dietary treatments, perhaps even as first-line therapy, including infantile spasms, myoclonic-astatic epilepsy (Doose syndrome), Dravet syndrome, and status epilepticus (including FIRES syndrome).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22322415", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 120, 
          "text": "First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266062", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 187, 
          "text": "INTRODUCTION: We evaluated the long-term efficacy and tolerability of the orphan drug rufinamide (RUF) in children with pharmacoresistant myoclonic-astatic epilepsy (MAE, Doose syndrome).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266062", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 251, 
          "text": "Mutations in SCN1A gene, encoding the voltage-gated sodium channel \u03b11-subunit, are found to be associated with severe myoclonic epilepsy in infancy or Dravet syndrome (DS), but only rarely with the myoclonic astatic epilepsy (MAE, or Doose syndrome). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21396429", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1022, 
          "offsetInEndSection": 1305, 
          "text": "The difficulty early in the course of Lennox-Gastaut syndrome is distinguishing this diagnosis from severe myoclonic epilepsy of infancy (Dravet syndrome) or from myoclonic-astatic epilepsy (Doose syndrome), as the seizure patterns in these three syndromes may overlap at the onset. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21351810", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 66, 
          "text": "Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20722665", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 155, 
          "text": "Doose syndrome, otherwise traditionally known as myoclonic-astatic epilepsy, was first described as a unique epilepsy syndrome by Dr Hermann Doose in 1970.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20722665", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 536, 
          "offsetInEndSection": 769, 
          "text": "Of 38 patients, 22 had Lennox-Gastaut syndrome (58%); 6 had myoclonic-astatic epilepsy of Doose (16%); 5 had symptomatic generalized epilepsy, not otherwise specified (13%); and 5 had symptomatic localization-related epilepsy (13%). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20472190", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 872, 
          "offsetInEndSection": 1080, 
          "text": "With felbamate treatment, 6 patients (16%) became seizure free, including 4 of the 6 patients with myoclonic-astatic epilepsy of Doose; 24 patients (63%) had a greater than 50% reduction in seizure frequency.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20472190", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 547, 
          "offsetInEndSection": 738, 
          "text": "Less commonly observed phenotypes include myoclonic-astatic epilepsy (MAE or Doose syndrome), Lennox-Gastaut syndrome (LGS), infantile spasms, and vaccine-related encephalopathy and seizures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20301494", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 87, 
          "offsetInEndSection": 343, 
          "text": "This includes syndromes with multiple etiologies, including Lennox-Gastaut syndrome and infantile spasms; developmental syndromes of unknown etiology, such as Landau-Kleffner syndrome; and idiopathic epilepsies, such as myoclonic-astatic (Doose) epilepsy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19049588", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 188, 
          "offsetInEndSection": 303, 
          "text": "It should be considered early in the treatment of Dravet syndrome and myoclonic-astatic epilepsy (Doose syndrome). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18990309", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "The purpose of this article is to present a short review of the natural history of myoclonic astatic epilepsy (MAE; Doose syndrome) and the Lennox-Gastaut syndrome (LGS). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17105462", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "[Clinical case of the month. Myoclonic-astatic epilepsy in a young child (MAE) or Doose syndrome].", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12073789", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 601, 
          "offsetInEndSection": 771, 
          "text": "His refractory epilepsy which started 7 years ago shares symptoms and signs of both epilepsy with myoclonic-astatic seizures (Doose Syndrome) and Lennox-Gastaut Syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10768159", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 224, 
          "text": "PURPOSE: Before 1986, the spectrum of childhood epilepsies, including Lennox-Gastaut syndrome (LGS) and Doose syndrome (DS), known collectively as \"epilepsia myoclonica astatica,\" was believed to represent a single disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9184597", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 99, 
          "text": "We reported a 7-year-old girl with myoclonic-astatic epilepsy of early childhood (Doose syndrome). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8753132", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 451, 
          "offsetInEndSection": 1005, 
          "text": "Other myoclonic epilepsy syndromes with onset in the first year of life (Aicardi's Neonatal (Early) Myoclonic Encephalopathy, West's Syndrome, Dravet's Severe Myoclonic Epilepsy, and Dravet's Benign Myoclonic Epilepsy of Infancy), in early childhood (Lennox-Gastaut-Dravet Syndrome, Myoclonic Variant of Lennox Gastaut Dravet Syndrome, Myoclonic-Astatic Epilepsy of Doose, Benign Myoclonic Epilepsies (BME), or even in late childhood (Childhood Absence Epilepsy with myoclonias, vs. Myoclonic Absence Epilepsy) are probably genetically complex diseases. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8891396", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 176, 
          "text": "A study of epileptic drop attacks (EDA) by simultaneous video-polygraphic recordings was carried out in one epileptic patient with myoclonic astatic seizures (Doose syndrome). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8214350", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 627, 
          "offsetInEndSection": 981, 
          "text": "A number of variants or atypical forms have been proposed. As a result, differential diagnosis presents a major challenge and includes specific generalized epilepsies, i.e., metabolic or inflammatory; secondarily generalized epilepsies, i.e., those arising from the frontal lobe; and severe forms of idiopathic generalized epilepsy, i.e., Doose syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8243377", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Video-EEG analysis of drop seizures in myoclonic astatic epilepsy of early childhood (Doose syndrome).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1396420", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 972, 
          "offsetInEndSection": 1204, 
          "text": " The clinical and EEG pattern, the high familial incidence are shared by the Doose syndrome, of which the present series seems to be a subgroup, as are other well-defined syndromes: benign and severe myoclonic epilepsies of infancy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2115971", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List signaling molecules (ligands) that interact with the receptor EGFR?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24323361", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24204699", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24124521", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23959273", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23888072", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23821377", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23787814", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23729230", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23399900", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23382875", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23212918", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23099994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23089711", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22260327", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22247333", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21514161"
      ], 
      "type": "list", 
      "id": "55046d5ff8aee20f27000007", 
      "snippets": [
        {
          "offsetInBeginSection": 1085, 
          "offsetInEndSection": 1199, 
          "text": "the epidermal growth factor receptor (EGFR) ligands, such as epidermal growth factor (EGF) and amphiregulin (AREG)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24323361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1139, 
          "offsetInEndSection": 1247, 
          "text": " EGFR ligands epidermal growth factor (EGF), amphiregulin (AREG) and transforming growth factor alpha (TGF\u03b1)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24124521", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 72, 
          "offsetInEndSection": 97, 
          "text": " EGFR and its ligand EGF ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23959273", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 903, 
          "offsetInEndSection": 1058, 
          "text": "Among EGFR ligands, heparin-binding EGF-like growth factor, TGF-\u03b1 and Betacellulin (BTC) are produced in the tumor microenvironment of FDC-S at RNA level. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23888072", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 322, 
          "offsetInEndSection": 493, 
          "text": ". Plasma amphiregulin (AR), epidermal growth factor (EGF), transforming growth factor-\u03b1, and heparin binding-EGF were assessed by ELISA in 45 chemorefractory mCRC patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821377", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 346, 
          "offsetInEndSection": 414, 
          "text": "Among EGFR ligands, heparin-binding epidermal growth factor (HB-EGF)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23787814", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 357, 
          "offsetInEndSection": 521, 
          "text": " Of the six known EGFR ligands, transforming growth factor alpha (TGF\u03b1) was expressed more highly in triple-negative breast tumors than in tumors of other subtypes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729230", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 781, 
          "offsetInEndSection": 923, 
          "text": "the 7 known EGFR ligands (EGF, betacellulin, epiregulin, heparin-binding EGF, transforming growth factor-\u03b1 [TGF-\u03b1], amphiregulin, and epigen) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23399900", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1393, 
          "offsetInEndSection": 1472, 
          "text": "EGFR ligands based on the two affinity classes: EGF>HB-EGF>TGF-\u03b1>BTC>EPR>EPG>AR", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23382875", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 197, 
          "offsetInEndSection": 320, 
          "text": "In this article, however, we demonstrate that PEPD directly binds to and activates epidermal growth factor receptor (EGFR),", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23212918", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1559, 
          "offsetInEndSection": 1607, 
          "text": "four EGFR ligands (AR, HB-EGF, TGF-\u03b1, and EREG) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23099994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "Epidermal growth factor (EGF) family peptides are ligands for the EGF receptor (EGFR). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22260327", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 240, 
          "offsetInEndSection": 490, 
          "text": "oluble amphiregulin (AR), transforming growth factor alpha (TGF\u03b1), neuregulin 2 beta, and epigen stimulate greater EGFR coupling to cell proliferation and DNA synthesis than do EGF, betacellulin, heparin-binding EGF-like growth factor, and epiregulin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22260327", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 387, 
          "offsetInEndSection": 563, 
          "text": "Here, we demonstrate that histamine releases 2 EGFR ligands, amphiregulin and heparin-binding epidermal growth factor-like growth factor (HB-EGF), from airway epithelial cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247333", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 72, 
          "offsetInEndSection": 231, 
          "text": "mammalian EGFR ligands including EGF, TGF-\u03b1 (TGF\u03b1), amphiregulin (AREG), heparin-binding EGF-like growth factor (HB-EGF), betacellulin, epiregulin, and epigen.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21514161", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Explain the concept proteostasis.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24126073", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24094931", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24116849", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24079818", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23986914", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23986815", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23894132", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23833797", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23746257", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23463216", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23479439", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23119163"
      ], 
      "type": "summary", 
      "id": "55048939f8aee20f27000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Protein homeostasis, or proteostasis, refers to a proper balance between synthesis, maturation, and degradation of cellular proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126073", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 100, 
          "offsetInEndSection": 240, 
          "text": "Mechanisms that promote the homeostasis of the proteome, or proteostasis, can slow aging and decrease the incidence of age-related diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24094931", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 468, 
          "text": "The eukaryotic cell possesses specialized pathways to turn over and degrade redundant proteins and organelles. Each pathway is unique and responsible for degradation of distinctive cytosolic material. The ubiquitin-proteasome system and autophagy (chaperone-mediated, macro, micro and organelle specific) act synergistically to maintain proteostasis. Defects in this equilibrium can be deleterious at cellular and organism level, giving rise to various disease states.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24116849", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 232, 
          "offsetInEndSection": 268, 
          "text": " protein homeostasis (proteostasis) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24079818", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 207, 
          "text": "The folding biology common to all three kingdoms of life (Archaea, Bacteria, and Eukarya) is proteostasis. The proteostasis network (PN) functions as a \u201ccloud\u201d to generate, protect, and degrade the proteome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23986914", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 256, 
          "text": "Maintaining the dynamic proteome of a living cell in the face of an ever-changing environment depends on a fine-tuned balance of protein synthesis and protein degradation. Molecular chaperones exert key functions during protein homeostasis (proteostasis). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23986815", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 334, 
          "offsetInEndSection": 631, 
          "text": "This research highlighted the central importance of protein homeostasis, or proteostasis for short, defined as the cellular state in which the proteome is both stable and functional. It implicates an equilibrium between synthesis, folding, trafficking, aggregation, disaggregation and degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23894132", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 184, 
          "text": "Protein homeostasis, also called proteostasis, is critical for cellular health and its dysregulation is implicated in aging, cancer, metabolic disease, and neurodegenerative disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23833797", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 138, 
          "offsetInEndSection": 174, 
          "text": " protein homeostasis (proteostasis) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23746257", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 237, 
          "offsetInEndSection": 343, 
          "text": " Disruption of proteostasis is implicated in aging and the pathogenesis of numerous degenerative diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23746257", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "Protein homeostasis, proteostasis, is essential to understand cell function. Protein degradation is a crucial component of the proteostatic mechanisms of the cell.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23119163", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 494, 
          "text": "Maintaining correct cellular function is a fundamental biological process for all forms of life. A critical aspect of this process is the maintenance of protein homeostasis (proteostasis) in the cell, which is largely performed by a group of proteins, referred to as the protein quality control (PQC) network. This network of proteins, comprised of chaperones and proteases, is critical for maintaining proteostasis not only during favourable growth conditions, but also in response to stress. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23479439", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 205, 
          "offsetInEndSection": 521, 
          "text": "All organisms--Bacteria, Archaea and Eukarya--have evolved a protein homeostasis, or proteostasis, network comprising chaperones and folding factors, degradation components, signalling pathways and specialized compartmentalized modules that manage protein folding in response to environmental stimuli and variation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23463216", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which bone protein is used in archaelogy for dating and species identification?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24327307", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24019191", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22956324", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22517758", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22125157", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21959970", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21953954", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21953952", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21800128", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21606484", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20131322", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19899187", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18174420", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16921562", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16323185", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1910520"
      ], 
      "type": "factoid", 
      "id": "55054f8af73303d458000002", 
      "snippets": [
        {
          "offsetInBeginSection": 322, 
          "offsetInEndSection": 503, 
          "text": "Collagen was extracted from modern and archaeological cod bones using a weak HCl solution and analysed for its sulphur isotopic composition by isotope ratio mass spectrometry (IRMS)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24019191", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 346, 
          "offsetInEndSection": 514, 
          "text": "With the high sensitivity of current generation mass spectrometers, ZooMS provides a non-destructive and highly cost-effective method to characterise collagen peptides.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22956324", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "Archaeological bones are usually dated by radiocarbon measurement of extracted collagen. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22517758", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 262, 
          "offsetInEndSection": 451, 
          "text": "we describe three complementary preparative HPLC procedures suitable for separating and isolating single amino acids from bone collagen or hair keratin with minimal isotopic contamination. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22125157", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 388, 
          "offsetInEndSection": 508, 
          "text": "Bulk bone collagen isotopic analysis of 11 skeletons of Iron Age and Roman date gave a typical C(3) terrestrial signal (", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21959970", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 267, 
          "text": "Comparison of liquid chromatography-isotope ratio mass spectrometry (LC/IRMS) and gas chromatography-combustion-isotope ratio mass spectrometry (GC/C/IRMS) for the determination of collagen amino acid \u03b413C values for palaeodietary and palaeoecological reconstruction.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21953954", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 230, 
          "offsetInEndSection": 501, 
          "text": "Although the primary focus was the compound-specific stable carbon isotope analysis of bone collagen AAs, because of its growing application for palaeodietary and palaeoecological reconstruction, the results are relevant to any field where AA \u03b4(13)C values are required. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21953954", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 151, 
          "text": "In archaeological studies, the isotopic enrichment values of carbon and nitrogen in bone collagen give a degree of information on dietary composition. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21953952", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 107, 
          "text": "Liquid chromatography/isotope ratio mass spectrometry measurement of \u03b413C of amino acids in plant proteins.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21953952", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "A new procedure for extraction of collagen from modern and archaeological bones for 14C dating.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21800128", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 238, 
          "text": "Bones are potentially the best age indicators in a stratigraphic study, because they are closely related to the layer in which they are found. Collagen is the most suitable fraction and is the material normally used in radiocarbon dating.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21800128", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 733, 
          "offsetInEndSection": 932, 
          "text": "The developed strategy permitted unprecedented biochemical analyses of bone-matrix proteins, including collagen modifications, using nearly nanoscale amounts of exceptionally homogenous bone tissue. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21606484", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 185, 
          "text": "Amino acid delta13C analysis of hair proteins and bone collagen using liquid chromatography/isotope ratio mass spectrometry: paleodietary implications from intra-individual comparisons.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20131322", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 299, 
          "text": "We report a novel method for the chromatographic separation and measurement of stable carbon isotope ratios (delta(13)C) of individual amino acids in hair proteins and bone collagen using the LC-IsoLink system, which interfaces liquid chromatography (LC) with isotope ratio mass spectrometry (IRMS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20131322", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "Species identification by analysis of bone collagen using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19899187", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 419, 
          "offsetInEndSection": 612, 
          "text": "Analysis of the collagen from 32 different mammal species identified a total of 92 peptide markers that could be used for species identification, for example, in processed food and animal feed.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19899187", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 206, 
          "text": "We used authentication tests developed for ancient DNA to evaluate claims by Asara et al. (Reports, 13 April 2007, p. 280) of collagen peptide sequences recovered from mastodon and Tyrannosaurus rex fossils", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174420", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Analysis of amino acid 13C abundance from human and faunal bone collagen using liquid chromatography/isotope ratio mass spectrometry.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16921562", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 89, 
          "offsetInEndSection": 317, 
          "text": "Stable nitrogen (delta(15)N) and carbon (delta(13)C) isotope ratios were measured in bone collagen and dentine from human skeletons excavated from this site in order to establish a weaning curve in mid-Holocene hunter-gatherers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16323185", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 264, 
          "text": "Mass spectrometric analysis of the stable carbon isotope composition (13C/12C or delta 13C) of bone collagen from human remains recovered at archaeological sites provides a direct chemical method for investigating dietary patterns of prehistoric human populations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1910520", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1356, 
          "offsetInEndSection": 1541, 
          "text": "Coupled with more traditional archaeological methods, stable carbon isotope analysis of bone collagen can significantly enhance reconstruction of dietary patterns of prehistoric humans.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1910520", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which protein is the E3-ubiquitin ligase that targets the tumor suppressor p53 for proteasomal degradation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23150437", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23671280", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22666487", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23581014", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19934289", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18235222", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16339144", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16082221", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15632057", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15013777", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12832479", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11948425", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24174547", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21075307", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19166840"
      ], 
      "type": "factoid", 
      "id": "55058af6f73303d458000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 322, 
          "text": "p53 levels and activity are controlled in large part through regulated ubiquitination and subsequent destruction by the 26S proteasome. Monoubiquitination of p53 is mediated primarily by the RING-finger E3 ubiquitin ligase MDM2 and impacts p53 activity through modulation of p53 localization and transcription activities. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150437", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 222, 
          "text": "The RING domain E3 ubiquitin ligase Mdm2 is the master regulator of the tumor suppressor p53. It targets p53 for proteasomal degradation, restraining the potent activity of p53 and enabling cell survival and proliferation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23671280", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 359, 
          "text": "The p53 transcription factor and tumor suppressor is regulated primarily by the E3 ubiquitin ligase Mdm2, which ubiquitinates p53 to target it for proteasomal degradation. Aside from its ubiquitin ligase function, Mdm2 has been believed to be capable of suppressing p53's transcriptional activity by binding with and masking the transactivation domain of p53.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666487", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 300, 
          "text": "The regulation of p53 expression levels is critical in controlling p53 activity in normal and damaged cells. This is well illustrated by the E3 ubiquitin ligase MDM2 that targets p53 for proteasomal degradation under normal conditions and is essential for controlling p53 activity during development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23581014", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 232, 
          "text": "p53 is inactivated in many human malignancies through missense mutations or overexpression of the human homologue of Mdm2 (Hdm2), an E3 ubiquitin ligase that ubiquitinates p53, thereby promoting its proteasomal degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19934289", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 530, 
          "text": "Mdm2 has been thought to regulate the tumor suppressor p53 in two ways: by masking p53's access to transcriptional machinery, and by ubiquitinating p53, targeting it for proteasomal degradation. This dogma was recently challenged by data generated from knockin mice in which Mdm2's RING E3 ubiquitin ligase activity was abrogated by a single point mutation. The RING mutant Mdm2 is fully capable of binding with p53, yet cannot suppress p53 activity, suggesting that Mdm2 cannot block p53 by binding alone, without ubiquitination.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18235222", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 228, 
          "text": "MDM2 is an E3 ubiquitin ligase that regulates the proteasomal degradation and activity of proteins involved in cell growth and apoptosis, including the tumor suppressors p53 and retinoblastoma and the transcription factor E2F1. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16339144", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 322, 
          "text": "The p53 tumor suppressor protein has a major role in protecting genome integrity. Under normal circumstances Mdmx and Mdm2 control the activity of p53. Both proteins inhibit the transcriptional regulation by p53, while Mdm2 also functions as an E3 ubiquitin ligase to target both p53 and Mdmx for proteasomal degradation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16082221", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 515, 
          "text": "p53 is a critical coordinator of a wide range of stress responses. To facilitate a rapid response to stress, p53 is produced constitutively but is negatively regulated by MDM2. MDM2 can inhibit p53 in multiple independent ways: by binding to its transcription activation domain, inhibiting p53 acetylation, promoting nuclear export, and probably most importantly by promoting proteasomal degradation of p53. The latter is achieved via MDM2's E3 ubiquitin ligase activity harbored within the MDM2 RING finger domain.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15632057", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 260, 
          "text": "Mdm2 is a RING finger E3 ubiquitin ligase, which promotes ubiquitination and proteasomal degradation of the p53 tumor suppressor protein. Acetylation of p53 regulates p53's transcriptional activity and inhibits Mdm2-mediated p53 ubiquitination and degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15013777", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 325, 
          "text": "MDM2 is an E3 ubiquitin ligase that targets p53 for proteasomal degradation. Recent studies have shown, however, that the ring-finger domain (RFD) of MDM2, where the ubiquitin E3 ligase activity resides, is necessary but not sufficient for p53 ubiquitination, suggesting that an additional activity of MDM2 might be required.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12832479", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 355, 
          "text": "The Mdm2 proto-oncogene is amplified and over-expressed in a variety of tumors. One of the major functions of Mdm2 described to date is its ability to modulate the levels and activity of the tumor suppressor protein p53. Mdm2 binds to the N-terminus of p53 and, through its action as an E3 ubiquitin ligase, targets p53 for rapid proteasomal degradation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11948425", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 450, 
          "text": "The HDM2-p53 loop is crucial for monitoring p53 level and human pathologies. Therefore, identification of novel molecules involved in this regulatory loop is necessary for understanding the dynamic regulation of p53 and treatment of human diseases. Here, we characterized that the ribosomal protein L6 binds to and suppresses the E3 ubiquitin ligase activity of HDM2, and subsequently attenuates HDM2-mediated p53 polyubiquitination and degradation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24174547", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1229, 
          "offsetInEndSection": 1399, 
          "text": "Together, our study identifies the crucial function of RPL6 in regulating HDM2-p53 pathway, which highlights the importance of RPL6 in human genetic diseases and cancers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24174547", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 137, 
          "offsetInEndSection": 356, 
          "text": "Targeting the E3 ubiquitin ligase HDM2 can lead to a therapeutic surge in p53 levels. However, the efficacy of HDM2 inhibition can be compromised by overexpression of HDMX, an HDM2 homolog that binds and sequesters p53.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21075307", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "The p53 tumour suppressor protein is tightly controlled by the E3 ubiquitin ligase, mouse double minute 2 (MDM2), but maintains MDM2 expression as part of a negative feedback loop. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19166840", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What does mTOR stands for?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24312415", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24312355", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24311635", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24309100", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24307346", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24290217", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24295418", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24289602", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24287118", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24276258", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24270265"
      ], 
      "type": "factoid", 
      "id": "5505a587f73303d458000005", 
      "snippets": [
        {
          "offsetInBeginSection": 141, 
          "offsetInEndSection": 178, 
          "text": " mammalian target of rapamycin (mTOR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24312415", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 282, 
          "offsetInEndSection": 318, 
          "text": "mammalian target of rapamycin (mTOR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24312355", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 16, 
          "offsetInEndSection": 52, 
          "text": "mammalian target of rapamycin (mTOR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24311635", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 74, 
          "offsetInEndSection": 110, 
          "text": "mammalian target or rapamycin (mTOR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24309100", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 95, 
          "offsetInEndSection": 131, 
          "text": "mammalian target of rapamycin (mTOR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24307346", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 531, 
          "offsetInEndSection": 568, 
          "text": "mammalian target of rapamycin (mTOR) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24290217", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 45, 
          "offsetInEndSection": 82, 
          "text": " mammalian target of rapamycin (mTOR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24295418", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 77, 
          "offsetInEndSection": 111, 
          "text": " mammal target of rapamycin (mTOR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24289602", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 602, 
          "offsetInEndSection": 639, 
          "text": " mammalian target of rapamycin (mTOR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24287118", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 440, 
          "offsetInEndSection": 476, 
          "text": "mammalian Target of Rapamycin (mTOR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24276258", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 304, 
          "offsetInEndSection": 342, 
          "text": " mammalian target of rapamycin (mTOR) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24270265", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does the protein mTOR regulate autophagy?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24326530", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24275748", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24278483", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24275666", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24265855", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24255881", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24209762", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24131573", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24092929", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24024901", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23982275", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23940798"
      ], 
      "type": "yesno", 
      "id": "5505ad7ff73303d458000007", 
      "snippets": [
        {
          "offsetInBeginSection": 614, 
          "offsetInEndSection": 700, 
          "text": "autophagy is negatively regulated by the mammalian target of rapamycin receptor (mTOR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24326530", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 147, 
          "offsetInEndSection": 300, 
          "text": "Subjecting cells to starvation or rapamycin efficiently induces autophagy by inhibiting the MTOR signaling pathway triggering increased autophagic flux. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24275748", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 429, 
          "offsetInEndSection": 501, 
          "text": "Several pathways, including mTOR, have been shown to regulate autophagy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24278483", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1029, 
          "offsetInEndSection": 1205, 
          "text": "these results provide insights into the mechanism by which hyperactivation of mTORC1 promotes breast cancer progression through increasing autophagy and Akt activation in vivo.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24275666", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 78, 
          "offsetInEndSection": 126, 
          "text": " the canonical mTOR-controlled autophagy pathway", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265855", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2935, 
          "offsetInEndSection": 3019, 
          "text": "mTOR inhibition severely impairs liver regeneration and increases autophagy after PH", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255881", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 485, 
          "offsetInEndSection": 537, 
          "text": "mTOR remains at a high level and inhibits autophagy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24209762", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 120, 
          "text": "AKT is involved in granulosa cell autophagy regulation via mTOR signaling during rat follicular development and atresia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24131573", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 231, 
          "offsetInEndSection": 309, 
          "text": "mammalian target of rapamycin (mTOR), a major negative regulator of autophagy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24131573", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1593, 
          "offsetInEndSection": 1633, 
          "text": "mTOR suppresses granulosa cell autophagy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24131573", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1204, 
          "offsetInEndSection": 1275, 
          "text": "Mammalian target of rapamycin (mTOR), a potent suppressor of autophagy,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24092929", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 215, 
          "text": "The mTOR signaling pathway integrates inputs from a variety of upstream stimuli to regulate diverse cellular processes including proliferation, growth, survival, motility, autophagy, protein synthesis and metabolism", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24024901", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1156, 
          "offsetInEndSection": 1291, 
          "text": "The activation of mammalian target of rapamycin (mTOR) signaling pathway blocks the effects of ghrelin-induced autophagy and apoptosis,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23982275", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1516, 
          "offsetInEndSection": 1580, 
          "text": " inducing apoptosis and autophagy via the mTOR signaling pathway", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23982275", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 128, 
          "text": " The mTOR gene regulates cell growth by controlling mRNA translation, ribosome biogenesis, autophagy, and metabolism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23940798", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List markers for autophagy.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24291536", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24231340", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24255881", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24141623", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24126619", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23940944", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23822101", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23737395", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23727153", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23608825", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23626658", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23598404", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23437259", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23193914", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23182945", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23117929", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22652752", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22807527"
      ], 
      "type": "list", 
      "id": "5505b9ff8e1671127b000001", 
      "snippets": [
        {
          "offsetInBeginSection": 536, 
          "offsetInEndSection": 580, 
          "text": ". Light chain 3/Atg8 as an autophagy marker ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24291536", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 888, 
          "offsetInEndSection": 1235, 
          "text": "increased conversion of microtubule-associated protein, 1A/1B-light chain 3, from its cytosolic form (LC3B-I) to its lipidated form (LC3B-II), increased Beclin-1 levels, and increased acridine orange staining as determined by flow cytometry analysis, providing further evidence of \u03b3-tocotrienol-induced autophagy in these mammary cancer cell lines", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24231340", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 926, 
          "offsetInEndSection": 1070, 
          "text": "Western blotting was used to detect hepatic microtubule-associated protein 1 light chain 3 (LC3)-II protein expression as a marker for autophagy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255881", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1821, 
          "offsetInEndSection": 1844, 
          "text": "autophagy marker LC3-II", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255881", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 19, 
          "offsetInEndSection": 41, 
          "text": "autophagy marker LC3B ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141623", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 498, 
          "offsetInEndSection": 522, 
          "text": "the autophagy marker LC3", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126619", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 519, 
          "offsetInEndSection": 562, 
          "text": "autophagy marker molecules, p62 and LC3-II ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23940944", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1635, 
          "offsetInEndSection": 1742, 
          "text": " LC3-I into LC3-II and has been confirmed in multiple mammalian cell lines with multiple autophagy markers ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23822101", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 634, 
          "offsetInEndSection": 685, 
          "text": " light chain 3 (LC3), which is an autophagy marker.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737395", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 876, 
          "offsetInEndSection": 904, 
          "text": "LC3 (tfLC3) autophagy marker", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23727153", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 659, 
          "offsetInEndSection": 684, 
          "text": "the autophagy marker LC3,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23608825", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 624, 
          "offsetInEndSection": 731, 
          "text": "autophagy marker beclin 1 and microtubule-associated protein light chain 3 (LC3) were analyzed in control, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23626658", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 888, 
          "offsetInEndSection": 925, 
          "text": " LC3-II levels (an autophagy marker);", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23598404", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 851, 
          "offsetInEndSection": 918, 
          "text": "autophagy marker, microtubule-associated protein light chain3 (LC3)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23437259", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1229, 
          "offsetInEndSection": 1257, 
          "text": "the autophagy marker LC3B-II", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23193914", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 404, 
          "offsetInEndSection": 480, 
          "text": "utophagy marker protein microtubule-associated protein 1 light chain 3 (LC3)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182945", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 574, 
          "offsetInEndSection": 594, 
          "text": "autophagy marker LC3", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23117929", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 225, 
          "offsetInEndSection": 320, 
          "text": "We used the expression of LC3-II and BECN1 as well as SQSTM1 as markers of autophagy activity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22652752", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1082, 
          "offsetInEndSection": 1102, 
          "text": "autophagy marker LC3", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22807527", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List the components of mTOR Complex 2 (mTORC2).", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24077282", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24244675", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23673367", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23455608", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23049074", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22820188", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22773877", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22678916", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22595285", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22532249"
      ], 
      "type": "list", 
      "id": "5505c9008e1671127b000002", 
      "snippets": [
        {
          "offsetInBeginSection": 104, 
          "offsetInEndSection": 192, 
          "text": "mTOR is the major component of two protein complexes: mTOR complex 1 (mTORC1) and mTORC2", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24077282", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 222, 
          "offsetInEndSection": 259, 
          "text": " Rictor, an mTORC2-specific component", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24244675", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 888, 
          "offsetInEndSection": 960, 
          "text": "f Rictor (rapamycin-insensitive companion of mTOR), an mTORC2 component,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23673367", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 248, 
          "offsetInEndSection": 398, 
          "text": " The mammalian target of rapamycin (mTOR) complex 2 (mTORC2), which contains the regulatory protein Rictor (rapamycin-insensitive companion of mTOR), ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23455608", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 656, 
          "offsetInEndSection": 690, 
          "text": " Rictor, a key component of mTORC2", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23049074", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 793, 
          "offsetInEndSection": 841, 
          "text": "SIN1, a key component of mTOR complex 2 (mTORC2)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22820188", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 179, 
          "offsetInEndSection": 218, 
          "text": " the essential mTORC2 component rictor ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22773877", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 144, 
          "offsetInEndSection": 203, 
          "text": "Sin1 is an essential component of mTOR complex 2 (mTORC2). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22678916", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 782, 
          "offsetInEndSection": 844, 
          "text": " SIN1 or Rictor, two key components of mTOR complex 2 (mTORC2)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22595285", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 174, 
          "offsetInEndSection": 297, 
          "text": " Mammalian target of rapamycin complex 2 (mTORC2) is a kinase complex comprised of mTOR, Rictor, mSin1, mLST8/G\u03b2L and PRR5 ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22532249", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the structures formed when keratin molecules come together?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23396250", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23331681", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22963508", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22585043", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22507538", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22502568", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22250786", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22238362", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22168818", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21945137", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21844209", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21721843"
      ], 
      "type": "factoid", 
      "id": "5505db6a8e1671127b000003", 
      "snippets": [
        {
          "offsetInBeginSection": 512, 
          "offsetInEndSection": 619, 
          "text": " Keratins form the intermediate filaments of the cytoskeleton and provide scaffold structures within cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23396250", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 29, 
          "offsetInEndSection": 59, 
          "text": "keratin intermediate filaments", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23396250", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 612, 
          "offsetInEndSection": 642, 
          "text": "keratin intermediate filaments", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23331681", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 56, 
          "offsetInEndSection": 94, 
          "text": "keratin intermediate filament protein.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22963508", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 57, 
          "text": "Keratin is a protein in the intermediate filament family ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22963508", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 519, 
          "offsetInEndSection": 571, 
          "text": "Keratins are the intermediate filament (IF) proteins", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22585043", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 577, 
          "offsetInEndSection": 658, 
          "text": "squamous keratinocytes contain polymerized keratin intermediate filament bundles ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22507538", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 451, 
          "offsetInEndSection": 470, 
          "text": " keratin filaments ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22502568", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 385, 
          "offsetInEndSection": 506, 
          "text": " In this study, we have examined the distribution of four groups of IFs [cytokeratins (CKs), vimentin, desmin and lamins]", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22250786", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 547, 
          "offsetInEndSection": 571, 
          "text": "keratin filament network", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22238362", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 180, 
          "text": "An intact keratin 5/keratin 14 intermediate filament cytoskeleton is vital for the integrity of basal keratinocytes and for the development and maintenance of epidermal structures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22168818", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 860, 
          "offsetInEndSection": 903, 
          "text": "keratin intermediate filament cytoskeleton.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21945137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 846, 
          "offsetInEndSection": 864, 
          "text": "keratin filaments,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21844209", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1119, 
          "offsetInEndSection": 1148, 
          "text": "keratin filamentous network. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21721843", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What kind of chromatography is HILIC?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23217321", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23073287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22946920", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21737084", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21316059", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21238772"
      ], 
      "type": "factoid", 
      "id": "5505edac8e1671127b000005", 
      "snippets": [
        {
          "offsetInBeginSection": 2, 
          "offsetInEndSection": 96, 
          "text": "hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC LC-MS/MS) method", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23217321", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Hydrophilic-interaction liquid chromatography (HILIC) is a widely used technique for small polar molecule analysis ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23073287", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 383, 
          "offsetInEndSection": 417, 
          "text": "hydrophilic-interaction LC (HILIC)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22946920", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "A hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC LC-MS/MS) method ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21737084", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 60, 
          "offsetInEndSection": 107, 
          "text": "Hydrophilic Interaction Chromatography (HILIC) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21316059", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 295, 
          "offsetInEndSection": 365, 
          "text": "n this study a hydrophilic interaction chromatographic (HILIC) method ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21238772", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List the main proteases used for sample digestion in proteomics.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22324799", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20218731", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24168082", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24144163", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24136523", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24140975", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24133050", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24116745", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24106208", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24012793", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23943586", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23819575", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23792921", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23775586", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23728546", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23710360", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23703833", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23606249", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23580477", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23576383", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23454304"
      ], 
      "type": "list", 
      "id": "5505eed08e1671127b000006", 
      "snippets": [
        {
          "offsetInBeginSection": 1144, 
          "offsetInEndSection": 1199, 
          "text": "the consecutive use of endoproteinases LysC and trypsin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22324799", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1208, 
          "offsetInEndSection": 1226, 
          "text": " Asp-N to trypsin ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20218731", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 449, 
          "offsetInEndSection": 467, 
          "text": " tryptic digestion", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24168082", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1349, 
          "offsetInEndSection": 1363, 
          "text": "tryptic digest", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24144163", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 115, 
          "offsetInEndSection": 175, 
          "text": "enzymatic digestion is most commonly performed using trypsin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24144163", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 10, 
          "offsetInEndSection": 40, 
          "text": "chymotrypsin/trypsin digestion", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24136523", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 550, 
          "offsetInEndSection": 744, 
          "text": "In this method, chymotrypsin, single or in combination with trypsin, was used, which enabled to obtain proteolytic peptides from the hydrophobic regions and to identify new oil bodies' proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24136523", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 87, 
          "offsetInEndSection": 124, 
          "text": "proteins were digested by thermolysin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140975", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 13, 
          "offsetInEndSection": 30, 
          "text": "tryptic digestion", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24133050", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 95, 
          "offsetInEndSection": 123, 
          "text": "protein digestion by trypsin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24133050", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "Trypsin is an endoprotease commonly used for sample preparation in proteomics experiments", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24116745", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 54, 
          "offsetInEndSection": 72, 
          "text": "tryptic digestion ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24106208", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 176, 
          "offsetInEndSection": 200, 
          "text": "direct tryptic digestion", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24012793", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 277, 
          "offsetInEndSection": 295, 
          "text": " trypsin digestion", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23943586", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Tryptic digestion is an important component of most proteomics experiments", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23819575", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 637, 
          "offsetInEndSection": 753, 
          "text": "We evaluated nine trypsin-based digestion protocols, based on standard in-solution or on spin filter-aided digestion", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23792921", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 66, 
          "text": "Getting intimate with trypsin, the leading protease in proteomics.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23775586", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 593, 
          "offsetInEndSection": 633, 
          "text": "sample preparation via trypsin digestion", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728546", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 575, 
          "offsetInEndSection": 664, 
          "text": " in-gel digested with trypsin, chymotrypsin, Asp-N, or trypsin plus Asp-N in triplicate. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23710360", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "In this study, we examined the use of multiple proteases (trypsin, LysC, tandem LysC/trypsin) on both protein identification and quantification ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703833", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 471, 
          "offsetInEndSection": 503, 
          "text": "digested with LysC and trypsin, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23606249", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 696, 
          "offsetInEndSection": 720, 
          "text": "In-gel trypsin digestion", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23580477", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "Magnetic bead cellulose activated with divinyl sulfone was used for the immobilization of Staphylococcus aureus endoproteinase Glu-C (EC 3.4.21.19).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23576383", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 781, 
          "offsetInEndSection": 820, 
          "text": "protease digestion with AspN or trypsin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23454304", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19481088", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18192322", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17388107", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16772299", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10811908", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9033809", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8611507", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2540000"
      ], 
      "type": "factoid", 
      "id": "550618f58e1671127b000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 930, 
          "text": "The type 1 protein phosphatase (PP1) is a critical negative regulator of Ca(2+) cycling and contractility in the cardiomyocyte. In particular, it mediates restoration of cardiac function to basal levels, after beta-adrenergic stimulation, by dephosphorylating key phospho-proteins. PP1 is a holoenzyme comprised of its catalytic and auxiliary subunits. These regulatory proteins dictate PP1's subcellular localization, substrate specificity and activity. Amongst them, inhibitor-1 is of particular importance since it has been implicated as an integrator of multiple neurohormonal pathways, which finely regulate PP1 activity, at the level of the sarcoplasmic reticulum (SR). In fact, perturbations in the regulation of PP1 by inhibitor-1 have been implicated in the pathogenesis of heart failure, suggesting that inhibitor-1-based therapeutic interventions may ameliorate cardiac dysfunction and remodeling in the failing heart. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19481088", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 277, 
          "text": "Aberrant beta-adrenergic signaling and depressed calcium homeostasis, associated with an imbalance of protein kinase A and phosphatase-1 activities, are hallmarks of heart failure. Phosphatase-1 is restrained by its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18192322", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 144, 
          "offsetInEndSection": 333, 
          "text": "Using this technology, we showed that inhibition of the protein phosphatase 1, by its constitutively active inhibitor-1, significantly increases cardiac contractility and calcium handling. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17388107", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 857, 
          "offsetInEndSection": 1151, 
          "text": "Thus, long-term cardiac specific overexpression of the protein phosphatase 1 inhibitor-1 and the associated increases in cardiac contractility appear to herald changes in a rather small number of proteins, which may reflect important compensatory adaptations in a hyperdynamic heart [corrected]", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17388107", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 227, 
          "text": "Inhibitor-1 becomes a potent inhibitor of protein phosphatase 1 when phosphorylated by cAMP-dependent protein kinase at Thr(35). Moreover, Ser(67) of inhibitor-1 serves as a substrate for cyclin-dependent kinase 5 in the brain.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16772299", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 202, 
          "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase. Nonphosphorylated I-1 is inactive, whereas phosphorylated I-1 is a potent PP1 inhibitor. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10811908", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "Ser67-phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10811908", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 339, 
          "offsetInEndSection": 473, 
          "text": "PP1 activity was inhibited by protamine, heparin, okadaic acid (IC50 50 nM) and mammalian inhibitor-1 (IC50 2 nM). On the other hand. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9033809", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 463, 
          "text": "The cDNA encoding human brain protein phosphatase inhibitor-1 (I-1) was expressed in Escherichia coli. Following PKA phosphorylation at a threonine, recombinant human I-1 was indistinguishable from rabbit skeletal muscle I-1 as a potent and specific inhibitor of the type-1 protein serine/threonine phosphatase (PP1). N-Terminal phosphopeptides of I-1 that retained the selectivity of intact human I-1 highlighted a functional domain that mediates PP1 inhibition.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8611507", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 323, 
          "text": "Protein phosphatase inhibitor-1 was purified from bovine adipose tissue. The protein had an apparent molecular mass of 32 kDa by SDS/PAGE and a Stokes' radius of 3.4 nm. It was phosphorylated by cAMP-dependent protein kinase on a threonyl residue; this phosphorylation was necessary for inhibition of protein phosphatase-1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2540000", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 324, 
          "offsetInEndSection": 559, 
          "text": "Bovine adipose tissue inhibitor-1 was compared directly with rabbit skeletal muscle inhibitor-1 and with a 32000-Mr, dopamine- and cAMP-regulated phosphoprotein from bovine brain (DARPP-32), also an inhibitor of protein phosphatase-1. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2540000", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which protein phosphatases have been found to dephosphorylate phospholamban?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/1849481"
      ], 
      "type": "list", 
      "id": "5506a7a48e1671127b000008", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 785, 
          "text": "The protein phosphatases which dephosphorylate native, sarcoplasmic reticulum (SR)-associated phospholamban were studied in cardiac muscle extracts and in a Triton fraction prepared by detergent extraction of myofibrils, the latter fraction containing 70-80% of the SR-associated proteins present in the tissue. At physiological concentrations of free Mg2+ (1 mM), protein phosphatase 1 (PP1) accounted for approximately 70% of the total phospholamban phosphatase activity in these fractions towards either Ser-16 (the residue labelled by cAMP-dependent protein kinase, PK-A) or Thr-17 (the residue phosphorylated by an SR-associated Ca2+/calmodulin-dependent protein kinase). Protein phosphatase 2A (PP2A) and protein phosphatase 2C (PP2C) accounted for the remainder of the activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1849481", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23441899", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22119380", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22075452", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21903118", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21672583", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20447431", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19593760", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19423954", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18855935", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17727839", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17310075", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16960421", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16497099", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15878358", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16495765", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16842776", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15703202", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15678087", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15556149", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15231867", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11877314", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11408549"
      ], 
      "type": "factoid", 
      "id": "5506c3e38e1671127b00000a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 341, 
          "text": "The plasma membrane Na(+)/Ca(2+) exchanger (NCX) is a bidirectional ion transporter that couples the translocation of Na(+) in one direction with that of Ca(2+) in the opposite direction. This system contributes to the regulation of intracellular Ca(2+) concentration via the forward mode (Ca(2+) efflux) or the reverse mode (Ca(2+) influx).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23441899", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 891, 
          "offsetInEndSection": 1161, 
          "text": "Concerning the role of NCX in NO cytotoxicity, we have found, using the specific inhibitor of NCX 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400), that NCX is involved in NO-induced cytotoxicity in cultured microglia, astrocytes, and neuronal cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23441899", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 496, 
          "text": "The Na(+)/Ca(2+)exchanger (NCX) principal function is taking 1 Ca(2+) out of the cytoplasm and introducing 3 Na(+). The increase of cytoplasmic Na(+) concentration induces the NCX reverse mode (NCX(REV)), favoring Ca(2+) influx. NCX(REV) can be inhibited by: KB-R7943 a non-specific compound that blocks voltage-dependent and store-operated Ca(2+) channels; SEA0400 that appears to be selective for NCX(REV), but difficult to obtain and SN-6, which efficacy has been shown only in cardiomyocytes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22119380", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1050, 
          "offsetInEndSection": 1187, 
          "text": "SEA0400 (1 \u03bcM), a pharmacological inhibitor of NCX, significantly shortened the MAP duration (P < .01) and reduced dispersion (P < .05). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22075452", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 575, 
          "text": "We have recently shown that the Na(+)/Ca(2+) exchanger (NCX) is involved in nitric oxide (NO)-induced cytotoxicity in cultured astrocytes and neurons. However, there is no in vivo evidence suggesting the role of NCX in neurodegenerative disorders associated with NO. NO is implicated in the pathogenesis of neurodegenerative disorders such as Parkinson's disease. This study examined the effect of SEA0400, the specific NCX inhibitor, on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity, a model of Parkinson's disease, in C57BL/6J mice.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21903118", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 626, 
          "text": "The Na(+)/Ca(2+) exchanger (NCX) plays a role in the regulation of intracellular Ca(2+) levels, and nitric oxide (NO) is involved in many pathological conditions including neurodegenerative disorders. We have previously found that sodium nitroprusside (SNP), an NO donor, causes apoptotic-like cell death in cultured glial cells via NCX-mediated pathways and the mechanism for NO-induced cytotoxicity is cell type-dependent. The present study examined using the specific NCX inhibitor 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400) whether NCX is involved in NO-induced injury in cultured neuronal cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21672583", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 396, 
          "offsetInEndSection": 690, 
          "text": "In view of the previous observation that NO stimulates the activity of the Na(+)/Ca(2+) exchanger (NCX), this study examines the involvement of NCX in cytotoxicity. The specific NCX inhibitor SEA0400 blocked SNP-induced phosphorylation of ERK, JNK and p38 MAPK, and decrease in cell viability. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20447431", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 533, 
          "text": "The sodium-calcium exchanger (NCX) is one of the transporters contributing to the control of intracellular calcium (Ca(2+)) concentration by normally mediating net Ca(2+) efflux. However, the reverse mode of the NCX can cause intracellular Ca(2+) concentration overload, which exacerbates the myocardial tissue injury resulting from ischemia. Although the NCX inhibitor SEA0400 has been shown to therapeutically reduce myocardial injury, no in vivo technique exists to monitor intracellular Ca(2+) fluctuations produced by this drug.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19593760", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 146, 
          "text": "We examined the involvement of the Na(+)/Ca(2+) exchanger in the automaticity of the pulmonary vein myocardium with a specific inhibitor, SEA0400.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19423954", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 276, 
          "text": "We investigated the expression of Na(+)/Ca(2+) exchanger (NCX) and the functional role of NCX in retinal damage by using NCX1-heterozygous deficient mice (NCX1(+/-)) and SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy] phenoxy]-5-ethoxyaniline), a selective NCX inhibitor in vivo. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18855935", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 172, 
          "text": "SEA0400 is a selective inhibitor of the Na(+)/Ca(2+) exchanger having equal potencies to suppress both the forward and reverse mode operation of the Na(+)/Ca(2+) exchanger.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17727839", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "Involvement of the Na+/Ca2+ exchanger in ouabain-induced inotropy and arrhythmogenesis was examined with a specific inhibitor, SEA0400.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17310075", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 136, 
          "offsetInEndSection": 431, 
          "text": "In right ventricular papillary muscle isolated from guinea-pig ventricle, 1 microM SEA0400, which specifically inhibits the Na+/Ca2+ exchanger by 80%, reduced the ouabain (1 microM)-induced positive inotropy by 40%, but had no effect on the inotropy induced by 100 microM isobutyl methylxantine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17310075", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 389, 
          "text": "The effects of SEA0400, a selective inhibitor of the Na(+)/Ca(2+) exchanger (NCX), on Na(+)-dependent Ca(2+) uptake and catecholamine (CA) release were examined in bovine adrenal chromaffin cells that were loaded with Na(+) by treatment with ouabain and veratridine. SEA0400 inhibited Na(+)-dependent (45)Ca(2+) uptake and CA release, with the IC(50) values of 40 and 100 nM, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16960421", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 482, 
          "text": "Given the potential clinical benefit of inhibiting Na+/Ca2+ exchanger (NCX) activity during myocardial ischemia reperfusion (I/R), pharmacological approaches have been pursued to both inhibit and clarify the importance of this exchanger. SEA0400 was reported to have a potent NCX selectivity. Thus, we examined the effect of SEA0400 on NCX currents and I/R induced intracellular Ca2+ overload in mouse ventricular myocytes using patch clamp techniques and fluorescence measurements.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16497099", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1207, 
          "offsetInEndSection": 1349, 
          "text": "The results suggested that SEA0400 is a potent NCX inhibitor, which can protect mouse cardiac myocytes from Ca2+ overload during I/R injuries.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16497099", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 233, 
          "text": "The effect of SEA0400, a novel Na+-Ca2+ exchanger inhibitor, on mechanical and electrophysiological parameters of coronary-perfused guinea-pig right ventricular tissue preparation was examined during no-flow ischemia and reperfusion.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15878358", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 286, 
          "text": "The Ca2+ overload by Ca2+ influx via Na+/Ca2+ exchanger (NCX) is a critical mechanism in myocardial ischemia/reperfusion injury. We investigated protective effects of a novel selective inhibitor of NCX, SEA0400, on cardiac function and energy metabolism during ischemia and reperfusion.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16495765", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "The cardioprotective effects of SEA0400, a novel Na(+)-Ca(2+) exchanger inhibitor, were examined in isolated guinea pig myocardial tissue and ventricular myocytes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16842776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 403, 
          "text": "The effects of a new, potent, and selective inhibitor of the Na(+)/Ca(2+) exchange, SEA-0400 (SEA), on steady-state outward (forward exchange), inward (reverse exchange), and Ca(2+)/Ca(2+) transport exchange modes were studied in internally dialyzed squid giant axons from both the extra- and intracellular sides. Inhibition by SEA takes place preferentially from the intracellular side of the membrane.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15703202", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 3, 
          "offsetInEndSection": 256, 
          "text": "Using SEA0400, a potent and selective inhibitor of the Na+-Ca2+ exchanger (NCX), we examined whether NCX is involved in nitric oxide (NO)-induced disturbance of endoplasmic reticulum (ER) Ca2+ homeostasis followed by apoptosis in cultured rat microglia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15678087", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 327, 
          "text": "Activation of the Na+/Ca2+ exchanger may contribute to Ca2+ overload during reperfusion after transient ischemia. We examined the effects of 2-[4-[(2,5-difluorophenyl) methoxy]phenoxy]-5-ethoxyaniline (SEA0400), a selective inhibitor of Na+/Ca2+ exchange, on a canine model of ischemia/reperfusion injury (myocardial stunning).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15556149", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 392, 
          "text": "SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline) has recently been described as a potent and selective inhibitor of Na(+)-Ca(2+) exchange in cardiac, neuronal, and renal preparations. The inhibitory effects of SEA0400 were investigated on the cloned cardiac Na(+)-Ca(2+) exchanger, NCX1.1, expressed in Xenopus laevis oocytes to gain insight into its inhibitory mechanism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15231867", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 780, 
          "text": "The effects of 2-[4-[(2,5-difluorophenyl) methoxy]phenoxy]-5-ethoxyaniline (SEA0400), a newly synthesized Na(+)-Ca(2+) exchanger (NCX) inhibitor, on the NCX current and other membrane currents were examined in isolated guinea-pig ventricular myocytes and compared with those of 2-[2-[4-(4-nitrobenzyloxy) phenyl]ethyl]isothiourea (KB-R7943). SEA0400 concentration-dependently inhibited the NCX current with a 10 fold higher potency than that of KB-R7943; 1 microM SEA0400 and 10 microM KB-R7943 inhibited the NCX current by more than 80%. KB-R7943, at 10 microM, inhibited the sodium current, L-type calcium current, delayed rectifier potassium current and inwardly rectifying potassium current by more than 50%, but SEA0400 (1 microM) had no significant effect on these currents.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11877314", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 781, 
          "offsetInEndSection": 997, 
          "text": "These results indicate that SEA0400 is a potent and highly selective inhibitor of NCX, and would be a powerful tool for further studies on the role of NCX in the heart and the therapeutic potential of its inhibition.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11877314", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 254, 
          "text": "The effect of the newly synthesized compound 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400) on the Na+-Ca2+ exchanger (NCX) was investigated and compared against that of 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea (KB-R7943).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11408549", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 255, 
          "offsetInEndSection": 850, 
          "text": "In addition, the effects of SEA0400 on reperfusion injury in vitro and in vivo were examined. SEA0400 was extremely more potent than KB-R7943 in inhibiting Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia: IC50s of SEA0400 and KB-R7943 were 5 to 33 nM and 2 to 4 microM, respectively. SEA0400 at the concentration range that inhibited NCX exhibited negligible affinities for the Ca2+ channels, Na+ channels, K+ channels, norepinephrine transporter, and 14 receptors, and did not affect the activities of the Na+/H+ exchanger, Na+,K+-ATPase, Ca2+-ATPase, and five enzymes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11408549", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1340, 
          "offsetInEndSection": 1515, 
          "text": "These results indicate that SEA0400 is the most potent and selective inhibitor of NCX, and suggest that the compound may exert protective effects on postischemic brain damage.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11408549", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which protein phosphatase has been found to interact with the heat shock protein, HSP20?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24244723", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21493896"
      ], 
      "type": "factoid", 
      "id": "5506ce078e1671127b00000b", 
      "snippets": [
        {
          "offsetInBeginSection": 1120, 
          "offsetInEndSection": 1453, 
          "text": " Moreover, protein phosphatase-1 activity is regulated by two binding partners, inhibitor-1 and the small heat shock protein 20, Hsp20. Indeed, human genetic variants of inhibitor-1 (G147D) or Hsp20 (P20L) result in reduced binding and inhibition of protein phosphatase-1, suggesting aberrant enzymatic regulation in human carriers. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24244723", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 117, 
          "text": "Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493896", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 510, 
          "offsetInEndSection": 1420, 
          "text": " Hsp20 overexpression in intact animals resulted in significant enhancement of cardiac function, coupled with augmented Ca cycling and sarcoplasmic reticulum Ca load in isolated cardiomyocytes. This was associated with specific increases in phosphorylation of phospholamban (PLN) at both Ser16 and Thr17, relieving its inhibition of the apparent Ca affinity of SERCA2a. Accordingly, the inotropic effects of Hsp20 were abrogated in cardiomyocytes expressing nonphosphorylatable PLN (S16A/T17A). Interestingly, the activity of type 1 protein phosphatase (PP1), a known regulator of PLN signaling, was significantly reduced by Hsp20 overexpression, suggesting that the Hsp20 stimulatory effects are partially mediated through the PP1-PLN axis. This hypothesis was supported by cell fractionation, coimmunoprecipitation, and coimmunolocalization studies, which revealed an association between Hsp20, PP1, and PLN.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493896", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1564, 
          "offsetInEndSection": 1799, 
          "text": "Hsp20 is a novel regulator of sarcoplasmic reticulum Ca cycling by targeting the PP1-PLN axis. These findings, coupled with the well-recognized cardioprotective role of Hsp20, suggest a dual benefit of targeting Hsp20 in heart disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493896", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the subunits of the IkB protein kinase (IKK)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24266532", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24242761", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23294515", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22627374", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22301997", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21784860", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21603248", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21314234", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21294676", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20300203", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19830703", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19666475", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19079347", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17977820", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17924664"
      ], 
      "type": "list", 
      "id": "5506e2ff8e1671127b00000d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 169, 
          "text": "NEMO (NF-\u03baB essential modulator) associates with catalytic subunits IKK\u03b1 and IKK\u03b2 to form the I\u03baB kinase (IKK) complex and is a key regulator of NF-\u03baB pathway signaling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24266532", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 186, 
          "offsetInEndSection": 510, 
          "text": "All known NF-\u03baB activators converge on the IkappaB kinase (IKK) complex to activate the canonical and non-canonical NF-\u03baB pathways. The IKK complex contains two catalytic subunits (IKK\u03b1 and IKK\u03b2) and a regulatory subunit NEMO/IKK\u03b3 that regulates the canonical NF-\u03baB pathway, whereas IKK\u03b1 regulates the non-canonical pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24242761", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 110, 
          "text": "I\u03baB kinase (IKK) complex, the master kinase for NF-\u03baB activation, contains two kinase subunits, IKK\u03b1 and IKK\u03b2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23343355", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 410, 
          "offsetInEndSection": 555, 
          "text": " The IKK protein complex is comprised of IKK\u03b1, IKK\u03b2 and NEMO subunits, with IKK\u03b2 thought to play the dominant role in modulating NF-\u03baB activity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23294515", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 435, 
          "text": "The I\u03baB kinase (IKK) complex plays a crucial role in the activation of the transcription factor NF-\u03baB by phosphorylating an inhibitory molecule I\u03baB\u03b1. Recently, we showed that IKK2 (also called IKK\u03b2), a catalytic subunit of the IKK complex, induces immunoglobulin E-mediated degranulation in mast cells by phosphorylating SNAP-23, the target-membrane soluble N-ethylmaleimide-sensitive fusion factor attachment protein receptor (SNARE).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627374", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 154, 
          "offsetInEndSection": 474, 
          "text": "The depletion of any of the three subunits of the inhibitor of NF\u03baB (I\u03baB) kinase (IKK\u03b1, IKK\u03b2, IKK\u03b3/NEMO), each of which is essential for the canonical NF\u03baB activation pathway, limits autophagy induction by physiological or pharmacological triggers, while constitutive active IKK subunits suffice to stimulate autophagy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22301997", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 340, 
          "offsetInEndSection": 505, 
          "text": "NF-\u03baB activation is tightly regulated by the I\u03baB kinase (IKK) complex, which is composed of two catalytic subunits IKK\u03b1 and IKK\u03b2, and a regulatory subunit IKK\u03b3/NEMO.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21784860", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 414, 
          "offsetInEndSection": 583, 
          "text": "Activation of the classical NF-\u03baB pathway is mediated through the activity of the IKK kinase complex, which consists of a heterotrimer of IKK\u03b1, IKK\u03b2, and IKK\u03b3 subunits. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21603248", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 14, 
          "offsetInEndSection": 193, 
          "text": "NF-kB is a key regulator of inflammation and immunity in cancer development. The IkB kinase (IKK) is a multisubunit complex containing catalytic subunits termed IKK-\u03b1, -\u03b2 and -\u03b3. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21314234", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 220, 
          "offsetInEndSection": 369, 
          "text": "Activation of NF-\u03baB involves the I\u03baB kinase (IKK)-complex composed of two catalytic subunits, IKK\u03b1 and IKK\u03b2, and a regulatory scaffold protein, IKK\u03b3.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21294676", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 170, 
          "text": "The IKK kinase complex is the core element of the NF-kappaB cascade. It is essentially made of two kinases (IKKalpha and IKKbeta) and a regulatory subunit, NEMO/IKKgamma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20300203", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 171, 
          "offsetInEndSection": 275, 
          "text": "Additional components may exist, transiently or permanently, but their characterization is still unsure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20300203", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 162, 
          "offsetInEndSection": 363, 
          "text": "Activation of NF-kappaB subunits is regulated by the upstream IkappaB kinase (IKK) complex which contains IKKalpha, IKKbeta, and IKKgamma; the latter also known as NF-kappaB essential modulator (NEMO).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19830703", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 236, 
          "text": "Proinflammatory NF-kappaB activation requires the IkappaB (inhibitor of NF-kappaB) kinase (IKK) complex that contains two catalytic subunits named IKKalpha and IKKbeta and a regulatory subunit named NF-kappaB essential modulator (NEMO).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19666475", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 214, 
          "offsetInEndSection": 463, 
          "text": "Inhibition of NF-kappaB by suppressing the canonical NF-kappaB activation pathway, for instance by knockdown of the three subunits of the inhibitor of NF-kappaB (I kappaB) kinase (IKK) complex (IKK1, IKK2 and NEMO) triggers apoptosis in such cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19079347", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 350, 
          "text": "The IkappaB-Kinase (IKK) complex is a multisubunit protein complex crucial for signal-induced phosphorylation of the IkappaB proteins and thus controls the activity of the transcription factor NF-kappaB. Besides the two kinases IKKalpha and IKKbeta, the IKK complex contains NEMO/IKKgamma, an additional subunit with regulatory and adaptor functions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17977820", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 291, 
          "text": "Activation of a large multisubunit protein kinase, called the inhibitor kappaB kinase (IKK) complex, is central to the induction of the family of transcription factors nuclear factor kappaB. IKK is comprised of two catalytic subunits, IKKalpha and IKKbeta, and a regulatory IKKgamma subunit.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17924664", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the subunits of the transcription factor NF-kappaB in the canonical pathway activation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23636254", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22726116", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17686849"
      ], 
      "type": "list", 
      "id": "5506eca18e1671127b00000f", 
      "snippets": [
        {
          "offsetInBeginSection": 228, 
          "offsetInEndSection": 559, 
          "text": "In this study, we demonstrated that the HSV-1 UL42 protein, a DNA polymerase processivity factor, was a novel antagonism of the canonical NF-\u03baB signaling pathway. UL42 was shown to significantly suppress TNF-\u03b1 mediated NF-\u03baB activation. Co-immunoprecipitation experiment revealed that UL42 bound to the NF-\u03baB subunits p65 and p50. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23636254", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1010, 
          "offsetInEndSection": 1337, 
          "text": "Thus, it was first time we demonstrated that HSV-1 UL42 appeared to prevent NF-\u03baB-dependent gene expression by retaining p65 and p50 in the cytoplasm, and UL42-dependent transcriptional activation were inherently coupled to promote HSV-1 lytic replication, which also may contribute to immune evasion and pathogenesis of HSV-1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23636254", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 642, 
          "offsetInEndSection": 811, 
          "text": "The review describes NF-\u03baB and its two pathways: the canonical, mediated by the p65 and p50 subunits, and the non-canonical, mediated by the subunits RelB, p52 and p50. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22726116", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 198, 
          "offsetInEndSection": 725, 
          "text": "The function of the TTV open reading frame (ORF) in the nuclear factor kappaB (NF-kappaB) pathway has not yet been established. In this study, we found for the first time that the TTV ORF2 protein could suppress NF-kappaB activity in a dose-dependent manner in the canonical NF-kappaB pathway. By Western blot analysis, we proved that the TTV ORF2 protein did not alter the level of NF-kappaB expression but prevented the p50 and p65 subunits from entering the nucleus due to the inhibition of IkappaBalpha protein degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17686849", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 147, 
          "text": "Herpes simplex virus 1 DNA polymerase processivity factor UL42 inhibits TNF-\u03b1-induced NF-\u03baB activation by interacting with p65/RelA and p50/NF-\u03baB1.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23636254", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Which mutations in the cardiac isoform of the ryanodine receptor (RyR2) have been found to be related to CPVT?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23746327", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23498838", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23152493", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22828895", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21659649", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20676041", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18483626", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15890976", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14571276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12919952"
      ], 
      "type": "list", 
      "id": "550712739d0faaa527000008", 
      "snippets": [
        {
          "offsetInBeginSection": 575, 
          "offsetInEndSection": 737, 
          "text": "Recently, a novel CPVT RyR2 mutation, G230C, was found to increase the cytosolic, but not the luminal, Ca2+ sensitivity of single RyR2 channels in lipid bilayers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23746327", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1513, 
          "offsetInEndSection": 1743, 
          "text": "These data suggest that the G230C mutation enhances the propensity for SOICR by sensitizing the channel to luminal and cytosolic Ca2+ activation, and that G230C has an intrinsic structural impact on the N-terminal domains of RyR2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23746327", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 118, 
          "offsetInEndSection": 765, 
          "text": "The novel RYR2-S4153R mutation has been implicated as a cause of CPVT and atrial fibrillation. The mutation has been functionally characterized via store-overload-induced Ca(2+) release (SOICR) and tritium-labelled ryanodine ([(3)H]ryanodine) binding assays. The S4153R mutation enhanced propensity for spontaneous Ca(2+) release and reduced SOICR threshold but did not alter Ca(2+) activation of [(3)H]ryanodine binding, a common feature of other CPVT gain-of-function RYR2 mutations. We conclude that the S4153R mutation is a gain-of-function RYR2 mutation associated with a clinical phenotype characterized by both CPVT and atrial fibrillation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23498838", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 345, 
          "offsetInEndSection": 535, 
          "text": "To determine the molecular and cellular mechanisms by which a novel RyR2-V2475F mutation associated with CPVT in humans triggers Ca(2+)-dependent arrhythmias in whole hearts and intact mice.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152493", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1752, 
          "offsetInEndSection": 1888, 
          "text": "The mutation RyR2-V2475F is phenotypically strong among other CPVT mutations and produces heterogeneous mechanisms of RyR2 dysfunction. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152493", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 546, 
          "offsetInEndSection": 1117, 
          "text": "We generated 3 knock-in mice with mutations introduced into RyR2 that result in leaky channels and cause exercise induced polymorphic ventricular tachycardia in humans [catecholaminergic polymorphic ventricular tachycardia (CPVT)]. We examined AF susceptibility in these three CPVT mouse models harboring RyR2 mutations to explore the role of diastolic SR Ca2+ leak in AF. AF was stimulated with an intra-esophageal burst pacing protocol in the 3 CPVT mouse models (RyR2-R2474S+/-, 70%; RyR2-N2386I+/-, 60%; RyR2-L433P+/-, 35.71%) but not in wild-type (WT) mice (P<0.05).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22828895", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1300, 
          "offsetInEndSection": 1917, 
          "text": "The RyR2-G230C mutant exhibits similar biophysical defects compared with previously characterized CPVT mutations: decreased binding of the stabilizing subunit calstabin2 and a leftward shift in the Ca(2+) dependence for activation under conditions that simulate exercise, consistent with a \"leaky\" channel. Both RyR2-G230C and RyR2-P2328S channels exhibit normal luminal Ca(2+) activation. Thus, diastolic sarcoplasmic reticulum Ca(2+) leak caused by reduced calstabin2 binding and a leftward shift in the Ca(2+) dependence for activation by diastolic levels of cytosolic Ca(2+) is a common mechanism underlying CPVT.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21659649", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1058, 
          "offsetInEndSection": 1527, 
          "text": "A novel CPVT mutation, E189D, was identified. The E189D mutation does not alter the affinity of the channel for FKBP12.6, but it increases the propensity for store-overload-induced Ca(2+) release (SOICR). Furthermore, the E189D mutation enhances the basal channel activity of RyR2 and its sensitivity to activation by caffeine. The E189D RyR2 mutation is causative for CPVT and functionally increases the propensity for SOICR without altering the affinity for FKBP12.6.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20676041", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 468, 
          "offsetInEndSection": 731, 
          "text": "We found that mice heterozygous for the R2474S mutation in Ryr2 (Ryr2-R2474S mice) exhibited spontaneous generalized tonic-clonic seizures (which occurred in the absence of cardiac arrhythmias), exercise-induced ventricular arrhythmias, and sudden cardiac death. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18483626", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 952, 
          "offsetInEndSection": 1085, 
          "text": " Thus, CPVT-associated mutant leaky Ryr2-R2474S channels in the brain can cause seizures in mice, independent of cardiac arrhythmias.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18483626", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 313, 
          "offsetInEndSection": 503, 
          "text": "We screened 12 Finnish CPVT probands for mutations in these genes and identified three novel RYR2 mutations (V2306I, P4902L, R4959Q), which were absent in unaffected and control individuals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14571276", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 149, 
          "offsetInEndSection": 567, 
          "text": "RyR2 mutations suggested to cause defective Ca2+ channel function have recently been identified in catecholaminergic polymorphic ventricular tachycardia (CPVT) and arrhythmogenic right ventricular dysplasia (ARVD) affected individuals. We report expression of three CPVT-linked human RyR2 (hRyR2) mutations (S2246L, N4104K, and R4497C) in HL-1 cardiomyocytes displaying correct targeting to the endoplasmic reticulum. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12919952", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 683, 
          "offsetInEndSection": 942, 
          "text": "We developed a conditional knock-in mouse model carrier of the R4496C mutation, the mouse equivalent to the R4497C mutations identified in CPVT families, to evaluate if the animals would develop a CPVT phenotype and if beta blockers would prevent arrhythmias.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15890976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1466, 
          "offsetInEndSection": 1645, 
          "text": "These data provide the first experimental demonstration that the R4496C RyR2 mutation predisposes the murine heart to VT and VF in response caffeine and/or adrenergic stimulation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15890976", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where in a protein can a signal sequence be found?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21834515", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21572038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19453274", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18931123", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12551941", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11575719", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11231276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9624150", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9551364", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9013954", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8955395", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8077949", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8307567"
      ], 
      "type": "factoid", 
      "id": "550718e9fd1abe1741000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "A transmembrane domain (TMD) at the N-terminus of a membrane protein is a signal sequence that targets the protein to the endoplasmic reticulum (ER) membrane. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21834515", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 353, 
          "offsetInEndSection": 384, 
          "text": " an N-terminal signal sequence,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21572038", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 865, 
          "offsetInEndSection": 916, 
          "text": "soluble AMO possesses an N-terminal signal sequence", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19453274", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 614, 
          "offsetInEndSection": 669, 
          "text": "n N-terminal \"twin arginine\" signal sequence suggested ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18931123", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "Proteins destined for the mitochondrial matrix space have leader sequences that are typically present at the most N-terminal end of the nuclear-encoded precursor protein. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12551941", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 33, 
          "offsetInEndSection": 60, 
          "text": "N-terminal signal sequence ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11575719", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 884, 
          "offsetInEndSection": 957, 
          "text": "The predicted amino-acid sequence includes an N-terminal signal sequence ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11231276", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 502, 
          "offsetInEndSection": 560, 
          "text": "These N-terminal sequences lack a typical signal sequence ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9624150", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 324, 
          "offsetInEndSection": 448, 
          "text": " TAP can be bypassed by targeting peptides directly to the endoplasmic reticulum (ER) using NH2-terminal signal sequences. T", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9551364", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 379, 
          "offsetInEndSection": 415, 
          "text": "The amino terminal signal sequence, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9013954", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 562, 
          "offsetInEndSection": 615, 
          "text": "An amino-terminal domain containing a signal sequence", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8955395", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 143, 
          "offsetInEndSection": 340, 
          "text": "A nuclear localization signal (NLS) sequence was previously defined by point mutations in three short adjacent clusters of basic amino acids located in the amino-terminal region of the E1 protein. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8077949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 618, 
          "offsetInEndSection": 688, 
          "text": "he human homologue also contains a putative N-terminal signal sequence", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8307567", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the different isoforms of the mammalian Notch receptor?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23028706", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21356309", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16307184", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11732008"
      ], 
      "type": "list", 
      "id": "55072c803b8a5dc045000001", 
      "snippets": [
        {
          "offsetInBeginSection": 346, 
          "offsetInEndSection": 597, 
          "text": "Here, we investigate protein interactions between NOTCH3 and other vascular Notch isoforms and characterize the effects of elevated NOTCH3 on smooth muscle gene regulation. We demonstrate that NOTCH3 forms heterodimers with NOTCH1, NOTCH3, and NOTCH4.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23028706", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1165, 
          "offsetInEndSection": 1388, 
          "text": "We conclude that CADASIL mutants of NOTCH3 complex with NOTCH1, 3, and 4, slow NOTCH3 clearance, and that overexpressed wild type and mutant NOTCH3 protein interfere with key NOTCH-mediated functions in smooth muscle cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23028706", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 245, 
          "text": "In the vertebrate embryo, skeletal muscle is derived from the myotome of the somites. Notch1-3 demonstrate overlapping and distinct expression patterns in mouse somites. Notch1 and Notch2 have been shown to be inhibitors of skeletal myogenesis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21356309", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 489, 
          "offsetInEndSection": 684, 
          "text": "In this study, we analyzed the immunohistochemical staining pattern of four Notch receptors (Notch1-4) and their ligands (Delta1 and Jagged1) in 14 synovial tissues obtained from 14 RA patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16307184", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 161, 
          "text": "Notch signaling is an evolutionarily conserved mechanism, used to regulate cell fate decisions. Four Notch receptors have been identified in man (Notch-1 to -4).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11732008", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 409, 
          "offsetInEndSection": 658, 
          "text": "All 4 receptors were expressed in the adult liver, with no significant differences in the levels of Notch-1, -2, and -4 messenger RNA (mRNA) between normal and diseased liver. However, Notch-3 expression appeared to be increased in diseased tissue. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11732008", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the RNA sequence of the canonical polyadenylation signal?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19169861", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19041263", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19032167", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24177577", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24152550", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22535384", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22306880", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22056681", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21943048", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19597839", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19509282", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18658125"
      ], 
      "type": "factoid", 
      "id": "550739cf3b8a5dc045000002", 
      "snippets": [
        {
          "offsetInBeginSection": 373, 
          "offsetInEndSection": 430, 
          "text": ". Two putative polyadenylation signal sequences (AATAAA) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 397, 
          "offsetInEndSection": 435, 
          "text": "polyadenylation signal sequence AATAAA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19041263", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 83, 
          "offsetInEndSection": 117, 
          "text": "The most canonical AAUAAA hexamer ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19032167", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 326, 
          "offsetInEndSection": 362, 
          "text": "polyadenylation signal site (AATAAA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24177577", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 303, 
          "offsetInEndSection": 330, 
          "text": "the canonical AATAAA motif ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24152550", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 660, 
          "offsetInEndSection": 717, 
          "text": "with a classical  polyadenylation signal sequence AATAAA,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22535384", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 192, 
          "offsetInEndSection": 237, 
          "text": "AATAAA hexanucleotide polyadenylation signal.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22306880", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 412, 
          "offsetInEndSection": 447, 
          "text": "olyadenylation signal site (AATAAA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22056681", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 382, 
          "offsetInEndSection": 411, 
          "text": "polyadenylation signal AATAAA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21943048", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 24, 
          "offsetInEndSection": 54, 
          "text": "polyadenylation signal AAUAAA ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19597839", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 389, 
          "offsetInEndSection": 418, 
          "text": "polyadenylation signal AAUAAA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19509282", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 77, 
          "offsetInEndSection": 176, 
          "text": "A polyadenylation signal (AAUAAA) nearby the 3' end of pre-mRNA is required for poly(A) synthesis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18658125", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are mutations in the STXBP1 gene associated with epilepsy?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24315539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24189369", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24170257", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24095819", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23531706", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23409955", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22787626", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22787616", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22722545", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22709267", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22612257", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22596016", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21967765", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21762454", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21770924", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21753172", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21364700", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21062273", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20887371", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20887364", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20876469", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20845763", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20493457", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19557857", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18469812", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21204804", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21277190"
      ], 
      "type": "yesno", 
      "id": "550748a3bde8548216000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 80, 
          "text": "Folinic acid responsive epilepsy in Ohtahara syndrome caused by STXBP1 mutation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24315539", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "A novel mutation in STXBP1 gene in a child with epileptic encephalopathy and an atypical electroclinical pattern.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24170257", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 246, 
          "text": "Mutations in STXBP1 gene, encoding the syntaxin binding protein 1, have been recently described in Ohtahara syndrome, or early infantile epileptic encephalopathy with suppression-burst pattern, and in other early-onset epileptic encephalopathies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24170257", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 278, 
          "text": "STXBP1 (MUNC18.1), encoding syntaxin binding protein 1, has been reported in Ohtahara syndrome, a rare epileptic encephalopathy with suppression burst pattern on EEG, in patients with infantile spasms and in a few patients with nonsyndromic mental retardation without epilepsy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24095819", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 176, 
          "offsetInEndSection": 368, 
          "text": "ed with severe developmental delay and poor prognosis. Mutations and deletions in the STXBP1 gene are associated with Ohtahara syndrome, also known as \"early infantile epileptic encephalopathy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23531706", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 204, 
          "offsetInEndSection": 382, 
          "text": "Here we show that de novo heterozygous mutations in the gene encoding STXBP1, also known as MUNC18-1, which is essential in synaptic vesicle release in multiple species, cause OS", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787616", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1105, 
          "offsetInEndSection": 1278, 
          "text": "STXBP1 haploinsufficiency results in progressive encephalopathy characterized by intellectual disability and may be accompanied by epilepsy, movement disorders, and autism. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722545", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 242, 
          "text": "Mutations of the syntaxin binding protein 1 (STXBP1) have been associated with severe infantile epileptic encephalopathies (Ohtahara syndrome and West syndrome), but also with moderate to severe cognitive impairment and nonsyndromic epilepsy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22596016", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 66, 
          "text": "A novel STXBP1 mutation causes focal seizures with neonatal onset.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22596016", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "STXBP1 mutations in early infantile epileptic encephalopathy with suppression-burst pattern.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20887364", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 10, 
          "offsetInEndSection": 148, 
          "text": "e novo STXBP1 mutations have been found in individuals with early infantile epileptic encephalopathy with suppression-burst pattern (EIEE)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20887364", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1876, 
          "offsetInEndSection": 2087, 
          "text": "Mutations in STXBP1 are relatively frequent in patients with infantile epileptic encephalopathies. STXBP1-related encephalopathy may present as drug-responsive infantile spasms with focal/lateralized discharges.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21762454", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 65, 
          "text": "De novo SCN1A mutations in migrating partial seizures of infancy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21753172", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18469812", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 170, 
          "text": "Mutations in STXBP1 have been identified in a subset of patients with early onset epileptic encephalopathy (EE), but the full phenotypic spectrum remains to be delineated", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23409955", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 621, 
          "offsetInEndSection": 704, 
          "text": "and STXBP1-related West/Ohtahara syndromes, are due to a mutation in a unique gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787626", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 720, 
          "offsetInEndSection": 829, 
          "text": "This is the first case report showing that STXBP1 mutations caused West syndrome from the onset of epilepsy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21204804", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the definition and the biological role of epithelial-mesenchymal transition (EMT)", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24090504", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22844540", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24278531", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20819124", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19249648", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17922020", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14644200"
      ], 
      "type": "summary", 
      "id": "55074fa8bde8548216000003", 
      "snippets": [
        {
          "offsetInBeginSection": 547, 
          "offsetInEndSection": 711, 
          "text": "Epithelial-to-mesenchymal transition (EMT) is a process known to contribute to metastasis in cancer and it is mainly characterized by loss of E-cadherin expression.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24090504", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 712, 
          "offsetInEndSection": 957, 
          "text": "The TGF-\u03b2 signaling pathway has an established role in promoting EMT by down-regulating E-cadherin via a number of transcription factors, such as Twist, Snail and Slug. EMT has also been reported to produce cells with stem cell-like properties. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24090504", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Epithelial to mesenchymal transition (EMT) has been hypothesized as a mechanism by which cells change phenotype during carcinogenesis, as well as tumor metastasis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22844540", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 532, 
          "text": "Epithelial-mesenchymal transition (EMT) is a complex process in which epithelial cells acquire the characteristics of invasive mesenchymal cells. EMT has been implicated in cancer progression and metastasis as well as the formation of many tissues and organs during development. Epithelial cells undergoing EMT lose cell-cell adhesion structures and polarity, and rearrange their cytoskeletons. Several oncogenic pathways such as transforming growth factor (TGF) -\u03b2, Wnt, and Notch signaling pathways, have been shown to induce EMT.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24278531", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 533, 
          "offsetInEndSection": 750, 
          "text": "These pathways have activated transcription factors including Snail, Slug, and the ZEB family which work as transcriptional repressors of E-cadherin, thereby making epithelial cells motile and resistant to apoptosis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24278531", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 218, 
          "text": "Epithelial-mesenchymal transition (EMT) is suggested to be crucial for the development of an invasive and metastatic carcinoma cell phenotype. Therefore, the definition of this phenotype is of great clinical interest. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20819124", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 759, 
          "offsetInEndSection": 1138, 
          "text": "Recent work has suggested that there may be a linkage between the stem cell phenotype and that induced by the process of epithelial-mesenchymal transition (EMT). EMT plays an important role in cell movement and organ formation during embryogenesis, and it is currently hypothesized to be a major mechanism by which epithelial cancers may generate cells that can form metastases. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19249648", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 389, 
          "text": "The term EMT (epithelial-mesenchymal transition) is used in many settings. This term is used to describe the mechanisms facilitating cellular repositioning and redeployment during embryonic development and tissue reconstruction after injury. Recently, EMT has also been applied to potential mechanisms for malignant progression and has appeared as a specific diagnostic category of tumors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17922020", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 234, 
          "text": "The epithelial-mesenchymal transition (EMT) is a fundamental process governing morphogenesis in multicellular organisms. This process is also reactivated in a variety of diseases including fibrosis and in the progression of carcinoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14644200", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What type of arrhythmia is known as bidirectional ventricular tachycardia (BDVT)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23094889", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21118730", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19682706", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17655675", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14556882", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1713403", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6180691"
      ], 
      "type": "summary", 
      "id": "5507ea9a0195c16935000008", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 198, 
          "text": "Bidirectional ventricular tachycardia (BVT) is an uncommon type of polymorphic ventricular tachycardia (PVT) with alternating polarity of the QRS complex most commonly described digitalis toxicity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23094889", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 572, 
          "text": "Bidirectional ventricular tachycardia (BVT), which is characterized by an alternating beat-to-beat ECG QRS axis, is a rare but intriguing arrhythmia associated with digitalis toxicity, familial catecholaminergic polymorphic ventricular tachycardia (CPVT), and several other conditions that predispose cardiac myocytes to delayed afterdepolarizations (DADs) and triggered activity. Evidence from human and animal studies attributes BVT to alternating ectopic foci originating from the distal His-Purkinje system in the left and/or right ventricle, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21118730", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 939, 
          "offsetInEndSection": 1478, 
          "text": "When the heart rate exceeded the threshold for bigeminy at the first site in the His-Purkinje system, ventricular bigeminy developed, causing the heart rate to accelerate and exceed the threshold for bigeminy at the second site. Thus, the triggered beat from the first site induced a triggered beat from the second site. The triggered beat from the second site next reciprocated by inducing a triggered beat from the first site, and so forth. Bigeminy from two sites produced BVT, and that from three or more sites produced polymorphic VT.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21118730", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1491, 
          "offsetInEndSection": 1675, 
          "text": "This \"ping pong\" mechanism of reciprocating bigeminy readily produces the characteristic ECG pattern of BVT and its degeneration to polymorphic VT if additional sites develop bigeminy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21118730", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 329, 
          "offsetInEndSection": 603, 
          "text": "The BVT, in this case, was most likely due to myocardial ischema. The ethiology of published BVT cases are most commonly digitalis toxicity and rarely herbal aconitine poisoning, hypokalemic periodic paralysis, cathecolaminergic VT, myocarditis, and Anderson-Tawil syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19682706", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 257, 
          "text": "Bidirectional ventricular tachycardia (BVT), although a rare arrhythmia in the general population, is frequently observed in patients with Andersen-Tawil syndrome and long QT interval. However, the pharmacologic treatment of this arrhythmia remains unknown.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17655675", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 948, 
          "offsetInEndSection": 1214, 
          "text": "This report suggests that flecainide can be effective in controlling BVT associated with Andersen-Tawil syndrome and indicates that the left ventricular dysfunction is secondary to the arrhythmia and not due to an associated phenotypic manifestation of the disorder.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17655675", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "Based on similarity of electrocardiographic features, bidirectional ventricular tachycardia has been considered a variant of long QT syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14556882", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 585, 
          "offsetInEndSection": 896, 
          "text": "Double ventricular ectopic rhythms had bizarre abnormal QRS complexes of two different morphologies and were inscribed in opposite directions. Ectopic rhythms in each case had parasystolic characteristics. These observations suggest bifocal automaticity as a mechanism for bidirectional ventricular tachycardia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1713403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 389, 
          "text": "Bidirectional ventricular tachycardia, defined as the rapid alternation of the QRS complexes with successive opposing axial deviation, is a rare arrhythmia. In the rare cases which have undergone endocavitary investigations, an infrahisian origin has generally been proved. However, the mechanism of these tachycardias remains poorly understood and is discussed with respect to a new case.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6180691", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1447, 
          "offsetInEndSection": 1703, 
          "text": "In the light of previously reported cases with documented endocavitary investigation and this new case, it seems possible to talk in terms of true \"bidirectional ventricular tachycardia\", a tachycardia whose mechanism is obscure but certainly not univocal.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6180691", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the biological role of K-48 linked protein ubiquitination?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24126522", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22389394", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20696248", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19887490", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19432818", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15728425"
      ], 
      "type": "summary", 
      "id": "5507fc114b2a315d41000003", 
      "snippets": [
        {
          "offsetInBeginSection": 191, 
          "offsetInEndSection": 392, 
          "text": "On the LCV, AnkB triggers docking of K(48)-linked polyubiquitinated proteins that are degraded by the host proteasomes to elevate cellular levels of amino acids needed for intracellular proliferation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126522", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1192, 
          "offsetInEndSection": 1560, 
          "text": "Transcription and injection of ankB is triggered by attached extracellular bacteria followed by rapid farnesylation and anchoring of AnkB to the cytosolic side of the plasma membrane beneath bacterial attachment, where K(48)-linked polyubiquitinated proteins are assembled and degraded by the proteasomes, leading to a rapid rise in the cellular levels of amino acids.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126522", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 316, 
          "text": "Ubiquitination is a posttranslational modification that regulates protein degradation and signaling in eukaryotes. Although it is acknowledged that pathogens exploit ubiquitination to infect mammalian cells, it remains unknown how microbes interact with the ubiquitination machinery in medically relevant arthropods.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23901084", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 478, 
          "text": "Although it has been known for a long time that ubiquitylation has a major role in the activation and regulation of the nuclear factor kappa B (NF-\u03baB) pathway, recent studies have revealed that the picture is a lot more complex than originally thought. NF-\u03baB and ubiquitylation initially became linked when it was recognised that lysine (K)48-linked ubiquitin chains are involved in the processing of NF-\u03baB precursors and the degradation of inhibitor of kappa B (I\u03baB) proteins. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22389394", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 318, 
          "text": "The proteasome, which identifies and destroys unwanted proteins rapidly, plays a vital role in maintaining cellular protein homeostasis. Proteins that are destined for proteasome-mediated degradation are usually tagged with a chain of ubiquitin linked via lysine (K) 48 that targets them to the proteolytic machinery. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20696248", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 256, 
          "text": "Covalent and reversible post-translational modifications of proteins are a common theme in signaling. Ubiquitin conjugation was originally described to target proteins to proteasomal degradation by ubiquitin polymerization involving lysine (K) 48 residues.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19887490", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "Proteins tagged with lysine (Lys, K) 48 polyubiquitins chains are destined for degradation by the 26S proteasomal system.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19432818", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 541, 
          "text": "Ubiquitination is best known for its role in targeting proteins for degradation by the proteasome, but evidence of the nonproteolytic functions of ubiquitin is also rapidly accumulating. One example of the regulatory, rather than proteolytic, function of ubiquitin is provided by study of the tumor necrosis factor (TNF) receptor-associated factor (TRAF) proteins, which function as ubiquitin ligases to synthesize lysine 63 (K(63))-linked polyubiquitin chains to mediate protein kinase activation through a proteasome-independent mechanism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15728425", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 963, 
          "offsetInEndSection": 1197, 
          "text": "Indeed, the TRAF2-interacting protein RIP can mediate IKK activation when it is modified by K(63) polyubiquitin chains, but is targeted to degradation by the proteasome when it is K(48)-polyubiquitinted by the NF-kappaB inhibitor A20.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15728425", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the biological role of SERCA2 SUMOylation in cardiac physiology and pathophysiology, such as in heart failure?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23710633", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21900893", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24225946", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22679139"
      ], 
      "type": "summary", 
      "id": "5508453a4b2a315d41000008", 
      "snippets": [
        {
          "offsetInBeginSection": 874, 
          "offsetInEndSection": 1132, 
          "text": "SERCA2a activity can be regulated at multiple levels of a signaling cascade comprised of phospholamban, protein phosphatase 1, inhibitor-1, and PKC\u03b1. SERCA2 activity is also regulated by post-translational modifications including SUMOylation and acetylation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23710633", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 457, 
          "offsetInEndSection": 880, 
          "text": "The small ubiquitin-related modifier (SUMO) can be conjugated to lysine residues of target proteins, and is involved in many cellular processes. Here we show that SERCA2a is SUMOylated at lysines 480 and 585 and that this SUMOylation is essential for preserving SERCA2a ATPase activity and stability in mouse and human cells. The levels of SUMO1 and the SUMOylation of SERCA2a itself were greatly reduced in failing hearts.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21900893", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1710, 
          "offsetInEndSection": 1924, 
          "text": "Taken together, our data show that SUMOylation is a critical post-translational modification that regulates SERCA2a function, and provide a platform for the design of novel therapeutic strategies for heart failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21900893", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 324, 
          "text": "Recently, the impact of small ubiquitin-related modifier 1 (SUMO-1) on the regulation and preservation of sarcoplasmic reticulum calcium adenosine triphosphatase (SERCA2a) function was discovered. The amount of myocardial SUMO-1 is decreased in failing hearts, and its knockdown results in severe heart failure (HF) in mice.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24225946", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1368, 
          "offsetInEndSection": 1618, 
          "text": "SUMO-1 gene transfer therefore improved cardiac function and stabilized LV volumes in a large-animal model of HF. These results support the critical role of SUMO-1 in SERCA2a function and underline the therapeutic potential of SUMO-1 for HF patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24225946", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 660, 
          "offsetInEndSection": 862, 
          "text": "However, the initial simple view of a PLN/SERCA regulatory complex has been modified by our recent identification of SUMO, S100 and the histidine-rich Ca-binding protein as regulators of SERCA activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22679139", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List the diseases that can be treated using Vedolizumab.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24300858", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24246983", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24160949", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24160948", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23980911", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23964933", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23964932", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23723689", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23718288", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23695427", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23591599", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23419117", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23394379", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23295705", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23314806", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23083349", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23046232", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23018007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22762276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22147460", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22113039", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21157649", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20594130", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19509315"
      ], 
      "type": "list", 
      "id": "5508685b4b2a315d4100000a", 
      "snippets": [
        {
          "offsetInBeginSection": 240, 
          "offsetInEndSection": 411, 
          "text": "A new gut-specific monoclonal antibody, vedolizumab, has been shown to be effective in inflammatory bowel disease, and in continued trials no patients have developed PML. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24300858", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 594, 
          "offsetInEndSection": 746, 
          "text": "Finally, several studies were presented on new drugs with new therapeutic targets, such as vedolizumab, in the treatment of inflammatory bowel disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 737, 
          "offsetInEndSection": 1045, 
          "text": "We review the role of vedolizumab, a humanized antibody against the \u03b14\u03b27 - integrin, in both ulcerative colitis (UC) and Crohn's disease (CD). Results from clinical trials show that vedolizumab is effective in the induction and maintenance of remission in active CD and UC and has a very good safety profile.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23980911", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 69, 
          "text": "Vedolizumab as induction and maintenance therapy for Crohn's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964933", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1895, 
          "offsetInEndSection": 2239, 
          "text": "NCLUSIONS: Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolizumab (rather than switching to placebo) were more likely to be in remission at week 52. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964933", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "Vedolizumab as induction and maintenance therapy for ulcerative colitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964932", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1937, 
          "offsetInEndSection": 2054, 
          "text": "CONCLUSIONS: Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964932", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "New and emerging treatments for ulcerative colitis: a focus on vedolizumab.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23723689", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 537, 
          "offsetInEndSection": 611, 
          "text": " This article reviews the emerging data on the use of vedolizumab for UC. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23723689", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1502, 
          "offsetInEndSection": 1596, 
          "text": " Newer treatments such as vedolizumab and tofacitinib may represent valuable future therapies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23718288", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 980, 
          "offsetInEndSection": 1166, 
          "text": "SUMMARY: New therapeutic targets in IBD patients who failed anti-TNF-\u03b1 therapy are urgently required, and tofacitinib, vedolizumab and ustekinumab appear to be the most promising drugs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23695427", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 165, 
          "text": "BACKGROUND: Vedolizumab, a gut-selective, anti-inflammatory monoclonal antibody, has shown preliminary efficacy in ulcerative colitis (UC) and Crohn's disease (CD). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23591599", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1455, 
          "offsetInEndSection": 1709, 
          "text": "CONCLUSION: Vedolizumab every 8 weeks for up to 78 weeks had an adverse event profile similar to that previously observed. Mean disease activity indices (partial Mayo score and Crohn's Disease Activity Index score) improved with all 3 doses investigated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23591599", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 484, 
          "offsetInEndSection": 812, 
          "text": "The new drugs discussed here are those that disturb lymphocyte homing to the gut (natalizumab, vedolizumab and anti-mucosal addressin cellular adhesion molecule); one that blocks interleukin (IL)-12 as well as the IL-23/T helper 17 (Th17) axis (ustekinumab) and one that blocks the signaling of multiple cytokines (tofacitinib).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23419117", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 33, 
          "text": "Vedolizumab  for Crohn's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394379", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 396, 
          "offsetInEndSection": 851, 
          "text": "AREAS COVERED: This review discusses the potential role of vedolizumab, a humanised monoclonal antibody that selectively blocks lymphocyte trafficking to the gut, for the treatment of CD. All randomised placebo-controlled trials that evaluated vedolizumab for the treatment of CD were reviewed and safety and efficacy data evaluated. EXPERT OPINION: Vedolizumab is an effective and well-tolerated drug that is an important advance for the treatment of CD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394379", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1202, 
          "offsetInEndSection": 1510, 
          "text": "Treatment strategies that appear particularly appealing include selective anti-integrin therapy with vedolizumab (anti-\u03b14\u03b27), etrolizumab (anti-\u03b27 antibody) and PF-00547,659 (anti-MAdCAM-1 antibody), anti-interleukin 12/23p40 therapy with ustekinumab and Janus kinase 1, 2 and 3 inhibition with toafacitinib.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23295705", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 447, 
          "offsetInEndSection": 933, 
          "text": "We discuss a number of them with specific focus on vedolizumab, a monoclonal antibody directed against the alpha4beta7 integrin on lymphocytes, ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, and tofacitinib, a small molecule targeting Janus-activated kinase. Most likely, these three agents will find their way to the market and offer significant therapeutic alternatives for the management of Crohn's disease and/or ulcerative colitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314806", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 316, 
          "offsetInEndSection": 565, 
          "text": "Natalizumab, vedolizumab, alicaforsen AJM300, rhuMAb \u03b27, CCX282-B, and PF-00547,659 are few of monoclonal antibodies that have shown high promise in trials with the potential for more attractive benefit:risk ratio than currently available therapies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23083349", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23046232", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 781, 
          "offsetInEndSection": 1060, 
          "text": "Here, we discuss the current treatment options available for patients with Crohn's disease or ulcerative colitis, the history of CAM inhibitors, the current state of development of vedolizumab and its future role in inflammatory bowel disease, if approved by regulatory agencies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23046232", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 294, 
          "offsetInEndSection": 725, 
          "text": "Biological agents will probably be used earlier and more widely; new information on levels of biological agents, mucosal healing and new comparative studies will also allow these agents to be used in a more precise and personalized way. In addition to infliximab, adalimumab, natalizumab and certolizumab, other biological agents will be employed; among the first of these to be used will be ustekinumab, golimumab and vedolizumab.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23018007", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 637, 
          "offsetInEndSection": 826, 
          "text": "Several antibodies exist which constitute selection adhesion molecule inhibitors, including Natalizumab, MLN-0002 (Vedolizumab) and ISIS 2302 (Alicaforsen) will be discussed in this review.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22762276", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 111, 
          "text": "Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22147460", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "BACKGROUND: Vedolizumab is a gut-selective biologic that has shown efficacy in ulcerative colitis (UC) and Crohn's disease (CD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22147460", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 641, 
          "offsetInEndSection": 955, 
          "text": "They are anti CD4+ T cell cytokine including interleukin (IL)-12/23 and IL-17 blockers, selective anti-adhesion molecule known as natalizumab, vedolizumab and alicaforsen, T-cell proliferation inhibitor, anti-inflammatory cytokine, immune stimulator, growth factor, and mitogen-activated protein kinase inhibitor. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22113039", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 125, 
          "text": "Vedolizumab, a humanized mAb against the \u03b14\u03b27 integrin for the potential treatment of ulcerative colitis and Crohn's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21157649", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1050, 
          "offsetInEndSection": 1458, 
          "text": "Data from phase II clinical trials of vedolizumab demonstrated efficacy with an attractive safety profile, especially in ulcerative colitis. Large phase III, multicenter trials in both ulcerative colitis and Crohn's disease will provide valuable data for the ongoing development of vedolizumab, which might evolve as a new anti-inflammatory treatment option for the management of therapy-refractory patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21157649", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 821, 
          "offsetInEndSection": 1036, 
          "text": "The development of a new specific molecule, vedolizumab, is currently under investigation in a large clinical trial. This novel specific anti-integrin drug seems to hold promise in the treatment of gut inflammation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20594130", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19509315", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1694, 
          "offsetInEndSection": 1932, 
          "text": "These pharmacologic properties of vedolizumab, in conjunction with the gastrointestinal tropism of alpha(4)beta(7) integrin function, may ultimately confer an improved risk-to-benefit profile for patients with inflammatory bowel diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19509315", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Matuzumab has been tested for treatment of which cancers?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23300028", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22832803", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22807624", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22763610", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21109448", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20978446", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20497967", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19691369", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19482958", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19276157", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19238629", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19433372", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18181050", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17671148", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17126894", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16857825", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16622465", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16533873", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16387666", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16336753", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15871762", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15011787"
      ], 
      "type": "list", 
      "id": "55086ea1098a1b487b000001", 
      "snippets": [
        {
          "offsetInBeginSection": 1002, 
          "offsetInEndSection": 1071, 
          "text": " Matuzumab and panitumumab have also been studied in phase II trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23300028", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 145, 
          "text": "A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22832803", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 56, 
          "offsetInEndSection": 261, 
          "text": "This phase I study investigated the tolerability, safety and pharmacokinetics (PK) of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer (NSCLC). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22832803", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1233, 
          "offsetInEndSection": 1330, 
          "text": "Matuzumab combined with paclitaxel was generally well tolerated in patients with advanced NSCLC. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22832803", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 470, 
          "offsetInEndSection": 680, 
          "text": "This article focuses on anti-Her-2 therapy, specifically trastuzumab, as well as other epidermal growth factor receptor antagonists such as cetuximab, panitumub, matuzumab, nimotzumab, gefitinib, and erlotinib.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22807624", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22763610", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 368, 
          "text": "BACKGROUND: To evaluate the safety and tolerability of two different weekly doses of the fully humanized epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab combined with high-dose 5-fluorouracil, leucovorin and cisplatin (PLF) in the first-line treatment of patients with EGFR-positive advanced gastric and esophagogastric adenocarcinomas.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22763610", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1117, 
          "offsetInEndSection": 1188, 
          "text": "Matuzumab and panitumumab have also been evaluated in phase II trials. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21109448", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20978446", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 282, 
          "text": "INTRODUCTION: This randomized phase II study investigated pemetrexed in combination with the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab compared with pemetrexed alone as second-line therapy for patients with advanced non-small cell lung cancer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20978446", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 247, 
          "text": "Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20497967", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 220, 
          "text": "BACKGROUND: Clinical data showed promising antitumour activity with feasible tolerability for matuzumab plus epirubicin, cisplatin and capecitabine (ECX) chemotherapy in untreated advanced oesophago-gastric (OG) cancer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20497967", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1490, 
          "offsetInEndSection": 1634, 
          "text": " CONCLUSION: Matuzumab 800 mg weekly combined with ECX chemotherapy does not increase response or survival for patients with advanced OG cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20497967", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 437, 
          "offsetInEndSection": 817, 
          "text": "In all studies, the patients had different types of advanced carcinoma - mainly colon, rectal and pancreatic cancer. They received matuzumab as multiple 1-hour intravenous infusions in a wide range of dosing regimens (development dataset: from 400 mg every 3 weeks to 2000 mg in the first week followed by 1600 mg weekly; evaluation dataset: from 100 mg weekly to 800 mg weekly). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19691369", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1302, 
          "offsetInEndSection": 1473, 
          "text": " Other anti-EGFR monoclonal antibodies, such as panitumumab, matuzumab, nimotuzumab, and ch806, are in different stages of development for the treatment of advanced NSCLC.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19482958", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276157", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 234, 
          "text": "Antibodies targeting epidermal growth factor receptor (EGFR) have proven to be effective in patients with non-small cell lung cancer (NSCLC) that express EGFR. We recently published a phase I study of weekly matuzumab plus paclitaxel.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276157", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1678, 
          "offsetInEndSection": 1837, 
          "text": "Our data suggest that EGFR expression and KRAS mutation status is predictive for clinical response to matuzumab +/- paclitaxel in patients with advanced NSCLC.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276157", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19238629", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 356, 
          "text": "To evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of the humanised antiepidermal growth factor receptor monoclonal antibody matuzumab combined with epirubicin, cisplatin and capecitabine (ECX) in patients as first-line treatment for advanced oesophagogastric cancer that express epidermal growth factor receptor (EGFR). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19238629", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 645, 
          "offsetInEndSection": 957, 
          "text": "Therefore, these first successes led to the development of several drugs including monoclonal antibodies (trastuzumab, panitumumab, matuzumab), TK inhibitors targeting one receptor as well as TK pan-inhibitors (lapatinib, HKI 272, PKI 166, EKB-569, AEE-788), currently assessed through clinical trials worldwide.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19433372", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17671148", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 379, 
          "text": "Matuzumab and panitumumab are antibodies against the epidermal growth factor receptor (EGFR) that are being evaluated in several malignancies including non-small cell lung cancer (NSCLC). In phase I trials of single-agent matuzumab in patients with EGFR-positive cancer, three tumor responses were documented in esophageal squamous cell carcinoma as well as colorectal carcinoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17671148", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 165, 
          "text": "A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17126894", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1085, 
          "offsetInEndSection": 1379, 
          "text": "CONCLUSIONS: Matuzumab at the dose and schedule selected is well tolerated. In this population of very heavily pretreated patients with epithelial ovarian and primary peritoneal malignancies, there was no evidence of significant clinical activity when matuzumab was administered as monotherapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17126894", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16622465", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 298, 
          "offsetInEndSection": 547, 
          "text": " Three groups of chemotherapy-naive advanced pancreatic adenocarcinoma patients (n=17) received escalating doses of matuzumab (400 mg weekly, 800 mg biweekly, or 800 mg weekly) and gemcitabine (1000 mg m-2 weekly in weeks 1-3 of each 4-week cycle). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16622465", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 226, 
          "text": "A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16533873", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 303, 
          "offsetInEndSection": 458, 
          "text": "This phase I study assessed the tolerability, pharmacokinetics and efficacy of the combination of matuzumab and paclitaxel in patients with advanced NSCLC.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16533873", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 342, 
          "offsetInEndSection": 430, 
          "text": "Other anti-EGFR monoclonal antibodies (panitunumab, matuzumab) are currently evaluated. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16387666", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 100, 
          "offsetInEndSection": 305, 
          "text": "It is the target for a class of agents at the forefront of development for the treatment of colorectal cancer, ie, the anti-EGFR monoclonal antibodies, which include cetuximab, panitumumab, and matuzumab. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16336753", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 810, 
          "offsetInEndSection": 1002, 
          "text": "Two other monoclonal antibodies, matuzumab (EMD 72000) and panitumumab (ABG-EGF), also have shown activity against EGFR-expressing CRC but are still in the early stage of clinical development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15871762", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 174, 
          "offsetInEndSection": 287, 
          "text": "Matuzumab is currently undergoing phase II clinical trials for gastric, cervical, pancreatic and ovarian cancers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15011787", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the advantage of neutral loss detection in phosphoproteomics?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23918812", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22844594", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21526838", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21033674", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21455477", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19504542", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19241031", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19056867", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18785766", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16641100", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15665377"
      ], 
      "type": "summary", 
      "id": "550889db098a1b487b000005", 
      "snippets": [
        {
          "offsetInBeginSection": 809, 
          "offsetInEndSection": 927, 
          "text": "The higher-order fragmentations of neutral loss ions enhance the fragment ion mass spectra of phosphorylated peptides.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22844594", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1256, 
          "offsetInEndSection": 1428, 
          "text": "we identified a novel fragmentation mechanism that generates a phosphorylation site-specific neutral loss derived x-ion, which directly pinpoints the phosphorylated residue", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21526838", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 520, 
          "offsetInEndSection": 624, 
          "text": "CID of phosphopeptides typically results in spectra dominated by a neutral loss of the phosphate group. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19504542", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 964, 
          "offsetInEndSection": 1143, 
          "text": "In this procedure we use a combination of tools to assign b-, y-, neutral loss, and internal fragment ions, with the goal of assigning all significant ions in the MS/MS spectrum. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19241031", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 555, 
          "offsetInEndSection": 777, 
          "text": "We extended the proteomic analysis to phosphoproteomic profiling using neutral loss scanning, and this yielded multiple novel phosphorylation sites, including serine-811 in the thiazide-sensitive Na-Cl co-transporter, NCC.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19056867", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 867, 
          "offsetInEndSection": 1025, 
          "text": "LC separation and MS/MS are followed by neutral loss-dependent MS/MS/MS for phosphopeptide identification using a linear ion trap (LTQ)-FT mass spectrometer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18785766", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 462, 
          "offsetInEndSection": 566, 
          "text": "phosphorylation site identification by liquid chromatography-mass spectrometry(n) neutral loss scanning.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16641100", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1356, 
          "offsetInEndSection": 1500, 
          "text": "MS/MS and neutral loss-directed MS/MS/MS analysis allowed detection and sequencing of phosphopeptides with exceptional accuracy and specificity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15665377", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 325, 
          "text": "The localization of phosphorylation sites in peptide sequences is a challenging problem in large-scale phosphoproteomics analysis. The intense neutral loss peaks and the coexistence of multiple serine/threonine and/or tyrosine residues are limiting factors for objectively scoring site patterns across thousands of peptides. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918812", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is p100 the precursor protein molecule of the NF-kappaB transcription factor subunit p50?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22282470", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20363924", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19302050", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17693123", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16223731", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15677466", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15485830", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12894228", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12505990", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11726516", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10597218"
      ], 
      "type": "yesno", 
      "id": "55088e412e93f0133a000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 325, 
          "text": "We previously reported that alymphoplasia (aly/aly) mice, which have a natural loss-of-function mutation in the Nik gene, which encodes a kinase essential for the processing of p100 to p52 in the alternative nuclear factor-\u03baB (NF-\u03baB) pathway, show mild osteopetrosis with an increase in several parameters of bone formation: ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22282470", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 188, 
          "text": "Proteolytic processing of the nuclear factor (NF)-kappaB2 precursor protein p100 generates the active NF-kappaB2 subunit p52, which in turn transcriptionally up-regulates p100 expression. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20363924", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 391, 
          "text": "The mammalian Rel/NF-kappaB family of transcription factors, including RelA, c-Rel, RelB, NF-kappaB1 (p50 and its precursor p105), and NF-kappaB2 (p52 and its precursor p100), plays a central role in the immune system by regulating several processes ranging from the development and survival of lymphocytes and lymphoid organs to the control of immune responses and malignant transformation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19302050", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 128, 
          "offsetInEndSection": 334, 
          "text": "NF-kappaB functions as a hetero- or homo-dimer which can be formed from five NF-kappaB subunits, NF-kappaB1 (p50 and its precursor p105), NF-kappaB2 (p52 and its precursor p100), RelA (p65), RelB and c-Rel.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17693123", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 179, 
          "text": "The non-canonical pathway based on processing of NF-kappaB2 precursor protein p100 to generate p52 plays a critical role in controlling B cell function and lymphoid organogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16223731", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "Processing of NF-kappaB2 precursor protein p100 to generate p52 is tightly controlled, which is important for proper function of NF-kappaB.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15677466", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "Processing of NF-kappa B2 precursor protein p100 to generate p52 is tightly regulated. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15485830", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "Processing of the NF-kappaB2 precursor protein p100 to generate p52 is an important step of NF-kappaB regulation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12894228", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Targeted disruption of the Rel/NF-kappaB family members NF-kappaB2, encoding p100/p52, and RelB in mice results in anatomical defects of secondary lymphoid tissues.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12505990", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 280, 
          "offsetInEndSection": 541, 
          "text": "Here, we show that in T cells infected with the human T-cell leukemia virus (HTLV), IKKalpha is targeted to a novel signaling pathway that mediates processing of the nfkappab2 precursor protein p100, resulting in active production of the NF-kappaB subunit, p52.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726516", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 202, 
          "text": "nfkb2 encodes two members of the NF-kappa B/Rel family of proteins: p52 and p100. The p100 polypeptide has been proposed to serve as a precursor of p52, which corresponds to the N-terminal half of p100.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10597218", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 834, 
          "offsetInEndSection": 985, 
          "text": "In most cells, small amounts of p52 are produced relative to the levels of p100, unlike the usually balanced production of nfkb1-derived p50 and p105. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10597218", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can exosomes be detected in urine?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24044569", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24060994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24069349", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24058411", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24315007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24250247", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24205503", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24196483", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24101370", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23585095"
      ], 
      "type": "yesno", 
      "id": "550895c12e93f0133a000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 370, 
          "text": "Exosomes are nanovesicles secreted into the extracellular environment upon internal vesicle fusion with the plasma membrane. The molecular content of exosomes is a fingerprint of the releasing cell type and of its status. For this reason, and because they are released in easily accessible body fluids such as blood and urine, they represent a precious biomedical tool. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24044569", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 67, 
          "text": "Exosomes are vesicles that are released from the kidney into urine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24060994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Quantification of human urinary exosomes by nanoparticle tracking analysis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24060994", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "Urinary extracellular vesicles (uEVs) are released by cells throughout the nephron and contain biomolecules from their cells of origin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24069349", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 66, 
          "text": "Urinary exosomes have been proposed as potential diagnostic tools.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058411", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 85, 
          "text": "Urinary exosomes as a source of kidney dysfunction biomarker in renal transplantation", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24315007", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 73, 
          "offsetInEndSection": 231, 
          "text": ". Here we sought to optimize the methodologies for the isolation and quantification of urinary exosomal microRNA as a prelude to biomarker discovery studies. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24250247", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 204, 
          "text": "Exosomes are small (30-150\u2009nm) vesicles containing unique RNA and protein cargo, secreted by all cell types in culture. They are also found in abundance in body fluids including blood, saliva, and urine. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24205503", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 173, 
          "text": "Urinary exosome-like vesicles (ELVs) are a heterogenous mixture (diameter 40-200\u2009nm) containing vesicles shed from all segments of the nephron including glomerular podocytes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24196483", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 141, 
          "text": "Exosomes are cytoplasm containing vesicles released by many cells that can be found in several biological fluids including urine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24101370", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "Proteomic analysis of urinary exosomes in cardiovascular and associated kidney diseases by two-dimensional electrophoresis and LC-MS/MS", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23585095", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Is K-63 linked protein ubiquitination related to proteasomal degradation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20663875", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19091944", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15728425"
      ], 
      "type": "yesno", 
      "id": "550899c92e93f0133a000003", 
      "snippets": [
        {
          "offsetInBeginSection": 236, 
          "offsetInEndSection": 364, 
          "text": "In contrast to K48-linked polyubiquitin chains, K63-linked polyubiquitin chains function in nonproteasomal biological processes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663875", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 234, 
          "text": "Modification of proteins by the addition of lysine (K)-63-linked polyubiquitin (polyUb) chains is suggested to play important roles in a variety of cellular events, including DNA repair, signal transduction, and receptor endocytosis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19091944", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 1310, 
          "text": "Ubiquitination is best known for its role in targeting proteins for degradation by the proteasome, but evidence of the nonproteolytic functions of ubiquitin is also rapidly accumulating. One example of the regulatory, rather than proteolytic, function of ubiquitin is provided by study of the tumor necrosis factor (TNF) receptor-associated factor (TRAF) proteins, which function as ubiquitin ligases to synthesize lysine 63 (K(63))-linked polyubiquitin chains to mediate protein kinase activation through a proteasome-independent mechanism. Some TRAF proteins, such as TRAF2 and TRAF3, have recently been shown to have a positive role in the canonical pathway that activates nuclear factor kappaB (NF-kappaB) through IkappaB kinase beta (IKKbeta), but a negative role in the noncanonical pathway that activates NF-kappaB through IKKalpha. These opposing roles of TRAF proteins may be linked to their ability to synthesize distinct forms of polyubiquitin chains. Indeed, the TRAF2-interacting protein RIP can mediate IKK activation when it is modified by K(63) polyubiquitin chains, but is targeted to degradation by the proteasome when it is K(48)-polyubiquitinted by the NF-kappaB inhibitor A20. Thus, ubiquitin chains are dynamic switches that can influence signaling outputs in dramatically different ways.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15728425", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the treatments of choice for GIST (gastrointestinal stromal tumor)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24325620", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22678007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19829995", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19343179", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19097381", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18958964", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18180842", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18082353", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17954092", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17643218", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17470686", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17229322", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16857109", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16821517", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16739060", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16566359", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16437936", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16136600", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15993051", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15672765", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15655606", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15508453", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15245670", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15221987", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14753595", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12394270", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11126742"
      ], 
      "type": "summary", 
      "id": "5509b6d22e93f0133a000005", 
      "snippets": [
        {
          "offsetInBeginSection": 178, 
          "offsetInEndSection": 258, 
          "text": "Traditionally, the treatment of choice for primary disease is surgical resection", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24325620", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 269, 
          "offsetInEndSection": 524, 
          "text": "no single surgeon or institution gets extensive exposure to these patients so appropriate decision-making is difficult, particularly since the introduction of the tyrosine kinase inhibitor imatinib, which has become an important additional management tool", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24325620", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1618, 
          "offsetInEndSection": 1686, 
          "text": "Surgery aiming at an R0 resection remains the mainstay of treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24325620", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 116, 
          "offsetInEndSection": 170, 
          "text": "The treatment of choice for GIST is surgical resection", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22678007", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1284, 
          "offsetInEndSection": 1422, 
          "text": "Extra luminal colonic gastrointestinal stromal tumors are very rare and can present as mass abdomen. Resection is the treatment of choice.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19829995", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 99, 
          "text": "Surgery remains the only curative treatment for gastrointestinal stromal tumour (GIST).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19343179", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 87, 
          "offsetInEndSection": 375, 
          "text": "When they are localized, the treatment of choice is surgical excision, but advanced tumors have a limited response to chemo or radiotherapy. Imatinib (STI571 or Glivec) is a selective inhibitor or tyrosine kinase proteins that has been used successfully in the treatment of advanced GIST.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18180842", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 632, 
          "offsetInEndSection": 717, 
          "text": "Therefore Imatinib can be a therapeutic alternative in patients with metastatic GIST.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18180842", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1550, 
          "offsetInEndSection": 1761, 
          "text": "The surgical resection is a treatment of choice for gastrointestinal stromal tumors. It has been shown that adequate surgical resection correlates with high 5-years survival rates for patients with gastric GIST.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19097381", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 442, 
          "offsetInEndSection": 737, 
          "text": "Approximately 80% of patients with metastatic GIST benefit from imatinib, although acquired resistance to the agent may develop. For patients with primary GIST, surgery remains the treatment of choice, and whether outcome is improved by adjuvant imatinib is currently under broad investigation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16136600", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 739, 
          "offsetInEndSection": 873, 
          "text": "combination of imatinib therapy and surgery also may be effective in a subset of patients with metastatic or unresectable primary GIST", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16136600", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the treatment of choice  for gastric lymphoma?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22368024", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15916100", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15672765", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15213617", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11682961", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11054376", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10796047", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9667473", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7975766", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7978750", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1377459", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3178044"
      ], 
      "type": "summary", 
      "id": "5509ba931180f13250000001", 
      "snippets": [
        {
          "offsetInBeginSection": 1169, 
          "offsetInEndSection": 1242, 
          "text": "The treatment of choice should be comprehensive therapy based on surgery.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22368024", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1140, 
          "offsetInEndSection": 1395, 
          "text": "The treatment of choice for localized primary GI lymphoma is controversial. Complete surgical resection may increase the chance of complete remission, but mortality and relapse rates might be higher than those observed with combination chemotherapy alone.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15916100", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 121, 
          "offsetInEndSection": 219, 
          "text": "The most common gastric lymphoma are low-grade marginal zone B-cell lymphoma (MZBCL) of MALT type.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15672765", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 348, 
          "offsetInEndSection": 646, 
          "text": "In early stages of disease, H. pylori eradication alone may lead to complete lymphoma remission in up to 75% of cases. Nonresponder or locally advanced lymphoma should be treated with radiation therapy. Advanced lymphoma may be treated with the nucleoside analogon cladribine within clinical trials", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15672765", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1746, 
          "offsetInEndSection": 2064, 
          "text": "In patients with primary gastric diffuse large cell lymphoma and aggressive histology, diffuse large cell lymphoma in early stage SCT achieved good results, but surgery was associated with some cases of lethal complications. Thus it appears that CT should be considered the treatment of choice in this patient setting.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15213617", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 176, 
          "text": "Controversy remains regarding the best treatment for primary gastric lymphoma (PGL). Recent developments in diagnosis and chemotherapy have changed strategies for this disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11682961", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1602, 
          "offsetInEndSection": 1798, 
          "text": "With the exception of eradication therapy in H. pylori-positive low-grade lymphoma of stage EI and the subgroup of locally advanced high-grade lymphoma, resection remains the treatment of choice. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11054376", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 254, 
          "text": "The treatment of primary gastric lymphoma is controversial. The role of surgery has come to be questioned with increasing knowledge about the pathogenesis of gastric lymphoma and with new therapeutic approaches such as eradication of Helicobacter pylori.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10796047", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 955, 
          "offsetInEndSection": 1108, 
          "text": "curative resection is the treatment of choice for gastric lymphoma, but radiation therapy may offer some benefit when complete resection is not feasible.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1377459", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What disease is small bowel lymphoma commonly associated with", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21532863", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18212211", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12002682", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10912475"
      ], 
      "type": "factoid", 
      "id": "5509bd6a1180f13250000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 105, 
          "text": "Marginal zone B-cell lymphoma of MALT in small intestine associated with amyloidosis: a rare association.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21532863", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 495, 
          "offsetInEndSection": 654, 
          "text": "This is the first case of marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) in the small intestine associated with amyloidosis in Korea", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21532863", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "MR enterography of small-bowel lymphoma: potential for suggestion of histologic subtype and the presence of underlying celiac disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18212211", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1571, 
          "offsetInEndSection": 1839, 
          "text": "We describe the characteristics of small-bowel lymphoma on MR enterography, identifying a number of key features that may help the interpreting radiologist in suggesting the underlying histologic subtype and whether the presence of underlying celiac disease is likely.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18212211", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 234, 
          "text": "Celiac disease is an autoimmune disorder triggered by ingestion of gluten-containing foods. Epidemiologic studies dating from the 1950s established its association with gastrointestinal malignancies, particularly small bowel lymphoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12002682", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 321, 
          "offsetInEndSection": 557, 
          "text": "An association between untreated coeliac disease and intestinal malignancy is well described so it is possible that patients with undiagnosed coeliac disease constitute a significant reservoir of preventable gastrointestinal malignancy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10912475", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "An increased incidence of small bowel lymphoma in patients with long-standing celiac sprue is well documented in the literature.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2754219", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is hyperosmia", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24302690", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23520356", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21250223"
      ], 
      "type": "factoid", 
      "id": "5509c52f1180f13250000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 176, 
          "text": "Hyperosmia is suspected in pregnancy; however, no empirical study using validated measures of olfactory function has clearly confirmed the anecdotal reports of this phenomenon.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24302690", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 591, 
          "offsetInEndSection": 676, 
          "text": "subjective hyperosmia is associated with primarily negative odor-related experiences.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23520356", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 40, 
          "text": "Hyperosmia is increased olfactory acuity", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21250223", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What colonoscopy findings have been reported in autism", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19214283", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16003132", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11241044", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11007230"
      ], 
      "type": "summary", 
      "id": "5509ce9ec2af5d5b70000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 40, 
          "text": "Autistic enterocolitis: fact or fiction?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19214283", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 315, 
          "offsetInEndSection": 565, 
          "text": "There have been several reports of a link between autism and chronic gastrointestinal symptoms. Endoscopy trials have demonstrated a higher prevalence of nonspecific colitis, lymphoid hyperplasia and focally enhanced gastritis compared with controls.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19214283", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 258, 
          "text": "Intestinal mucosal pathology, characterized by ileo-colonic lymphoid nodular hyperplasia (LNH) and mild acute and chronic inflammation of the colorectum, small bowel and stomach, has been reported in children with autistic spectrum disorder (ASD)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16003132", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 444, 
          "offsetInEndSection": 614, 
          "text": "One hundred and forty-eight consecutive children with ASD (median age 6 years; range 2-16; 127 male) with gastrointestinal symptoms were investigated by ileo-colonoscopy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16003132", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2160, 
          "offsetInEndSection": 2487, 
          "text": "Ileo-colonic LNH is a characteristic pathological finding in children with ASD and gastrointestinal symptoms, and is associated with mucosal inflammation. Differences in age at colonoscopy and diet do not account for these changes. The data support the hypothesis that LNH is a significant pathological finding in ASD children.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16003132", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 234, 
          "offsetInEndSection": 355, 
          "text": "Ileo-colonoscopy was performed in 21 consecutively evaluated children with autistic spectrum disorders and bowel symptoms", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11241044", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1453, 
          "offsetInEndSection": 1685, 
          "text": "Immunohistochemistry confirms a distinct lymphocytic colitis in autistic spectrum disorders in which the epithelium appears particularly affected. This is consistent with increasing evidence for gut epithelial dysfunction in autism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11241044", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 440, 
          "offsetInEndSection": 751, 
          "text": " Ileocolonoscopy and biopsy were performed on 60 affected children (median age 6 yr, range 3-16; 53 male). Developmental diagnoses were autism (50 patients), Asperger's syndrome (five), disintegrative disorder (two), attention deficit hyperactivity disorder (ADHD) (one), schizophrenia (one), and dyslexia (one)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11007230", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2061, 
          "offsetInEndSection": 2171, 
          "text": "A new variant of inflammatory bowel disease is present in this group of children with developmental disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11007230", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1265, 
          "offsetInEndSection": 1412, 
          "text": "Ileal LNH was present in 54 of 58 (93%) affected children and in five of 35 (14.3%) controls (p < 0.001). Colonic LNH was present in 18 of 60 (30%)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11007230", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is amiodarone a class I anti-arrhythmic drug?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21626366", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11825323", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20041841", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12491809"
      ], 
      "type": "yesno", 
      "id": "5509df4ac2af5d5b70000003", 
      "snippets": [
        {
          "offsetInBeginSection": 1185, 
          "offsetInEndSection": 1374, 
          "text": "Common class I agents are excluded due to the inherent abnormal cardiac structure and function in the setting of cardiogenic shock. Class III drug options include dofetilide and amiodarone.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21626366", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 318, 
          "text": "Amiodarone has been used as an anti-arrhythmic drug since the 1970s and has an established role in the treatment of ventricular tachyarrhythmias. Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11825323", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 413, 
          "text": "Amiodarone, an iodinated benzofuran derivative, introduced in 1960's as an anti-anginal agent, emerged as a potent anti-arrhythmic agent by 1970's and is currently one of the most commonly prescribed drugs in US for ventricular and atrial arrhythmias. Although amiodarone is considered a class III anti-arrhythmic agent, it also has class I, II, IV actions, making it a unique and effective anti-arrhythmic agent.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20041841", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 282, 
          "offsetInEndSection": 655, 
          "text": "Amiodarone, a representative class III agent, exerts negative dromotropism by suppressing the fast sodium current responsible for conduction in acute administration (class I effects). Chronic amiodarone causes prolongation of ERP (class III effects), which is sometimes associated with negative dromotropism based on the alteration of passive or active membrane properties.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12491809", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is HER2 active only when it dimerizes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23990774", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23988598", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23783223", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23474221", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23342251", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22983903", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22829865", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22782294", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21908901", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21630056", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21538107", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21147694", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19934333"
      ], 
      "type": "yesno", 
      "id": "5509ec41c2af5d5b70000006", 
      "snippets": [
        {
          "offsetInBeginSection": 211, 
          "offsetInEndSection": 320, 
          "text": "HER activation is driven by the formation of various dimer complexes between members of this receptor family.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23990774", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 377, 
          "offsetInEndSection": 516, 
          "text": "rtuzumab is the first humanized monoclonal antibody in a new class of drugs, the HER dimerization inhibitors, approved by the Food and Drug", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23988598", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 415, 
          "offsetInEndSection": 699, 
          "text": "Pertuzumab is a novel anti-HER2 monoclonal antibody, which blocks HER2 dimerization with other ligand-activated HER family members. Here, we explored the complement-mediated anti-tumor effects of trastuzumab and pertuzumab on HER2-positive tumor cells of various histological origins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23474221", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 710, 
          "offsetInEndSection": 917, 
          "text": "ays. In this study, we report that an anti-HER2 monoclonal antibody (HER2Mab), which blocks HER2 dimerization with HER3, induces HER3 dimerization with EGFR in both low and high HER2 expressing cancer cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23342251", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 117, 
          "offsetInEndSection": 402, 
          "text": "Recent evidence from both basic and clinical studies suggests that ERBB3 (HER3) serves as a key activator of downstream signaling through dimerization with other ERBB proteins and plays a critical role in the widespread clinical resistance to EGFR and HER2 targeting cancer therapies. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23342251", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22983903", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Dimerization among the EGFR family of tyrosine kinase receptors leads to allosteric activation of the kinase domains of the partners.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22983903", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1171, 
          "offsetInEndSection": 1338, 
          "text": "Our results show that quantification of HER dimerization provides information about receptor activation that cannot be obtained by quantification of single receptors. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22829865", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 362, 
          "text": "Pertuzumab is a novel humanized monoclonal antibody that blocks human epidermal growth factor receptor 2 (HER2) dimerization. It was recently approved by the US FDA for use in combination with trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22782294", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 245, 
          "offsetInEndSection": 398, 
          "text": "he HER dimerization status may be more important than HER receptor expression per se in determining sensitivity or resistance to a given therapeutic agen", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21908901", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1214, 
          "offsetInEndSection": 1247, 
          "text": " and HER2 dimerization inhibitors", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21630056", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 142, 
          "offsetInEndSection": 319, 
          "text": "One of the mechanisms by which tumor cell proliferation can be inhibited consists in hampering HER2 dimerization by targeting its extracellular domain with specific antibodies. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21538107", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 324, 
          "offsetInEndSection": 579, 
          "text": "Pertuzumab, a humanized monoclonal antibody, is the first HER2 dimerization inhibitor. It binds to the dimerization site on the HER2 domain and prevents ligand-driven pairing of HER2 with other HER receptors, thus inhibiting tumor cell growth and survival", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21147694", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 390, 
          "offsetInEndSection": 610, 
          "text": "Pertuzumab, another monoclonal antibody, is a HER2 dimerization inhibitor that binds to a different epitope on HER2 than trastuzumab and inhibits HER2 dimer formation with other HER family members such as HER3 and HER1. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19934333", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the method FASP used for?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24309553", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24289162", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24288579", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24051509", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24022122", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23784971", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23603217", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23436586", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23214492", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23126408", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22324799", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22092713", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22949036"
      ], 
      "type": "factoid", 
      "id": "5509f433c2af5d5b70000008", 
      "snippets": [
        {
          "offsetInBeginSection": 197, 
          "offsetInEndSection": 236, 
          "text": "FASP (filter-aided sample preparation) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24309553", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 593, 
          "offsetInEndSection": 684, 
          "text": "mouse brain tissue lysate was prepared using filter-aided sample preparation (FASP) method ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24289162", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 897, 
          "offsetInEndSection": 1047, 
          "text": " an increased number of confident protein identifications are attained with a filter-aided digestion approach as compared to an in-solution digestion.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24288579", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 859, 
          "offsetInEndSection": 897, 
          "text": "filter-aided sample preparation (FASP)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24051509", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 387, 
          "offsetInEndSection": 507, 
          "text": "In the second step the isolated cells are lysed and processed using 'filter aided sample preparation' (FASP) technique. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24022122", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 875, 
          "offsetInEndSection": 914, 
          "text": "filter-aided sample preparation (FASP),", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23784971", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1087, 
          "offsetInEndSection": 1135, 
          "text": "filter assisted sample preparation (FASP) method", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603217", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 237, 
          "offsetInEndSection": 278, 
          "text": "d filter-aided sample preparation (FASP)-", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23436586", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 86, 
          "offsetInEndSection": 125, 
          "text": " filter-aided sample preparation (FASP)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23214492", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 400, 
          "offsetInEndSection": 438, 
          "text": "filter-aided sample preparation (FASP)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23126408", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 318, 
          "offsetInEndSection": 486, 
          "text": "Filter Aided Sample Preparation (FASP), a type of proteomic reactor, in which samples dissolved in sodium dodecyl sulfate (SDS) are digested in an ultrafiltration unit.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22324799", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 305, 
          "offsetInEndSection": 354, 
          "text": " filter-aided sample preparation (FASP) protocol ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22092713", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 427, 
          "offsetInEndSection": 482, 
          "text": "by combining a filter-aided sample preparation method a", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22949036", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the number of long non coding RNAs in the human genome", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23126680", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23846593"
      ], 
      "type": "factoid", 
      "id": "535d2cf09a4572de6f000004", 
      "snippets": [
        {
          "offsetInBeginSection": 344, 
          "offsetInEndSection": 516, 
          "text": "The recent ENCODE (Encyclopedia of DNA Elements) study reported 9,640 lncRNA loci in the human genome, which corresponds to around half the number of protein-coding genes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23126680", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 487, 
          "offsetInEndSection": 695, 
          "text": "Over 18,000 transcripts are presently annotated as lncRNA, and encompass previously annotated classes of noncoding transcripts including large intergenic noncoding RNA, antisense RNA and processed pseudogenes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23846593", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the proportion of non canonical splice sites in the human genome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11058137", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11125105"
      ], 
      "type": "factoid", 
      "id": "535d35779a4572de6f000005", 
      "snippets": [
        {
          "offsetInBeginSection": 428, 
          "offsetInEndSection": 635, 
          "text": "Of these, 98.71% contain canonical GT-AG junctions (22 199 entries) and 0.56% have non-canonical GC-AG splice site pairs. The remainder (0.73%) occurs in a lot of small groups (with a maximum size of 0.05%).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11125105", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 155, 
          "offsetInEndSection": 396, 
          "text": "Of these, 98.71% contain canonical dinucleotides GT and AG for donor and acceptor sites, respectively; 0.56% hold non-canonical GC-AG splice site pairs; and the remaining 0.73% occurs in a lot of small groups (with a maximum size of 0.05%). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11058137", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does the histidine-rich Ca-binding protein (HRC) interact with triadin?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20807542", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22040806", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17526652", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25451386", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22952658", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19403607", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17030629", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12480542", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11504710", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11741309", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10531621"
      ], 
      "type": "yesno", 
      "id": "54c12fd1f693c3b16b000001", 
      "snippets": [
        {
          "offsetInBeginSection": 528, 
          "offsetInEndSection": 626, 
          "text": "The HRC effects on RyR may be regulated by the Ca(2+)-sensitivity of its interaction with triadin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20807542", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 157, 
          "offsetInEndSection": 286, 
          "text": "In rabbit skeletal and cardiac muscles, HRC binds to sarcoplasmic reticulum (SR) membranes via triadin, a junctional SR protein. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22040806", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1494, 
          "offsetInEndSection": 1684, 
          "text": "HRC may play a key role in the regulation of SR Ca cycling through its direct interactions with SERCA2 and triadin, mediating a fine cross talk between SR Ca uptake and release in the heart.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17526652", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 190, 
          "text": "Histidine-rich calcium binding protein (HRC) is located in the lumen of sarcoplasmic reticulum (SR) that binds to both triadin (TRN) and SERCA affecting Ca(2+) cycling in the SR.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952658", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 634, 
          "offsetInEndSection": 832, 
          "text": "HRC is a SR luminal Ca(2+) binding protein known to associate with both triadin and the sarcoplasmic reticulum Ca(2+)-ATPase, and may thus mediate the crosstalk between SR Ca(2+) uptake and release.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19403607", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 276, 
          "text": "The histidine-rich Ca(2+) binding protein (HRC) is a high capacity Ca(2+) binding protein in the sarcoplasmic reticulum (SR). Because HRC appears to interact directly with triadin, HRC may play a role in the regulation of Ca(2+) release during excitation-contraction coupling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12480542", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 275, 
          "offsetInEndSection": 463, 
          "text": "In the present study, we have performed co-immunoprecipitation experiments and show that HRC binds directly to triadin, which is an integral membrane protein of the sarcoplasmic reticulum.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11504710", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 194, 
          "text": "A direct binding of HRC (histidine-rich Ca(2+)-binding protein) to triadin, the main transmembrane protein of the junctional sarcoplasmic reticulum (SR) of skeletal muscle, seems well supported.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11741309", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 190, 
          "text": "The present study documents the binding interaction of skeletal muscle sarcoplasmic reticulum (SR) transmembrane protein triadin with peripheral histidine-rich, Ca(2+)-binding protein (HCP).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531621", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 967, 
          "offsetInEndSection": 1100, 
          "text": "In addition, the intra-luminal histidine-rich calcium binding protein (HRC) has been shown to interact with both SERCA2a and triadin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451386", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1101, 
          "offsetInEndSection": 1252, 
          "text": "Notably, there is physical and direct interaction between these protein players, mediating a fine-cross talk between SR Ca-uptake, storage and release.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451386", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 161, 
          "offsetInEndSection": 677, 
          "text": "The histidine-rich calcium-binding protein (HRCBP) is expressed in the junctional SR, the site of calcium release from the SR. HRCBP is expressed exclusively in muscle tissues and binds calcium with low affinity and high capacity. In addition, HRCBP interacts with triadin, a protein associated with the ryanodine receptor and thought to be involved in calcium release. Its calcium binding properties, localization to the SR, and interaction with triadin suggest that HRCBP is involved in calcium handling by the SR.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17030629", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 464, 
          "offsetInEndSection": 615, 
          "text": "Using a fusion protein binding assay, we further identified the histidine-rich acidic repeats of HRC as responsible for the binding of HRC to triadin. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11504710", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 686, 
          "offsetInEndSection": 1107, 
          "text": "The HRC binding domain of triadin was also localized by fusion protein binding assay to the lumenal region containing the KEKE motif that was previously shown to be involved in the binding of triadin to calsequestrin. Notably, the interaction of HRC and triadin is Ca(2+)-sensitive. Our data suggest that HRC may play a role in the regulation of Ca(2+) release from the sarcoplasmic reticulum by interaction with triadin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11504710", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 394, 
          "offsetInEndSection": 556, 
          "text": "Further support for colocalization of HRC with triadin cytoplasmic domain is provided here by experiments of mild tryptic digestion of tightly sealed TC vesicles.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11741309", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 739, 
          "offsetInEndSection": 888, 
          "text": "We demonstrate that HRC can be isolated as a complex with triadin, following equilibrium sucrose-density centrifugation in the presence of mM Ca(2+).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11741309", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 889, 
          "offsetInEndSection": 1146, 
          "text": "Here, we characterized the COOH-terminal portion of rabbit HRC, expressed and purified as a fusion protein (HRC(569-852)), with respect to Ca(2+)-binding properties, and to the interaction with triadin on blots, as a function of the concentration of Ca(2+).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11741309", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1147, 
          "offsetInEndSection": 1472, 
          "text": "Our results identify the polyglutamic stretch near the COOH terminus, as the Ca(2+)-binding site responsible, both for the acceleration in mobility of HRC on SDS-PAGE in the presence of millimolar concentrations of Ca(2+), and for the enhancement by high Ca(2+) of the interaction between HRC and triadin cytoplasmic segment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11741309", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 191, 
          "offsetInEndSection": 523, 
          "text": "In addition to providing further evidence that HCP coenriches with RyR1, FKBP-12, triadin and calsequestrin (CS) in sucrose-density-purified TC vesicles, using specific polyclonal antibody, we show it to be expressed as a single protein species, both in fast-twitch and slow-twitch fibers, and to identically localize to the I-band.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531621", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 524, 
          "offsetInEndSection": 773, 
          "text": "Colocalization of HCP and triadin at junctional triads is supported by the overlapping staining pattern using monoclonal antibodies to triadin. We show a specific binding interaction between digoxigenin-HCP and triadin, using ligand blot techniques.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531621", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 969, 
          "offsetInEndSection": 1143, 
          "text": "Suggesting that triadin dually interacts with HCP and with CS, at distinct sites, we have found that triadin-CS interaction in overlays does not require the presence of Ca2+.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531621", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1472, 
          "offsetInEndSection": 1667, 
          "text": "These differential effects form the basis for the hypothesis that HCP anchors to the junctional membrane domain of the SR, through binding to triadin short cytoplasmic domain at the NH2 terminus.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531621", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1668, 
          "offsetInEndSection": 1906, 
          "text": "Although the function of this interaction, as such, is not well understood, it seems of potential biological interest within the more general context of the structural-functional role of triadin at the triadic junction in skeletal muscle.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531621", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the classes of anti-arrhythmic drugs according to Vaughan-Williams classification?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10810787", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9803978"
      ], 
      "type": "list", 
      "id": "54d4e03a3706e89528000001", 
      "snippets": [
        {
          "offsetInBeginSection": 491, 
          "offsetInEndSection": 577, 
          "text": "Class II agents are antisympathetic drugs, particularly the beta-adrenoceptor blockers", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9803978", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 646, 
          "offsetInEndSection": 709, 
          "text": "Class III antiarrhythmic agents include sotalol and amiodarone.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9803978", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 835, 
          "offsetInEndSection": 923, 
          "text": "Class IV antiarrhythmic drugs are the calcium channel blockers verapamil and diltiazem. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9803978", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1000, 
          "offsetInEndSection": 1111, 
          "text": "Other agents which do not fall neatly into the Vaughan Williams classification include digoxin and perhexiline.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9803978", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 146, 
          "text": "Antiarrhythmic drugs can be divided into four Vaughan Williams classes (I-IV) according to defined electrophysiological effects on the myocardium.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10810787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 147, 
          "offsetInEndSection": 350, 
          "text": "Thus, the Vaughan Williams classification also coincides with the main myocardial targets of the antiarrhythmics, i.e., myocardial sodium-, potassium-, and calcium-channels or beta-adrenergic receptors. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10810787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 817, 
          "offsetInEndSection": 1079, 
          "text": "The sodium-channel blockade induced by class-I substances is enhanced with increasing heart rates. Thus, class-I antiarrhythmics can be subclassified as substances showing a more exponential, an approximately linear, or rather saturated block-frequency relation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10810787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1080, 
          "offsetInEndSection": 1270, 
          "text": "Class-III antiarrhythmics (potassium-channel blockade) can be further differentiated according to the component of the delayed rectifier potassium current (IK) which is inhibited by a drug. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10810787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1711, 
          "offsetInEndSection": 1863, 
          "text": "Class-III substances inhibiting the slowly activating IKs component are currently under investigation and are expected to show a direct rate dependence.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10810787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 298, 
          "text": "Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9803978", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the protein that is encoded by the gene GLT8D1?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24373612", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24114764"
      ], 
      "type": "factoid", 
      "id": "54d643023706e89528000007", 
      "snippets": []
    }, 
    {
      "body": "List disorders that have been associated to the polymorphism rs2535629.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24373612", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22472876", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25461954"
      ], 
      "type": "list", 
      "id": "54d646403706e89528000008", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 192, 
          "text": "A recent genome-wide analysis indicated that a polymorphism (rs2535629) of ITIH3 showed the strongest association signal with susceptibility to psychiatric disorders in Caucasian populations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24373612", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 193, 
          "offsetInEndSection": 336, 
          "text": "he aim of the study was to replicate the association of rs2535629 with schizophrenia and major depressive disorder (MDD) in Japanese subjects. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24373612", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1100, 
          "offsetInEndSection": 1323, 
          "text": "In the MDD-bipolar cross-disorder analysis, 15 SNPs exceeded genome-wide significance (P<5 \u00d7 10(-8)), and all were in a 248\u2009kb interval of high LD on 3p21.1 (chr3:52\u2009425\u2009083-53\u2009822\u2009102, minimum P=5.9 \u00d7 10(-9) at rs2535629).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22472876", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 686, 
          "offsetInEndSection": 790, 
          "text": "However, there was no preferential transmission at the ITIH3 rs52535629 polymorphism (\u03c7\u00b2=0.14, P=0.707).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25461954", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the target of the drug Olaparib?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25531448", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25526472", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25483710", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25481791", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25417706", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25374341", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25366685", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25302833", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25275045", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25221646", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25218906", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25144364", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25139258", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25128455", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25127709", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25120693"
      ], 
      "type": "factoid", 
      "id": "54d649843706e89528000009", 
      "snippets": [
        {
          "offsetInBeginSection": 97, 
          "offsetInEndSection": 168, 
          "text": "We show that targeting PARP by the small molecule inhibitors, Olaparib ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25531448", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 719, 
          "offsetInEndSection": 774, 
          "text": "Following treatment with the PARP1 inhibitor olaparib, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25526472", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 84, 
          "offsetInEndSection": 111, 
          "text": "the PARP inhibitor olaparib", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25483710", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 182, 
          "text": "Olaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated poly(ADP-ribose) polymerase (PARP) inhibitor currently under investigation in patients with solid tumors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25483710", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 62, 
          "text": "The poly(ADP-ribose) polymerase inhibitor olaparib", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25481791", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 522, 
          "offsetInEndSection": 569, 
          "text": "olaparib (poly(ADP ribose)polymerase inhibitor)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25417706", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 253, 
          "offsetInEndSection": 282, 
          "text": " olaparib, a PARP inhibitor, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25374341", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 67, 
          "text": "Olaparib is an oral poly (ADP-ribose) polymerase inhibitor", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 758, 
          "offsetInEndSection": 826, 
          "text": "olaparib, a small molecule inhibitor of the repair enzymes PARP1/2. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25302833", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 312, 
          "offsetInEndSection": 363, 
          "text": "he poly (ADP-ribose) polymerase inhibitor olaparib ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25275045", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1443, 
          "offsetInEndSection": 1468, 
          "text": " PARP-inhibitor, Olaparib", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25221646", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 63, 
          "text": "Olaparib is a poly(ADP-ribose) polymerase inhibitor", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25218906", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1008, 
          "offsetInEndSection": 1045, 
          "text": "olaparib, a specific PARP1 inhibitor.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25144364", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 24, 
          "text": "PARP inhibitor olaparib ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25139258", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 528, 
          "offsetInEndSection": 603, 
          "text": "We used two PARP inhibitors in clinical development, olaparib and rucaparib", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25128455", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 651, 
          "offsetInEndSection": 673, 
          "text": " the PARPi, olaparib, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25127709", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List genes that have been found mutated in CMT1A (Charcot-Marie-Tooth disease type 1 A).", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25522693", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25519680", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25500726", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25430934", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25429913", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25400662", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25385046", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24819634", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25150498"
      ], 
      "type": "list", 
      "id": "54d65b6b3706e8952800000c", 
      "snippets": [
        {
          "offsetInBeginSection": 26, 
          "offsetInEndSection": 77, 
          "text": "Most cases of CMT are caused by mutations in PMP22,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25522693", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 164, 
          "offsetInEndSection": 196, 
          "text": " structural myelin protein PMP22", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25519680", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Dynamin2 (DNM2) gene mutations may result in Charcot-Marie-Tooth disease and centronuclear myopathy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25492887", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1010, 
          "offsetInEndSection": 1185, 
          "text": "Dominantly inherited mutations of DYNC1H1 have been reported to cause spinal muscular atrophy with predominance of lower extremity involvement and Charcot-Marie-Tooth type 2O.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25484024", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 192, 
          "text": "Duplication of the gene encoding the peripheral myelin protein of 22 kDa (PMP22) underlies the most common inherited neuropathy, Charcot-Marie-Tooth 1A (CMT1A), a disease without a known cure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25150498", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 991, 
          "offsetInEndSection": 1085, 
          "text": ". Two patients showed rearrangements in the PMP22 gene, which is commonly associated with CMT1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24819634", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 139, 
          "offsetInEndSection": 290, 
          "text": "Many PMP22 mutants accumulate in excess in the endoplasmic reticulum (ER) and lead to the inherited neuropathies of Charcot-Marie-Tooth (CMT) disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "The T118M mutation in PMP22 gene is associated with Charcot Marie Tooth, type 1A (CMT1A).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400662", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 644, 
          "offsetInEndSection": 794, 
          "text": "In CMT1, PMP22 duplication was the most common mutation while the second gene in order of frequency was MPZ in familial and SH3TC2 in isolated cases. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25429913", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 739, 
          "offsetInEndSection": 762, 
          "text": "CMT1A/PMP22 duplication", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25430934", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 181, 
          "offsetInEndSection": 287, 
          "text": "he most frequent subtype is type 1A (CMT1A) caused by duplication in chromosome 17p12 that includes PMP22.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25500726", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the content of the METLIN database?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25496351", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25462372", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25322782", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24015273", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23829391", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23631600", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23593322", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23391889", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23185759", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22768229", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21696903", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20810534", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19137116", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18627180", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17951291", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16404815", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15801754"
      ], 
      "type": "factoid", 
      "id": "54d662113706e8952800000d", 
      "snippets": [
        {
          "offsetInBeginSection": 705, 
          "offsetInEndSection": 843, 
          "text": " The tandem mass spectrometry data acquisition enabled automatic search and matching against the METLIN tandem mass spectrometry database,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496351", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1146, 
          "offsetInEndSection": 1178, 
          "text": "the METLIN metabolomics database", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25462372", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 564, 
          "offsetInEndSection": 715, 
          "text": "Numbers of unique metabolites that are specific to a particular sample preparation approach were also identified by online available database, Metlin. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25322782", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 943, 
          "offsetInEndSection": 971, 
          "text": "Metlin metabolomics database", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24015273", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1441, 
          "offsetInEndSection": 1467, 
          "text": "METLIN metabolite database", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23829391", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 344, 
          "offsetInEndSection": 500, 
          "text": " Following high mass accuracy data analysis using MS and MS/MS, metabolites were identified by searching against major metabolite databases including METLIN", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23631600", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 820, 
          "offsetInEndSection": 902, 
          "text": "Untargeted features were annotated via matching to the METLIN metabolite database.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23593322", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "Liquid chromatography quadrupole time-of-flight mass spectrometry characterization of metabolites guided by the METLIN database.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23391889", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 641, 
          "offsetInEndSection": 667, 
          "text": "ETLIN metabolite database.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23391889", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 661, 
          "offsetInEndSection": 755, 
          "text": " The correlated metabolin and their metabolic pathways were identified using Metlin Database. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185759", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 191, 
          "offsetInEndSection": 334, 
          "text": " Major metabolite databases include Human Metabolome DataBase (HMDB), Madison Metabolomics Consortium Database (MMCD), Metlin, and LIPID MAPS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768229", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 840, 
          "offsetInEndSection": 942, 
          "text": "METLIN accurate mass matching database (DB) established according to those reported in the literatures", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21696903", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1291, 
          "offsetInEndSection": 1318, 
          "text": "METLIN Metabolite Database ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20810534", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 44, 
          "text": "METLIN: a metabolite mass spectral database.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16404815", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 380, 
          "offsetInEndSection": 636, 
          "text": " METLINincludes an annotated list of known metabolite structural information that is easily cross-correlated with its catalogue of high-resolution Fourier transform mass spectrometry (FTMS) spectra, tandem mass spectrometry (MS/MS) spectra, and LC/MS data.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16404815", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 565, 
          "offsetInEndSection": 623, 
          "text": "online database (METLIN) to find and identify metabolites ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17951291", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 414, 
          "offsetInEndSection": 517, 
          "text": "high quality experimental MS/MS data from known metabolites contained in a reference library (METLIN). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18627180", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is a P-body (processing body)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25529221", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25514416", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25482014", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25437551", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25416063", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25339350", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25128566", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25110034", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25110026", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24918601", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24862735", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24860588", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24755989", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24659297", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24569876", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24525673", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24504254", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24418890", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24292556"
      ], 
      "type": "summary", 
      "id": "54d8e59f4b1fd0d33c000001", 
      "snippets": [
        {
          "offsetInBeginSection": 803, 
          "offsetInEndSection": 855, 
          "text": " processing (P) bodies, a site for mRNA degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25514416", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 228, 
          "offsetInEndSection": 400, 
          "text": "processing bodies are RNA-containing granules that contribute to this process by modulating cellular signaling pathways, metabolic machinery, and stress response programs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25482014", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 172, 
          "offsetInEndSection": 304, 
          "text": "translationally repressed mRNAs localize to P-bodies and stress granules where their decay and storage, respectively, are directed. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25437551", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 440, 
          "offsetInEndSection": 479, 
          "text": "stress-dependent formation of P-bodies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25437551", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1086, 
          "offsetInEndSection": 1122, 
          "text": " P-bodies involved in RNA metabolism", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25416063", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 228, 
          "offsetInEndSection": 288, 
          "text": "cytoplasmic RNA granules called processing bodies (P-bodies)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25339350", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 156, 
          "text": "The 5'-to-3' mRNA degradation machinery localizes to cytoplasmic processing bodies (P-bodies), which are non-membranous structures found in all eukaryotes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25128566", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1044, 
          "offsetInEndSection": 1166, 
          "text": "This analysis demonstrates the dual role of P-bodies as decay sites and storage areas under regular and stress conditions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25128566", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 321, 
          "offsetInEndSection": 396, 
          "text": " mRNA P-bodies (processing bodies) harbour much of the mRNA decay machinery", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110034", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 183, 
          "offsetInEndSection": 256, 
          "text": "P-bodies contain the mRNA decay and translational repression machineries ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110026", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 239, 
          "text": "P-bodies belong to a large family of RNA granules that are associated with post-transcriptional gene regulation, conserved from yeast to mammals, and influence biological processes ranging from germ cell development to neuronal plasticity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24918601", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "In eukaryotic cells, components of the 5' to 3' mRNA degradation machinery can undergo a rapid phase transition. The resulting cytoplasmic foci are referred to as processing bodies (P-bodies). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24862735", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 278, 
          "offsetInEndSection": 402, 
          "text": "Processing bodies (P bodies, PB) are cytoplasmic protein complexes involved in degradation and translational arrest of mRNA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24860588", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 107, 
          "text": "The mRNA processing body (P-body) is a cellular structure that regulates the stability of cytoplasmic mRNA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24755989", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 96, 
          "offsetInEndSection": 215, 
          "text": "while most other messenger RNAs (mRNAs) are stored away in stress granules or degraded in processing bodies (P-bodies).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24659297", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "Numerous mRNAs are degraded in processing bodies (P bodies) in Saccharomyces cerevisiae.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24569876", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 187, 
          "text": "Processing (P)-bodies are cytoplasmic RNA protein aggregates responsible for the storage, degradation, and quality control of translationally repressed messenger RNAs in eukaryotic cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24525673", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 845, 
          "offsetInEndSection": 916, 
          "text": "in P-bodies (PBs), where translationally silenced mRNAs are deposited, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24292556", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 154, 
          "text": "Processing bodies (P-bodies) are cytoplasmatic mRNP granules containing non-translating mRNAs and proteins from the mRNA decay and silencing machineries. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24418890", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 251, 
          "text": "The control of mRNA translation and degradation is mediated in part by a set of proteins that can inhibit translation and promote decapping, as well as function in the assembly of cytoplasmic mRNP granules referred to as processing bodies (P-bodies). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24504254", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the mode of action of bedaquiline?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25203970", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25114537", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24563587", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24259600", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24173008"
      ], 
      "type": "summary", 
      "id": "54d9071a4b1fd0d33c000007", 
      "snippets": [
        {
          "offsetInBeginSection": 122, 
          "offsetInEndSection": 289, 
          "text": "Bedaquiline works by inhibiting bacterial adenosine triphosphate (ATP) synthase and represents the first novel class of antituberculosis agents in more than 40 years. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25203970", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 734, 
          "offsetInEndSection": 974, 
          "text": "Bedaquiline has an entirely novel mechanism of action and so should be active against otherwise highly resistant organisms. It acts on the transmembrane component of adenosine triphosphate synthase and acts by preventing electron transport.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25114537", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24563587", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 159, 
          "offsetInEndSection": 472, 
          "text": " Bedaquiline is an anti-tuberculosis drug with unique mechanism of action. It selectively inhibits the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis like active, dormant, replicating, non-replicating, intracellular and extracellular.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24563587", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 779, 
          "offsetInEndSection": 927, 
          "text": "DATA SYNTHESIS: Bedaquiline possesses a unique mechanism of action that disrupts the activity of the mycobacterial adenosine triphosphate synthase. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259600", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 626, 
          "offsetInEndSection": 764, 
          "text": "By directly inhibiting adenosine triphosphate (ATP) synthase, bedaquiline is effective against both replicating and dormant mycobacteria. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24173008", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1258, 
          "offsetInEndSection": 1396, 
          "text": "Enhanced sterilizing capacity via synergistic depletion of ATP further exhibits the promising potential of bedaquiline with pyrazinamide. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24173008", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which molecule is targeted by a monoclonal antibody Mepolizumab?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25199060", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25199059", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24685200", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24424174", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24322486", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23844029", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23742015", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23544105", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23362812", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23257685", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22998420", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22901886", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22541618", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22092535", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21824072", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21790283", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21443279", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21348536", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21346698", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20565230", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20110057", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20021987", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19929788", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19828470", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19264687", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19264686", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19243381", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18344568", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18298130", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17872493", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16931891", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16462679", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16184589", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15813818", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15175031", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14699394", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14523040", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12870444", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12704348", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12406833", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11496242"
      ], 
      "type": "factoid", 
      "id": "54d907c84b1fd0d33c000008", 
      "snippets": [
        {
          "offsetInBeginSection": 258, 
          "offsetInEndSection": 438, 
          "text": "Mepolizumab, a humanized monoclonal antibody that binds to and inactivates interleukin-5, has been shown to reduce asthma exacerbations in patients with severe eosinophilic asthma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25199060", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 473, 
          "offsetInEndSection": 704, 
          "text": " Patients were assigned to receive mepolizumab, a humanized monoclonal antibody against interleukin-5, which was administered as either a 75-mg intravenous dose or a 100-mg subcutaneous dose, or placebo every 4 weeks for 32 weeks. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25199059", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1036, 
          "offsetInEndSection": 1231, 
          "text": "Among developing therapies, biologics designed to block certain pro-inflammatory cytokines, such as IL-5 (mepolizumab) and IL-13 (lebrikizumab), have a greater chance of being used in the clinic.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24685200", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1283, 
          "offsetInEndSection": 1454, 
          "text": "Imatinib and mepolizumab, a humanized anti-interleukin 5 monoclonal antibody, may be useful in patients with eosinophilic myositis as part of a hypereosinophilic syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424174", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 787, 
          "offsetInEndSection": 978, 
          "text": " Recent results of the treatment of idiopathic hypereosinophilic syndrome (HES) with the anti-interleukin 5 monoclonal antibody mepolizumab showed its efficacy and manageable safety profile. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24322486", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 606, 
          "offsetInEndSection": 808, 
          "text": "Individuals also received a segmental bronchoprovocation with allergen (SBP-Ag) 1 month before and after administering a single dose of mepolizumab (anti-IL-5 monoclonal antibody) to reduce airway EOS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23844029", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 712, 
          "offsetInEndSection": 919, 
          "text": "For example, patients with the hypereosinophilic syndrome have received mepolizumab, an anti-IL-5 monoclonal antibody, for as long as 6 years and have not developed any characteristic set of adverse events. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23742015", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23544105", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 115, 
          "offsetInEndSection": 255, 
          "text": "Previous clinical trials have evaluated the efficacy and safety of mepolizumab, a monoclonal antibody against IL-5, in patients with asthma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23544105", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 275, 
          "text": "In this large (616 patients), double-blind, placebo-controlled, dose-ranging study of mepolizumab (a monoclonal antibody that blocks IL-5 binding to its receptor), patients were given placebo, 75-, 250- or 750-mg mepolizumab by intravenous infusion every 4 weeks for 1 year. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23362812", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 320, 
          "text": "BACKGROUND: We examined levels of hyaluronan, a matrix glycosaminoglycan and versican, a matrix proteoglycan, in the sputum of asthmatics treated with mepolizumab (anti-IL-5 monoclonal antibody) versus placebo to evaluate the utility of these measurements as possible biomarkers of asthma control and airway remodeling. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23257685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 345, 
          "offsetInEndSection": 526, 
          "text": "Mepolizumab is a humanized monoclonal antibody that blocks binding of the key cytokine implicated specifically in eosinophil maturation and survival, interleukin-5, to its receptor.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22998420", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 131, 
          "offsetInEndSection": 318, 
          "text": "Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22901886", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 513, 
          "offsetInEndSection": 752, 
          "text": "IL-5 antagonist therapies in current development include two monoclonal anti-IL-5 antibodies (mepolizumab, reslizumab), a monoclonal antibody directed at the IL-5 receptor (benralizumab), and anti-sense oligonucleotide therapy (TPI ASM8). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22541618", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 959, 
          "offsetInEndSection": 1053, 
          "text": "Two monoclonal antibodies have been designed to neutralize IL-5 (mepolizumab and reslizumab). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22092535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 584, 
          "offsetInEndSection": 703, 
          "text": "To date, two humanized monoclonal antibodies, mepolizumab and reslizumab, have been developed that bind to human IL-5. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21824072", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 249, 
          "text": "Mepolizumab (Bosatria(\u00ae), GlaxoSmithKline) is a biologic agent developed to treat asthma. It represents a humanized monoclonal antibody of IgG1 \u03ba type, which targets human IL-5 and thus prevents its interaction with the \u03b1-chain of the IL-5 receptor.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21790283", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1285, 
          "offsetInEndSection": 1462, 
          "text": "There has been a variable effect with the leukotriene receptor antagonist montelukast and promising early results with mepolizumab, a monoclonal antibody against interleukin-5. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21443279", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21348536", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 324, 
          "text": "Mepolizumab is a fully humanized monoclonal antibody (IgG1/\u03ba) targeting human interleukin-5 (IL-5), a key haematopoietin needed for eosinophil development and function. Mepolizumab blocks human IL-5 from binding to the \u03b1-chain of the IL-5 receptor complex on the eosinophil cell surface, thereby inhibiting IL-5 signalling. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21348536", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1263, 
          "offsetInEndSection": 1383, 
          "text": "Recently, encouraging results of treatment with monoclonal antibody neutralizing IL-5, mepolizumab, have been published.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21346698", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1306, 
          "offsetInEndSection": 1524, 
          "text": "This manuscript reviews the available treatments for HES and the range of side-effects associated with long-term corticosteroid use, and then focuses on the anti-IL-5 monoclonal antibodies, mepolizumab and reslizumab. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20565230", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1119, 
          "offsetInEndSection": 1810, 
          "text": "The therapeutic progress is primarily due to an explosion of biological therapies, particularly four of them very useful for internists (in an off label use) : Interleukin 1 inhibitors (anakinra, Canakinumab) to treat some auto inflammatory diseases (cryopirin associated periodic syndromes and deficency of interleukin 1 receptor antagonist), monoclonal antibody against interleukin 5 (mepolizumab) to treat some hypereosinophilic syndromes and Churg and Strauss angiitis, interleukin 6 inhibitiors to treat multifocal Castleman's disease and adult Still disease, a monoclonal antibody against vascular endothelial growth factor (Bevacizumab) to treat hereditary hemorrhagic telangiectasia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20110057", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 710, 
          "offsetInEndSection": 826, 
          "text": " Besides steroid therapy, the anti-IL-5 monoclonal antibody mepolizumab is considered as a target therapy for L-HES.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20021987", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 320, 
          "offsetInEndSection": 475, 
          "text": "Mepolizumab is a humanized monoclonal antibody (mAb) with potent IL-5 neutralizing effects that represents a potential treatment for eosinophilic diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19929788", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19828470", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 183, 
          "offsetInEndSection": 299, 
          "text": "The pharmacodynamic effect of mepolizumab (a humanised anti-interleukin-5 monoclonal antibody) in EoO was evaluated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19828470", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 302, 
          "offsetInEndSection": 529, 
          "text": "We studied the prednisone-sparing effect of mepolizumab, a monoclonal antibody against interleukin-5, in a rare subgroup of patients who have sputum eosinophilia and airway symptoms despite continued treatment with prednisone. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19264687", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 510, 
          "offsetInEndSection": 667, 
          "text": "Subjects received infusions of either mepolizumab, an anti-interleukin-5 monoclonal antibody (29 subjects), or placebo (32) at monthly intervals for 1 year. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19264686", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1169, 
          "offsetInEndSection": 1424, 
          "text": "A recent study showed that a monoclonal antibody to IL-5, mepolizumab, reduced glucocorticoid therapy in HES patients who did not possess the FIP1L1-PDGFRA mutation while controlling eosinophilia and preventing recurrence or progression of tissue damage. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19243381", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 346, 
          "offsetInEndSection": 579, 
          "text": "METHODS: We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18344568", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18298130", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 301, 
          "text": "Mepolizumab is an anti-interleukin-5 monoclonal antibody that is in clinical trials with GlaxoSmithKline (GSK) for the treatment of severe asthma, nasal polyposis and hypereosinophilic syndrome and eosinophilic oesophagitis (the latter two indications are classed as eosinophilia in the phase table). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18298130", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 322, 
          "offsetInEndSection": 480, 
          "text": "A previous small dose-finding study found that mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, had no effect on allergen challenge in humans.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17872493", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16931891", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 150, 
          "offsetInEndSection": 346, 
          "text": "Mepolizumab is a monoclonal antibody to interleukin-5, which reduces peripheral blood eosinophils. Previously, we reported that mepolizumab treatment did not result in clinical improvement in AD. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16931891", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1266, 
          "offsetInEndSection": 1357, 
          "text": "Mepolizumab, an anti-IL-5 monoclonal antibody, currently being evaluated, seems promising. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462679", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1261, 
          "offsetInEndSection": 1389, 
          "text": "These include imatinib mesylate, a tyrosine kinase inhibitor, and more recently, mepolizumab, an anti-IL-5 monoclonal antibody. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16184589", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 105, 
          "text": "Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15813818", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 179, 
          "offsetInEndSection": 273, 
          "text": "A monoclonal antibody to human interleukin-5 (mepolizumab) was developed for atopic diseases. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15813818", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 190, 
          "text": "Anti-IL-5 monoclonal antibody (mepolizumab) reduces baseline bronchial mucosal eosinophils and deposition of extracellular matrix proteins in the reticular basement membrane in mild asthma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15175031", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 422, 
          "offsetInEndSection": 677, 
          "text": "Skin biopsies were performed in 24 atopic subjects at allergen- and diluent-injected sites before 6 and 48 h after, three infusions of a humanized, monoclonal antibody against IL-5 (mepolizumab) using a randomized double-blind, placebo-controlled design. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15175031", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 358, 
          "offsetInEndSection": 547, 
          "text": "OBJECTIVE: We aimed to assess the safety and efficacy of a humanized blocking monoclonal antibody against IL-5 (mepolizumab) in patients with several forms of hyper-eosinophilic syndromes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14699394", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 73, 
          "text": "Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14699394", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 202, 
          "offsetInEndSection": 409, 
          "text": "Bronchial biopsies were obtained before and after three infusions of a humanized, anti-IL-5 monoclonal antibody (mepolizumab) in 24 atopic asthmatics in a randomized, double-blind, placebo-controlled study. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14523040", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 188, 
          "text": "GlaxoSmithKline (formerly SmithKline Beecham) is developing mepolizumab (SB-240563), a monoclonal antibody directed against IL-5, as a potential treatment for asthma and atopic dermatitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12870444", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 549, 
          "offsetInEndSection": 748, 
          "text": "METHODS: Blood, bone marrow, and airway mucosal biopsy specimens were examined before and after anti-IL-5 (mepolizumab) treatment of asthmatic individuals in a double-blind, placebo-controlled trial.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12704348", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 165, 
          "text": "Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12704348", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 285, 
          "text": "The role of eosinophils as effector cells in asthma pathogenesis has been questioned since an anti-interleukin (IL)-5 monoclonal antibody (mepolizumab), which depleted blood and sputum eosinophils, failed to inhibit allergen-induced bronchoconstriction and airway hyperresponsiveness. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12406833", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 310, 
          "offsetInEndSection": 454, 
          "text": "Mepolizumab (SB-240563), a humanized monoclonal antibody (mAb) specific for human IL-5, is currently in clinical trials for treatment of asthma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11496242", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2091, 
          "offsetInEndSection": 2366, 
          "text": "CONCLUSION: These studies demonstrate that chronic antagonism of IL-5 by mepolizumab in monkeys is safe and has the potential, through long-term reductions in circulating and tissue-resident eosinophils, to be beneficial therapy for chronic inflammatory respiratory diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11496242", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11496242", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the synonym of the lubag disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25004170", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23614923", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23184149", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21047175", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20694531", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18609312", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17579361", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16242937", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15596620", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15465396", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15390042", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12471465", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12465067", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8041372", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8351010", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8338342", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8341310", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1672807"
      ], 
      "type": "factoid", 
      "id": "54df695b1388e8454a000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 183, 
          "text": "IMPORTANCE: Despite recessive inheritance, X-linked dystonia-parkinsonism (Lubag disease) has also been described in women presenting with a late-onset isolated parkinsonian syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25004170", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Anesthesia for deep brain stimulation in a patient with X-linked dystonia-parkinsonism/Lubag disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23614923", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "Lubag disease is a genetic X-linked dystonia-parkinsonism syndrome afflicting Filipino men. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23614923", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 166, 
          "text": "X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and dopamine metabolism.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184149", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 145, 
          "text": "X-chromosomal dystonia parkinsonism syndrome (XDP, 'lubag') is associated with sequence changes within the TAF1/DYT3 multiple transcript system. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184149", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 82, 
          "text": "The unique phenomenology of sex-linked dystonia parkinsonism (XDP, DYT3, \"Lubag\").", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047175", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 179, 
          "text": "Sex-linked dystonia parkinsonism (XDP, DYT3, \"Lubag\") is an adult-onset, progressive, debilitating movement disorder first described in Filipino males from Panay Islands in 1975. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047175", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 294, 
          "offsetInEndSection": 992, 
          "text": "We cover dopa-responsive dystonia, Wilson's disease, Parkin-, PINK1-, and DJ-1-associated parkinsonism (PARK2, 6, and 7), x-linked dystonia-parkinsonism/Lubag (DYT3), rapid-onset dystonia-parkinsonism (DYT12) and DYT16 dystonia, the syndromes of Neurodegeneration with Brain Iron Accumulation (NBIA) including pantothenate kinase (PANK2)- and PLA2G6 (PARK14)-associated neurodegeneration, neuroferritinopathy, Kufor-Rakeb disease (PARK9) and the recently described SENDA syndrome; FBXO7-associated neurodegeneration (PARK15), autosomal-recessive spastic paraplegia with a thin corpus callosum (SPG11), and dystonia parkinsonism due to mutations in the SLC6A3 gene encoding the dopamine transporter.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20694531", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 119, 
          "text": "Neuropsychological profile of a Filipino gentleman with X-linked dystonia-parkinsonism: a case report of Lubag disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18609312", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "X-Linked Dystonia-Parkinsonism (XDP or \"Lubag\") is a progressive neurodegenerative disorder unique to the Island of Panay in the Philippines.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18609312", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "First case of X-linked dystonia-parkinsonism (\"Lubag\") to demonstrate a response to bilateral pallidal stimulation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17579361", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "\"Lubag\" or X-linked dystonia-parkinsonism (XDP) is a genetic syndrome afflicting Filipino men.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17579361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 82, 
          "text": "First case report of X linked dystonia parkinsonism (XDP) or 'lubag' in Australia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16242937", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "PURPOSE: To present the first genetically supported case of X linked dystonia parkinsonism (XDP) or 'lubag' reported in an Australian hospital. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16242937", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "Phenotypic and molecular analyses of X-linked dystonia-parkinsonism (\"lubag\") in women.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15596620", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "BACKGROUND: X-linked dystonia-parkinsonism (XDP) or \"lubag\" is an X-linked recessive disorder that afflicts Filipino men, and rarely, women. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15596620", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Smell testing is abnormal in 'lubag' or X-linked dystonia-parkinsonism: a pilot study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15465396", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 303, 
          "text": "We administered a culturally corrected University of Pennsylvania Smell Identification Test (ccUPSIT) consisting of 25 odor items to 20 patients with 'Lubag' or X-linked dystonia-parkinsonism and 20 control subjects matched by sex, age, educational background, smoking history, and geographical origin. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15465396", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 321, 
          "offsetInEndSection": 458, 
          "text": "Three affected siblings were found to share an identical haplotype at the X-linked dystonia-parkinsonism locus (XDP; Lubag; OMIM*314250).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15390042", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1053, 
          "offsetInEndSection": 1216, 
          "text": "These neuropathological findings differed from those of Parkinson's disease or juvenile parkinsonism, but mimic to those of X-linked dystonia parkinsonism (Lubag).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12471465", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 59, 
          "text": "Phenomenology of \"Lubag\" or X-linked dystonia-parkinsonism.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12465067", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 211, 
          "text": "X-linked dystonia-parkinsonism (XDP), or Lubag syndrome, is known to cause progressive dystonia, with or without parkinsonism, among Filipino male adults with maternal roots from the Philippine island of Panay. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12465067", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "Adductor laryngeal breathing dystonia in a patient with lubag (X-linked dystonia-Parkinsonism syndrome).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8041372", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 154, 
          "text": "We report a patient with Lubag (X-linked dystonia-parkinsonism) who presented with severe respiratory stridor from adductor laryngeal breathing dystonia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8041372", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "Phenotypic expression of X-linked dystonia-parkinsonism (lubag) in two women.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8351010", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "Lubag (X-linked dystonia-parkinsonism) has been considered a sex-linked recessive trait and has been mapped to the pericentromeric region of the X chromosome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8351010", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 212, 
          "text": "Regional and global metabolic rates for glucose (rCMRGlc and GMR) were estimated using [18F]fluorodeoxyglucose and positron emission tomography in 3 patients with Filipino X-linked dystonia-parkinsonism (lubag). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8338342", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 57, 
          "text": "Neuropathology of lubag (x-linked dystonia parkinsonism).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8341310", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 125, 
          "text": "Lubag is an x-linked recessive dystonia parkinsonism that affects Filipino men originating principally from the Panay Island.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8341310", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "Genetic mapping of \"Lubag\" (X-linked dystonia-parkinsonism) in a Filipino kindred to the pericentromeric region of the X chromosome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1672807", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 167, 
          "text": "\"Lubag\" is an X-linked disorder causing dystonia and parkinsonism that has only been described in families from the Philippines, principally from the island of Panay. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1672807", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which proteins induce inhibition of LINE-1 and Alu retrotransposition?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24367644", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24035396", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21715505"
      ], 
      "type": "list", 
      "id": "54dfbed11388e8454a000008", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "APOBEC3G oligomerization is associated with the inhibition of both Alu and LINE-1 retrotransposition", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24367644", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 221, 
          "offsetInEndSection": 374, 
          "text": "We have previously demonstrated that antiretroviral restriction factors, human APOBEC3 (hA3) proteins (A-H), differentially inhibit L1 retrotransposition", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24367644", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 376, 
          "offsetInEndSection": 548, 
          "text": "In this present study, we found that hA3 members also restrict Alu retrotransposition at differential levels that correlate with those observed previously for L1 inhibition", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24367644", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Modulation of LINE-1 and Alu/SVA retrotransposition by Aicardi-Gouti\u00e8res syndrome-related SAMHD1", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24035396", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 223, 
          "offsetInEndSection": 518, 
          "text": "Here, we demonstrate that the Aicardi-Gouti\u00e8res syndrome gene product SAMHD1, recently revealed to be an inhibitor of HIV/simian immunodeficiency virus (SIV) infectivity and neutralized by the viral Vpx protein, is also a potent regulator of LINE-1 and LINE-1-mediated Alu/SVA retrotransposition", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24035396", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 520, 
          "offsetInEndSection": 627, 
          "text": "We also found that mutant SAMHD1s of Aicardi-Gouti\u00e8res syndrome patients are defective in LINE-1 inhibition", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24035396", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 691, 
          "offsetInEndSection": 750, 
          "text": "SAMHD1 inhibits LINE-1 retrotransposition in dividing cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24035396", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 119, 
          "offsetInEndSection": 322, 
          "text": "we found that the predominantly nuclear A3B only weakly restricted infection by HIV-1, HIV-1\u0394vif, and human T-cell leukemia virus type 1 (HTLV-1), while significantly inhibiting LINE-1 retrotransposition", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715505", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 324, 
          "offsetInEndSection": 515, 
          "text": "The chimeric construct A3G/B, in which the first 60 amino acids of A3B were replaced with those of A3G, restricted HIV-1, HIV-1\u0394vif, and HTLV-1 infection, as well as LINE-1 retrotransposition", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715505", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the main functions of the APOBEC3 family of proteins?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22915799", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22720156", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22203821", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21966267"
      ], 
      "type": "list", 
      "id": "54dfc6501388e8454a000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 199, 
          "text": "The APOBEC3 cytidine deaminases play a critical role in host-mediated defense against exogenous viruses, most notably, human immunodeficiency virus type-1 (HIV-1) and endogenous transposable elements", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22915799", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 6, 
          "offsetInEndSection": 82, 
          "text": "the identification of APOBEC3G (A3G) as a potent restriction factor of HIV-1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22720156", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 472, 
          "offsetInEndSection": 631, 
          "text": "additional A3 family members have been identified as antiviral proteins, mechanistic details of the restrictive capacity of these proteins have been elucidated", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22720156", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 183, 
          "text": "Human APOBEC3 (A3) proteins are cellular cytidine deaminases that potently restrict the replication of retroviruses by hypermutating viral cDNA and/or inhibiting reverse transcription", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22203821", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 316, 
          "offsetInEndSection": 367, 
          "text": "A3F and A3G are the most potent inhibitors of HIV-1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22203821", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21966267", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 626, 
          "offsetInEndSection": 727, 
          "text": "we demonstrate that the pool of APOBEC3A in target cells inhibits the early phases of HIV-1 infection", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21966267", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1154, 
          "offsetInEndSection": 1374, 
          "text": "Our results indicate that APOBEC3A is a previously unrecognized antiviral factor that targets primate lentiviruses specifically in myeloid cells and that acts during the early phases of infection directly in target cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21966267", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the mechanism of action of APOBEC3G cytidine deaminase to inhibit HIV-1 replication?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24859335", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24651717", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24345943", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23152537", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22787460"
      ], 
      "type": "summary", 
      "id": "54dfcdf81388e8454a00000a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "APOBEC3G inhibits HIV-1 RNA elongation by inactivating the viral trans-activation response element", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24859335", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 362, 
          "text": "Deamination of cytidine residues in viral DNA is a major mechanism by which APOBEC3G (A3G) inhibits vif-deficient human immunodeficiency virus type 1 (HIV-1) replication. dC-to-dU transition following RNase-H activity leads to viral cDNA degradation, production of non-functional proteins, formation of undesired stop codons and decreased viral protein synthesis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24859335", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 509, 
          "offsetInEndSection": 933, 
          "text": "HIV-1 transcription elongation is regulated by the trans-activation response (TAR) element, a short stem-loop RNA structure required for elongation factors binding. Vif-deficient HIV-1-infected cells accumulate short viral transcripts and produce lower amounts of full-length HIV-1 transcripts due to A3G deamination of the TAR apical loop cytidine, highlighting the requirement for TAR loop integrity in HIV-1 transcription", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24859335", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 447, 
          "text": "The APOBEC3 deoxycytidine deaminase family functions as host restriction factors that can block replication of Vif (virus infectivity factor) deficient HIV-1 virions to differing degrees by deaminating cytosines to uracils in single-stranded (-)HIV-1 DNA. Upon replication of the (-)DNA to (+)DNA, the HIV-1 reverse transcriptase incorporates adenines opposite the uracils, thereby inducing C/G\u2192T/A mutations that can functionally inactivate HIV-1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24651717", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 164, 
          "offsetInEndSection": 409, 
          "text": "APOBEC3G is a member of this family that inhibits HIV-1 replication in the absence of the viral infectivity factor Vif. Inhibition of HIV replication occurs by both deamination of viral single-stranded DNA and a deamination-independent mechanism", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24345943", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 190, 
          "text": "Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152537", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 157, 
          "offsetInEndSection": 332, 
          "text": "These proteins exert their suppressive effects through the inhibition of viral reverse transcription as well as the induction of cytidine deamination within nascent viral cDNA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152537", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 745, 
          "offsetInEndSection": 969, 
          "text": "We demonstrate that APOBEC3 proteins impart a profound deficiency to reverse transcription from the initial stages of cDNA synthesis, as well as excessive cytidine deamination (hypermutation) of the DNAs that are synthesized", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152537", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 304, 
          "offsetInEndSection": 771, 
          "text": "Without Vif, A3 proteins, particularly APOBEC3G (A3G) and APOBEC3F (A3F), inhibit HIV-1 replication by blocking reverse transcription and/or integration and hypermutating nascent viral cDNA. The molecular mechanisms of this antiviral activity have been primarily attributed to two biochemical characteristics common to A3 proteins: catalyzing cytidine deamination in single-stranded DNA (ssDNA) and a nucleic acid-binding capability that is specific to ssDNA or ssRNA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787460", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the mechanism by which HIV-1-encoded Vif protein allows virus replication?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23707381", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23689841", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23316055", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22728817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21725586", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20147392", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19887642"
      ], 
      "type": "summary", 
      "id": "54dfce9b1388e8454a00000b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23707381", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 279, 
          "text": "The human immunodeficiency virus type 1 (HIV-1) Vif protein counteracts the antiviral activity of the apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 (APOBEC3) family of proteins by targeting the proteins for degradation through the ubiquitin-proteasome pathway", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23707381", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 199, 
          "text": "The host protein APOBEC3G (A3G) can limit HIV-1 replication. Its protective effect is overcome by the HIV-1 'viral infectivity factor' (Vif), which targets A3G for proteosomal degradation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23689841", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 439, 
          "offsetInEndSection": 589, 
          "text": " Vif is thought to primarily overcome APOBEC3G through an interaction that mediates APOBEC3G ubiquitination and results in its proteasomal degradation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23316055", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 591, 
          "offsetInEndSection": 694, 
          "text": "However, Vif may also inhibit APOBEC3G mRNA translation, virion encapsidation, and deamination activity", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23316055", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 174, 
          "offsetInEndSection": 470, 
          "text": "Vif counteracts the packaging of two cellular cytidine deaminases named APOBEC3G (A3G) and A3F by diverse mechanisms including the recruitment of an E3 ubiquitin ligase complex and the proteasomal degradation of A3G/A3F, the inhibition of A3G mRNA translation or by a direct competition mechanism", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22728817", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 472, 
          "offsetInEndSection": 757, 
          "text": "In addition, Vif appears to be an active partner of the late steps of viral replication by participating in virus assembly and Gag processing, thus regulating the final stage of virion formation notably genomic RNA dimerization and by inhibiting the initiation of reverse transcription", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22728817", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 311, 
          "text": "Human apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like (APOBEC) 3G (A3G) is an antiviral protein that blocks HIV-1 replication. However, the antiviral activity of A3G is overcome by the HIV-1 protein Vif. This inhibitory function of Vif is related to its ability to degrade A3G in the proteasome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21725586", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "Polyubiquitination of APOBEC3G is essential for its degradation by HIV-1 Vif", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20147392", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 684, 
          "offsetInEndSection": 798, 
          "text": "These data suggest that polyubiquitination of APOBEC3G, not that of HIV-1 Vif, is crucial for APOBEC3G degradation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20147392", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 412, 
          "text": "During coevolution with the host, HIV-1 developed the ability to hijack the cellular ubiquitin/proteasome degradation pathway to counteract the antiviral activity of APOBEC3G (A3G), a host cytidine deaminase that can block HIV-1 replication. Abrogation of A3G function involves the HIV-1 Vif protein, which binds A3G and serves as an adapter molecule to recruit A3G to a Cullin5-based E3 ubiquitin ligase complex", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19887642", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List two chemotherapeutic agents that are used for treatment of Subependymal Giant Cell Astrocytoma", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24756805", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24729041", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24667713", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24518170", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24293099", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24276039", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23689226", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23686401", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23567018", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23325902", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23231513", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23158522", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22805244", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22262746", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22136276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22000822", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21806479", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21047224", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18952591"
      ], 
      "type": "list", 
      "id": "54e061ee1388e8454a00000c", 
      "snippets": [
        {
          "offsetInBeginSection": 273, 
          "offsetInEndSection": 612, 
          "text": "Everolimus has been approved by the FDA and the EMA for the treatment of advanced renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TSC), pancreatic neuroendocrine tumors (PNET), in combination with exemestane in advanced hormone-receptor (HR)-positive, HER2-negative breast cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24756805", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 228, 
          "text": "The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24729041", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 153, 
          "offsetInEndSection": 751, 
          "text": "Our objective was to evaluate everolimus, an mTOR inhibitor, in the treatment of angiomyolipoma in patients with subependymal giant cell astrocytoma (SEGA) associated with TSC. METHODS: EXamining everolimus In a Study of Tuberous Sclerosis Complex-1 (NCT00789828), a prospective, double-blind, randomized, placebo-controlled, Phase 3 study, examined everolimus in treating SEGA associated with TSC. Patients with serial SEGA growth from pre-baseline to baseline scans were randomly assigned (2:1) to receive 4.5 mg/m(2)/day everolimus (target blood trough: 5-15 ng/mL; n = 78) or placebo (n = 39). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24729041", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1693, 
          "offsetInEndSection": 1816, 
          "text": "CONCLUSIONS: Everolimus showed efficacy in reducing angiomyolipoma lesion volume in patients with SEGA associated with TSC.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24729041", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 334, 
          "offsetInEndSection": 798, 
          "text": "Everolimus has demonstrated substantial clinical benefit in randomized, controlled, phase III studies leading to approval for the treatment of advanced renal cell carcinoma, advanced neuroendocrine tumors of pancreatic origin, renal angiomyolipoma and subependymal giant-cell astrocytoma associated with tuberous sclerosis complex, as well as advanced hormone-receptor-positive (HR(+)) and human epidermal growth factor receptor-2-negative advanced breast cancer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667713", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293099", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 174, 
          "text": "We are reporting on a 13.5-year-old girl with tuberous sclerosis complex (TSC) who was treated with everolimus because of giant cell astrocytoma and bilateral angiomyolipoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293099", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24276039", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "BACKGROUND: Brain subependymal giant cell astrocytomas (SEGAs) in patients with tuberous sclerosis have been reported to respond to everolimus. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24276039", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 777, 
          "offsetInEndSection": 881, 
          "text": "CONCLUSIONS: We describe a rare case of metastatic SEGA, which was successfully treated with everolimus.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24276039", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 601, 
          "offsetInEndSection": 749, 
          "text": "Additional oncology indications for everolimus include renal angiomyolipoma with tuberous sclerosis complex and subependymal giant-cell astrocytoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23689226", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 453, 
          "text": "Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in combination with exemestane, for hormone receptor-positive HER2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23686401", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 178, 
          "text": "Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567018", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 565, 
          "offsetInEndSection": 742, 
          "text": "AIMS: To show the long-term safety data and the effect of everolimus treatment on epilepsy in children under the age of 3 who received everolimus for SEGAs associated with TSC. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567018", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1394, 
          "offsetInEndSection": 1577, 
          "text": "CONCLUSIONS: This study suggests that everolimus is effective and safe in infants and young children with epilepsy and SEGA associated with TSC and offers a valuable treatment option.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567018", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 80, 
          "text": "Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23325902", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 185, 
          "text": "OBJECTIVE: To report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (SEGA) in patients with tuberous sclerosis complex (TSC).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23325902", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1291, 
          "offsetInEndSection": 1665, 
          "text": "CONCLUSION: Everolimus therapy is safe and effective for longer term (median exposure 34.2 months) treatment of patients with TSC with SEGA. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that everolimus, titrated to trough serum levels of 5-15 ng/mL, was effective in reducing tumor size in patients with SEGA secondary to TSC for a median of 34 months.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23325902", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23231513", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 172, 
          "offsetInEndSection": 580, 
          "text": "In patients with subependymal giant cell astrocytomas (SEGAs) associated with tuberous sclerosis complex who are not candidates for surgery, single-agent everolimus has demonstrated the ability to significantly reduce SEGA volume with good tolerability. In the Phase III, randomized, placebo-controlled trial, everolimus was associated with a SEGA response rate of 35% compared with 0% in the placebo group. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23231513", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 189, 
          "text": "Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23158522", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 320, 
          "offsetInEndSection": 625, 
          "text": "In an open-label, phase 1/2 study, the mTOR inhibitor everolimus substantially and significantly reduced the volume of subependymal giant cell astrocytomas. We assessed the efficacy and safety of everolimus in patients with subependymal giant cell astrocytomas associated with tuberous sclerosis complex. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23158522", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2272, 
          "offsetInEndSection": 2408, 
          "text": "INTERPRETATION: These results support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23158522", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 140, 
          "text": "Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22805244", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 252, 
          "text": "A recent phase 1/2 study demonstrated that treatment with the mammalian target of rapamycin inhibitor everolimus reduced subependymal giant cell astrocytoma volume by 30% in 75% of the patients, all of whom were poor candidates for surgical resection. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22805244", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 442, 
          "offsetInEndSection": 592, 
          "text": "All 4 experienced over 50% initial reduction in the volume of their subependymal giant cell astrocytoma after 2 to 3 years of therapy with everolimus.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22805244", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 264, 
          "offsetInEndSection": 437, 
          "text": "METHODS: Recently, a phase I/II trial of everolimus demonstrated significant reductions in subependymal giant cell astrocytoma (SEGA) volume and decreased seizure frequency.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22262746", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 509, 
          "offsetInEndSection": 632, 
          "text": "TSC patients with SEGA received everolimus, titrated to tolerability to achieve target trough concentrations of 5-15 ng/mL.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22262746", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136276", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 345, 
          "text": "Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR). Everolimus (starting dosage 3.0\u2009mg/m(2)) was associated with a significant reduction in the volume of the largest subependymal giant cell astrocytoma (SEGA) in 28 patients aged \u22653 years with tuberous sclerosis complex (TSC) in a phase II trial (C2485). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136276", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 579, 
          "offsetInEndSection": 785, 
          "text": "During the extension phase of this trial (median duration 34 months), the reduction in SEGA volume was maintained, with no everolimus recipient requiring surgery or other therapy for SEGA or hydrocephalus. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136276", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 169, 
          "text": "Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22000822", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 143, 
          "text": "We present successful everolimus treatment of a huge subependymal giant cell astrocytoma in a 10-year old boy with tuberous sclerosis complex. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22000822", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 73, 
          "text": "Everolimus tablets for patients with subependymal giant cell astrocytoma.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21806479", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 382, 
          "offsetInEndSection": 483, 
          "text": "Recently, mTOR inhibitors such as everolimus have shown encouraging benefit for patients with SEGAs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21806479", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 690, 
          "offsetInEndSection": 1001, 
          "text": "The authors also examine the rationale for targeted agents against this pathway therapeutically and describe the clinical evidence underlying the FDA approval of everolimus for patients with inoperable SEGAs. EXPERT OPINION: Everolimus (Afinitor) selectively targets a molecular defect of SEGAs in TSC patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21806479", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047224", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 152, 
          "offsetInEndSection": 327, 
          "text": "An alternative may be the use of everolimus, which inhibits the mammalian target of rapamycin, a protein regulated by gene products involved in the tuberous sclerosis complex.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047224", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 781, 
          "offsetInEndSection": 1087, 
          "text": "Everolimus therapy was associated with a clinically meaningful reduction in volume of the primary subependymal giant-cell astrocytoma, as assessed on independent central review (P<0.001 for baseline vs. 6 months), with a reduction of at least 30% in 21 patients (75%) and at least 50% in 9 patients (32%). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047224", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2030, 
          "offsetInEndSection": 2288, 
          "text": "CONCLUSIONS: Everolimus therapy was associated with marked reduction in the volume of subependymal giant-cell astrocytomas and seizure frequency and may be a potential alternative to neurosurgical resection in some cases, though long-term studies are needed.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047224", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18952591", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which agents are included in the FLAMSA chemotherapy regimen?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23728608", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23652585", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22983588", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21963618", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21358688", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19430496", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18176613"
      ], 
      "type": "list", 
      "id": "54e071e11388e8454a00000d", 
      "snippets": [
        {
          "offsetInBeginSection": 560, 
          "offsetInEndSection": 770, 
          "text": "After 3 days of rest, RIC was carried out, consisting of 4 Gy total body irradiation, antithymocyte globulin (ATG-Fresenius), and cyclophosphamide (fludarabine, amsacrine, and cytarabine (FLAMSA)-RIC protocol).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728608", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 99, 
          "offsetInEndSection": 402, 
          "text": "We report a retrospective single center analysis of aplasia-inducing chemotherapy using fludarabine, cytarabine, and amsacrine (FLAMSA) followed by reduced-intensity conditioning (RIC) for allogeneic hematopoietic cell transplantation (HCT) in 62 consecutive primary refractory or relapsed AML patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23652585", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 856, 
          "offsetInEndSection": 1041, 
          "text": "A sequential regimen of cytoreductive chemotherapy (fludarabine, high-dose AraC, amsacrine) followed by reduced intensity conditioning (FLAMSA-RIC), was uniformly used for conditioning.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22983588", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 482, 
          "offsetInEndSection": 661, 
          "text": "Between November 2003 and June 2010, 30 patients (20 high-risk MDS, 10 sAML) received fludarabine (4 \u00d7 30 mg/m(2)), amsacrine (4 \u00d7 100 mg/m(2)), and Ara-C (4 \u00d7 2 g/m(2), FLAMSA). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21963618", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 301, 
          "offsetInEndSection": 457, 
          "text": "The preparative regimen consisted of fludarabine, Ara-C and amsacrine (FLAMSA) chemotherapy, followed by reduced intensity conditioning (RIC) 3 days later. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21358688", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 250, 
          "offsetInEndSection": 605, 
          "text": "Fifteen patients received fludarabine 30 mg/m(2), cytarabine 2000 mg/m(2), amsacrine 100 mg/m(2) on days -10, -9, -8 and -7, anti-thymocyte globulin (ATG-Fresenius) 20 mg/kg body weight on days -6, -5 and -4 and fractionated total body irradiation 2 x 2 Gy on days -3, -2 and -1 (FLAMSA-ATG-TBI) before allogeneic hematopoietic stem cell transplantation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19430496", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 237, 
          "text": "The goal of this analysis was to define the role of the moderate-intensity fludarabin Ara-C amsacrin (FLAMSA)-reduced intensity conditioning (RIC) regimen for patients with high-risk AML undergoing allogeneic SCT (alloSCT) in first CR1. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18176613", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which classes of endogenous retroelements are known to date?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22406018", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18636276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10697412"
      ], 
      "type": "list", 
      "id": "54e0ac041388e8454a00000f", 
      "snippets": [
        {
          "offsetInBeginSection": 135, 
          "offsetInEndSection": 427, 
          "text": "Transposons are divided into two general classes based on their transposition intermediate (DNA or RNA). Only one subclass, the non-LTR retrotransposons, which includes the Long INterspersed Element-1 (LINE-1 or L1), is currently active in humans as indicated by 96 disease-causing insertions", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22406018", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 93, 
          "text": "Diversity of LTR-retrotransposons and Enhancer/Suppressor Mutator-like transposons in cassava", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18636276", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 484, 
          "offsetInEndSection": 659, 
          "text": "Members of two classes of LTR-retrotransposons, Ty1/copia-like and Ty3/gypsy-like, and of Enhancer/Suppressor Mutator (En/Spm)-like transposons were isolated and characterised", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18636276", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 225, 
          "text": "Mammalian LINE-1 (L1) elements belong to the superfamily of autonomously replicating retrotransposable elements that lack the long terminal repeated (LTR) sequences typical of retroviruses and retroviral-like retrotransposons", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10697412", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is APOBEC3B protein predominantly cytoplasmic or nuclear?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22446380", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21715505", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23388464"
      ], 
      "type": "factoid", 
      "id": "54e0ace81388e8454a000010", 
      "snippets": [
        {
          "offsetInBeginSection": 350, 
          "offsetInEndSection": 418, 
          "text": "A3B is the only family member with steady-state nuclear localization", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446380", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 420, 
          "offsetInEndSection": 685, 
          "text": "Here, we show that A3B nuclear import is an active process requiring at least one amino acid (Val54) within an N-terminal motif analogous to the nuclear localization determinant of the antibody gene diversification enzyme AID (activation-induced cytosine deaminase)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446380", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1067, 
          "offsetInEndSection": 1238, 
          "text": "Our studies suggest that the present-day A3B enzyme retained the nuclear import mechanism of an ancestral AID protein during the expansion of the APOBEC3 locus in primates", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446380", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 110, 
          "offsetInEndSection": 322, 
          "text": "However, we found that the predominantly nuclear A3B only weakly restricted infection by HIV-1, HIV-1\u0394vif, and human T-cell leukemia virus type 1 (HTLV-1), while significantly inhibiting LINE-1 retrotransposition", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715505", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 517, 
          "offsetInEndSection": 887, 
          "text": "In contrast to the exclusively cytoplasmic A3G, which is inactive against LINE-1 retrotransposition, the A3G/B protein, while localized mainly to the cytoplasm, was also present in the nucleus. Further mutational analysis revealed that residues 18, 19, 22, and 24 in A3B were the major determinants for nuclear versus cytoplasmic localization and antiretroviral activity", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715505", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1465, 
          "offsetInEndSection": 1705, 
          "text": "these observations suggest that changing 4 residues in the amino terminus of A3B not only retargets the protein from the nucleus to the cytoplasm but also enhances its ability to restrict HIV while retaining inhibition of retrotransposition", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715505", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 904, 
          "offsetInEndSection": 999, 
          "text": "After mitosis, APOBEC3B becomes nuclear, and APOBEC3D, APOBEC3F and APOBEC3G become cytoplasmic", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23388464", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where is the metaxin complex localized?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19552401", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17981999", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17624330", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17510655", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11027586", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10381257", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9705320", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9045676"
      ], 
      "type": "factoid", 
      "id": "54e0ba781388e8454a000011", 
      "snippets": [
        {
          "offsetInBeginSection": 1554, 
          "offsetInEndSection": 1797, 
          "text": " The C-terminus plays an important role in targeting TSPO to mitochondria, whereas its import into the OMM is dependent upon the presence of the Schellman motif. Final integration of TSPO into the OMM occurs via its interaction with Metaxin 1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19552401", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 316, 
          "offsetInEndSection": 443, 
          "text": " TOM20 (translocase of the outer mitochondrial membrane), METAXIN, and mtOM64 (outer mitochondrial membrane protein of 64 kD). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17981999", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 862, 
          "offsetInEndSection": 1068, 
          "text": "The outer membrane protein METAXIN was characterized to play a role in the import of mitochondrial precursor proteins and likely plays a role in the assembly of beta-barrel proteins into the outer membrane.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17981999", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 183, 
          "text": "The mitochondrial inner membrane protein mitofilin exists as a complex with SAM50, metaxins 1 and 2, coiled-coil-helix coiled-coil-helix domain-containing protein 3 and 6 and DnaJC11.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17624330", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 440, 
          "offsetInEndSection": 838, 
          "text": " The functional role of this new complex is uncertain. However, a role in protein import related to maintenance of mitochondrial structure is suggested as mitofilin helps regulate mitochondrial morphology and at least four of the associated proteins (metaxins 1 and 2, SAM50 and CHCHD3) have been implicated in protein import, while DnaJC11 is a chaperone-like protein that may have a similar role.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17624330", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1097, 
          "offsetInEndSection": 1253, 
          "text": "We conclude that the pathway of VDAC biogenesis in human mitochondria involves the TOM complex, Sam50 and metaxins, and that it is evolutionarily conserved.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17510655", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "Functional analysis of human metaxin in mitochondrial protein import in cultured cells and its relationship with the Tom complex.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11027586", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Metaxin is an outer membrane protein of mammalian mitochondria which is suggested to be involved in protein import into the organelle.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11027586", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 119, 
          "text": "Metaxin 1 interacts with metaxin 2, a novel related protein associated with the mammalian mitochondrial outer membrane.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10381257", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 837, 
          "offsetInEndSection": 1021, 
          "text": "In subcellular fractions of mouse liver, a 29 kD immunoreactive protein, consistent in size with the predicted translation product of metaxin 2 cDNA, was found solely in mitochondria. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10381257", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1135, 
          "offsetInEndSection": 1313, 
          "text": ". Metaxin 2 in intact mitochondria was susceptible to digestion with proteinase K, indicating that metaxin 2 is located on the cytosolic face of the mitochondrial outer membrane.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10381257", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 204, 
          "offsetInEndSection": 285, 
          "text": "metaxin gene (Mtx), which encodes an outer mitochondrial membrane import protein.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9705320", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 107, 
          "text": "Metaxin is a component of a preprotein import complex in the outer membrane of the mammalian mitochondrion.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9045676", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Which enzyme is inhibited by Orteronel?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25537627", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25533464", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25297456", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25264242", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24965748", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24844235", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24799061", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24759590", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24418642", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24314737", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24276076", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23880851", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23856460", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23788266", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23371447", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23146910", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22249003", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21978946"
      ], 
      "type": "factoid", 
      "id": "54e0c3e71388e8454a000013", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "PURPOSE: Orteronel (TAK-700) is a non-steroidal, selective, reversible inhibitor of 17,20-lyase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25537627", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 883, 
          "offsetInEndSection": 984, 
          "text": "The drug orteronel selectively blocked the lyase reaction of P450 17A1 but only in the case of Prog. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25533464", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Preclinical assessment of Orteronel(\u00ae), a CYP17A1 enzyme inhibitor in rats.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25297456", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Orteronel (TAK-700) is a novel and selective inhibitor of CYP17A1, which is expressed in testicular, adrenal and prostate tumor tissues.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25297456", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "Orteronel is a nonsteroidal, selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25264242", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 244, 
          "offsetInEndSection": 480, 
          "text": "Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 \u00b5m, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 \u2009>\u2009100 \u00b5m).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25264242", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 170, 
          "text": "PURPOSE: Orteronel (TAK-700) is an investigational, nonsteroidal, oral, inhibitor of androgen synthesis with greater specificity for 17,20-lyase than for 17\u03b1-hydroxylase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24965748", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 425, 
          "offsetInEndSection": 705, 
          "text": "Based on these observations, potent agents targeting the AR axis were developed: 1) inhibitors of CYP17 (a key enzyme in the production of androgens), such as abiraterone and orteronel; 2) AR antagonists that bind to AR and impair AR activation, such as enzalutamide and ARN-509. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24844235", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 129, 
          "offsetInEndSection": 295, 
          "text": "Orteronel inhibits the 17,20 lyase activity of the enzyme CYP17A1, which is important for androgen synthesis in the testes, adrenal glands and prostate cancer cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799061", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 908, 
          "offsetInEndSection": 1309, 
          "text": "Inhibition of 17\u03b1-hydroxylase by abiraterone results in accumulation of upstream mineralocorticoids due to loss of cortisol-mediated suppression of pituitary adrenocorticotropic hormone (ACTH), providing a rationale for development of CYP17 inhibitors with increased specificity for 17,20-lyase (orteronel, galeterone and VT-464) that can potentially be administered without exogenous corticosteroids.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24759590", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24418642", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 153, 
          "offsetInEndSection": 319, 
          "text": "Orteronel (TAK-700) is an investigational, oral, nonsteroidal, selective, reversible inhibitor of 17,20-lyase, a key enzyme in the production of androgenic hormones. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24418642", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 688, 
          "offsetInEndSection": 833, 
          "text": "Hence, some molecules target the androgen biosynthesis, as abiraterone acetate and orteronel, which are selective inhibitors of the enzyme CYP17.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24314737", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1274, 
          "offsetInEndSection": 1667, 
          "text": "To achieve enhanced clinical benefits, new strategies are being explored that include selective inhibition of the C17,20-lyase activity of CYP17 and multi-targeting strategies that affect androgen synthesis and signalling at different points. Some of these strategies-including the drugs orteronel, VT-464 and galeterone--are supported by preclinical data and are being explored in the clinic.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24276076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 559, 
          "offsetInEndSection": 943, 
          "text": "Besides further CYP17 inhibitors (Orteronel, Galeterone, VT-464 and CFG920), androgen receptor antagonists (ARN-509, ODM-201, AZD-3514 and EZN-4176) and vaccine Prostvac, more drug candidates with various mechanisms or new indications of launched drugs are currently under evaluation in different stages of clinical trials, including various kinase inhibitors and platinum complexes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880851", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 211, 
          "text": "Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23856460", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "Orteronel (TAK-700) is an investigational, non-steroidal inhibitor of CYP17A1 with preferential inhibition of 17,20-lyase in NCI-H295 cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23856460", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1896, 
          "offsetInEndSection": 2171, 
          "text": "In summary, orteronel can suppress serum estradiol concentrations in hypophysectomized female rats and monkeys through selective inhibition of CYP17A1 activity, suggesting that orteronel might be effective for hormone-dependent breast cancers and estrogen-dependent diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23856460", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 182, 
          "text": "Development and validation of an RP-HPLC method for the quantitation of Orteronel (TAK-700), a CYP17A1 enzyme inhibitor, in rat plasma and its application to a pharmacokinetic study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23788266", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371447", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 769, 
          "offsetInEndSection": 966, 
          "text": "A new CYP17 inhibitor, with more selective inhibition of 17,20-lyase over 17\u03b1-hydroxylase, orteronel (TAK-700), is currently undergoing phase III clinical trials in pre- and postchemotherapy CRPC. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371447", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23146910", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 181, 
          "offsetInEndSection": 472, 
          "text": "Orteronel (TAK-700), 6-[(7S)-7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-N-methyl-2-naphthamide, is a novel, non-steroidal, selective inhibitor of the 17,20-lyase activity of CYP17A--a key enzyme in the production of steroidal hormones--and is being developed as a therapy for PC. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23146910", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 703, 
          "offsetInEndSection": 890, 
          "text": "Orteronel inhibited 17,20-lyase activity in rats with an IC(50) of 1200 nM but did not inhibit 17\u03b1-hydroxylase or 11\u03b2-hydroxylase (CYP11B1) activity in rats at concentrations up to 10 \u03bcM.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23146910", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 176, 
          "text": "Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249003", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 989, 
          "offsetInEndSection": 1532, 
          "text": "Orteronel (TAK-700), a novel, selective, and potent inhibitor of 17,20-lyase is under development as a drug to inhibit androgen synthesis. In this study, we quantified the inhibitory activity and specificity of orteronel for testicular and adrenal androgen production by evaluating its effects on CYP17A1 enzymatic activity, steroid production in monkey adrenal cells and human adrenal tumor cells, and serum levels of dehydroepiandrosterone (DHEA), cortisol, and testosterone after oral dosing in castrated and intact male cynomolgus monkeys.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249003", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2589, 
          "offsetInEndSection": 2738, 
          "text": " In summary, orteronel potently inhibited the 17,20-lyase activity of monkey and human CYP17A1 and reduced serum androgen levels in vivo in monkeys. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249003", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21978946", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Which enzyme is targeted by Evolocumab?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24661068", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24598985", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24509273", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24481874", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24477778", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24284914", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24255061", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25470376", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25410046", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25282520", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25282519", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25079474", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25052769", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25002170", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24961142", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24953396", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24953393", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24859266", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24825642", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24694531", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24691094", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24678979", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24662398"
      ], 
      "type": "factoid", 
      "id": "54e0d1491388e8454a000014", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661068", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 353, 
          "offsetInEndSection": 582, 
          "text": "AREAS COVERED: Evolocumab (AMG145) is a monoclonal antibody inhibiting the proprotein convertase subtilisin/kexin type 9 that binds to the liver LDL receptor and prevents it from normal recycling by targeting it for degradation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661068", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 212, 
          "text": "Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24598985", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 449, 
          "offsetInEndSection": 560, 
          "text": "We report a pooled analysis from four phase 2 studies of evolocumab (AMG 145), a monoclonal antibody to PCSK9. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24598985", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24509273", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 449, 
          "offsetInEndSection": 775, 
          "text": "METHODS: A pooled analysis of data from 1,359 patients in 4 phase II trials assessed the effects of evolocumab, a fully human monoclonal antibody to PCSK9, on Lp(a), the relationship between Lp(a) and lowering of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B, and the influence of background statin therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24509273", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1490, 
          "offsetInEndSection": 1597, 
          "text": "CONCLUSIONS: Inhibition of PCSK9 with evolocumab resulted in significant dose-related reductions in Lp(a). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24509273", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 467, 
          "offsetInEndSection": 703, 
          "text": "Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9, including evolocumab (previously AMG 145), dramatically lowered LDL-C in phase 2 clinical trials when administered alone or in combination with a statin. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24481874", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 545, 
          "offsetInEndSection": 722, 
          "text": "Evolocumab (AMG 145) is a fully human monoclonal antibody that binds PCSK9, inhibiting its interaction with the LDL receptor to preserve LDL-receptor recycling and reduce LDL-C.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24477778", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 701, 
          "offsetInEndSection": 1082, 
          "text": "Antibody therapeutics in Phase 3 studies are described, with an emphasis on those with study completion dates in 2014, including antibodies targeting interleukin-17a or the interleukin-17a receptor (secukinumab, ixekizumab, brodalumab), proprotein convertase subtilisin/kexin type 9 (alirocumab, evolocumab, bococizumab), and programmed death 1 receptor (lambrolizumab, nivolumab).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24284914", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 227, 
          "text": "BACKGROUND: Evolocumab (AMG 145), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein cholesterol (LDL-C) in phase 2 studies of 12 weeks' duration. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255061", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 479, 
          "offsetInEndSection": 876, 
          "text": "These compounds act either by reducing low-density lipoprotein (LDL) production by inhibiting apolipoprotein B synthesis with an antisense oligonucleotide (mipomersen) or by inhibiting microsomal triglyceride transfer protein (lomitapide), or by enhancing LDL catabolism via monoclonal antibody-mediated inhibition of the activity of proprotein convertase subtilisin/kexin 9 (PCSK9) (evolocumab). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25410046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 150, 
          "text": "Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25282520", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 292, 
          "offsetInEndSection": 433, 
          "text": "Evolocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), reduced LDL cholesterol by 16% in a pilot study. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25282520", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25282519", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 346, 
          "offsetInEndSection": 470, 
          "text": "We investigated the effect of PCSK9 inhibition with evolocumab (AMG 145) on LDL cholesterol in patients with this disorder. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25282519", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 989, 
          "offsetInEndSection": 1099, 
          "text": "Some of the anti-dyslipidemic drugs which work by PCSK9 inhibition include evolocumab, alirocumab and ALN-PCS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25079474", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 615, 
          "offsetInEndSection": 842, 
          "text": "We highlight the different steps of this adventure and review the published clinical trials especially those with the anti-PCSK9 antibodies evolocumab (AMG 145) and alirocumab (SAR236553/REGN727), which are in phase III trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052769", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 744, 
          "offsetInEndSection": 930, 
          "text": "Monoclonal antibodies against PCSK9 represent so far the most advanced approach in clinical development, with alirocumab, evolocumab and bococizumab under advanced clinical development. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25002170", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 301, 
          "offsetInEndSection": 554, 
          "text": "AREAS COVERED: Evolocumab and alirocumab are fully human monoclonal antibodies inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) that binds to hepatic LDL receptor and prevents it from normal recycling by targeting it for degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24961142", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 692, 
          "offsetInEndSection": 939, 
          "text": "Phase II (for evolocumab and alirocumab) and III (for evolocumab) trials show that PCSK9 inhibitors are equally well tolerated, with adverse events mainly limited to mild-to-moderate nasopharyngitis, injection-site pain, arthralgia and back pain. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24961142", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 837, 
          "offsetInEndSection": 1208, 
          "text": "Four classes of newer lipid-lowering drugs offer promising advances in treating FH, namely the apolipoprotein-B synthesis inhibitors (mipomersen), the microsomal transfer protein inhibitors (lomitapide), the cholesterol ester transfer protein inhibitors (anacetrapib, evacetrapib) and the proprotein convertase subtilisin/kexin type 9 inhibitors (evolocumab, alirocumab).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24953396", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 584, 
          "offsetInEndSection": 762, 
          "text": "Monoclonal antibodies that inhibit proprotein convertase subtilisin/ kexin type 9 (PCSK9), which degrades the LDL receptor, like alirocumab and evolocumab, are in phase 3 trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24953393", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 282, 
          "offsetInEndSection": 462, 
          "text": "In support of the drug development program for Evolocumab, a fully human IgG\u2082 antibody that targets PCSK9, a quantitative ELISA to measure free PCSK9 in human serum was developed. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24859266", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 147, 
          "text": "IMPORTANCE: In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24825642", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 168, 
          "text": "Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24694531", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 342, 
          "offsetInEndSection": 580, 
          "text": "Evolocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), demonstrated marked reductions in plasma low-density lipoprotein cholesterol (LDL-C) in a phase 2 study in statin-intolerant patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24694531", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24691094", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 173, 
          "offsetInEndSection": 342, 
          "text": "BACKGROUND: Evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced LDL-C in phase II trials. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24691094", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 206, 
          "text": "BACKGROUND: Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24678979", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 198, 
          "text": "Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24662398", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Which molecule is targeted by a monoclonal antibody Secukinumab?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25484038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25354738", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25243910", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25132411", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25007392", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24827753", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24677511", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24452484", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24354461", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24157091", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24035250", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23998727", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23858337", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23834907", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23730881", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23361084", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23290985", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23253932", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23106107", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22875601", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22595313", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22280236"
      ], 
      "type": "factoid", 
      "id": "54e0d7471388e8454a000015", 
      "snippets": [
        {
          "offsetInBeginSection": 670, 
          "offsetInEndSection": 993, 
          "text": "We identified 3 distinct clonotypes that efficiently neutralized IL17A in a cell-based in vitro assay. Their potencies were comparable to those of known neutralizing antibodies, including 2, AIN457 (secukinumab) and ixekizumab that are currently in clinical development for the treatment of various inflammatory disorders. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25484038", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "Secukinumab, a fully human anti-IL-17A monoclonal antibody, neutralizes IL-17A, a key cytokine in the pathogenesis of psoriasis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25354738", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 82, 
          "text": "BACKGROUND: Secukinumab is a fully human anti-interleukin-17A monoclonal antibody.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25243910", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 199, 
          "text": "BACKGROUND: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate-to-severe plaque psoriasis when administered via subcutaneous injection. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25132411", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 90, 
          "offsetInEndSection": 226, 
          "text": "We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25007392", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 750, 
          "offsetInEndSection": 1177, 
          "text": "Ustekinumab (a monoclonal antibody directed against the common p40 subunit of IL-23 and IL-12), secukinumab, ixekizumab (both monoclonal antibodies directed against IL-17A), and brodalumab a monoclonal antibody against the IL-17RA receptor) have been recently used in proof-of-concept and randomized trials in the ankylosing spondylitis and/or psoriatic arthritis subforms of SpA, with overall very promising clinical efficacy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24827753", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 125, 
          "text": "The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24677511", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 277, 
          "text": "The family of interleukin 17 receptors (IL17Rs), subtypes IL17RA-IL17RE, is targeted by the group of pro-inflammatory IL17 cytokines (IL17A-F) and moreover the newly developed anti-IL17A antibody secukinumab (AIN457) has shown promise in Phase II trials in multiple sclerosis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24677511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1197, 
          "offsetInEndSection": 1628, 
          "text": " Three agents neutralizing IL-17 (i.e., secukinumab and ixekizumab) or antagonizing its receptor (i.e., brodalumab) are currently being tested for efficacy and safety in the treatment of plaque psoriasis and PsA. Secukinumab is a fully human IgG1 monoclonal antibody that selectively binds and neutralizes IL-17A whose efficacy in the therapy of chronic plaque psoriasis has been demonstrated in different phase II clinical trial. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24452484", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 689, 
          "offsetInEndSection": 913, 
          "text": "Associations between IGA 0/1 responder rates and PASI scores were evaluated using data from two phase 2 studies with the anti-interleukin (IL)-17A monoclonal antibody secukinumab (AIN457) that utilized a similar 6-point IGA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24354461", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1060, 
          "offsetInEndSection": 1249, 
          "text": " Several IL-17A inhibitors have advanced into clinical trials, including the anti-IL-17A monoclonal antibodies, secukinumab and ixekizumab, and the anti-17RA monoclonal antibody brodalumab.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24157091", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 146, 
          "text": "Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24035250", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 336, 
          "offsetInEndSection": 480, 
          "text": "We assessed the efficacy and safety of the anti-IL-17A monoclonal antibody secukinumab in treating patients with active ankylosing spondylitis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24035250", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 236, 
          "offsetInEndSection": 445, 
          "text": "In a proof-of-concept study for the treatment of patients with Crohn's disease, secukinumab, a monoclonal antibody directed against IL-17A, was ineffective and associated with more adverse events than placebo.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23998727", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 679, 
          "offsetInEndSection": 898, 
          "text": "Several IL-17A blockers, including the anti-IL-17A monoclonal antibodies secukinumab and ixekizumab, and the anti-IL-17 receptor subunit A monoclonal antibody brodalumab have been evaluated in phase II clinical trials. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23858337", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1238, 
          "offsetInEndSection": 1426, 
          "text": "Further studies are needed to clarify whether the therapeutic blockade of IL-17A through the anti-IL-17A monoclonal antibody secukinumab is able to counteract the fibrogenic process in CD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23834907", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 141, 
          "offsetInEndSection": 339, 
          "text": "Th-17A antagonism has been investigated by a randomized controlled trial in PsA patients with secukinumab, a fully human, high-affinity, monoclonal antibody in a cohort of patients with active PsA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23730881", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 238, 
          "text": "Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23361084", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 169, 
          "text": "OBJECTIVE: To evaluate the efficacy and safety of secukinumab, a fully human, anti-interleukin (IL)-17A monoclonal antibody, in patients with psoriatic arthritis (PsA). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23361084", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "PURPOSE: To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23290985", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 66, 
          "text": "Effect of IL-17A blockade with secukinumab in autoimmune diseases.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23253932", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 797, 
          "offsetInEndSection": 1062, 
          "text": "Early clinical data are now available on secukinumab (AIN457), a recombinant, highly selective, fully human monoclonal anti-IL-17A antibody of the IgG1/\u03ba isotype, enabling a preliminary assessment of the effects of IL-17A inhibition in multiple autoimmune diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23253932", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1267, 
          "offsetInEndSection": 1607, 
          "text": "In conjunction with studies using the humanised anti-IL-17A monoclonal antibody (mAb) ixekizumab (LY2439821) and the fully human anti-IL-17RA mAb brodalumab (AMG 827), the findings on secukinumab provide evidence for the role of IL-17A in the pathophysiology of autoimmune disease and suggest the potential value of targeting this cytokine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23253932", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 485, 
          "offsetInEndSection": 673, 
          "text": "OBJECTIVES: To assess the efficacy and safety of different doses of secukinumab, a fully human anti-IL-17A IgG1\u03ba monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23106107", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 240, 
          "text": "Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22875601", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 190, 
          "text": "Our objective was to evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A (IL-17A) monoclonal antibody (MAb) secukinumab.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22875601", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1595, 
          "offsetInEndSection": 1778, 
          "text": "Blockade of IL-17A by secukinumab does not appear to interfere with efficacy of influenza and meningococcal vaccinations, as assessed by the achievement of protective antibody levels.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22875601", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 168, 
          "text": "Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22595313", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 168, 
          "text": "OBJECTIVE: The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22595313", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1162, 
          "offsetInEndSection": 1365, 
          "text": "Secukinumab is an IL-17A monoclonal antibody that is under development and preliminary results have suggested its efficacy in inflammatory mediated diseases such as psoriasis and ankylosing spondylitis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22280236", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List components of the CRSP/Med complex.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24820420", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19571180", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15195149", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15175162", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14759369", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12509459", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12050112", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11834832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10377381", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9989412"
      ], 
      "type": "list", 
      "id": "54e0dfa91388e8454a000018", 
      "snippets": [
        {
          "offsetInBeginSection": 622, 
          "offsetInEndSection": 1322, 
          "text": " Here we describe a new human factor, CRSP, that is required together with the TAF(II)s for transcriptional activation by Sp1. Purification of CRSP identifies a complex of approximate relative molecular mass 700,000 (M(r) approximately 700K) that contains nine subunits with M(r) values ranging from 33K to 200K. Cloning of genes encoding CRSP subunits reveals that CRSP33 is a homologue of the yeast mediator subunit Med7, whereas CRSP150 contains a domain conserved in yeast mediator subunit Rgr1. CRSP p200 is identical to the nuclear hormone-receptor co-activator subunit TRIP2/PBP. CRSPs 34, 77 and 130 are new proteins, but the amino terminus of CRSP70 is homologous to elongation factor TFIIS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9989412", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 805, 
          "offsetInEndSection": 905, 
          "text": "CRSP contains unique subunits as well as polypeptides that are shared with other cofactor complexes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10377381", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 432, 
          "text": "The multi-subunit, human CRSP coactivator-also known as Mediator (Med)-regulates transcription by mediating signals between enhancer-bound factors (activators) and the core transcriptional machinery. Interestingly, different activators are known to bind distinct subunits within the CRSP/Med complex. We have isolated a stable, endogenous CRSP/Med complex (CRSP/Med2) that specifically lacks both the Med220 and the Med70 subunits. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15175162", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What family do mDia proteins belong in?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24563699", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24333164", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24242070", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24025634", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23740402", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23721065", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23060957", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22179776", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21930699", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21278336", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20869367", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19768111", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19160018", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18362183", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18287523", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18239683", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18230650", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17682067", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17198702", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16487696", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16361707", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16361249", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16303559", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15371418", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15096506", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14765113", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14519394", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12857739", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12673949", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11591323", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11509578", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10629846", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10436006", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8144827"
      ], 
      "type": "factoid", 
      "id": "54e0e902ae9738404b000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "mDia proteins are members of the formin family of actin nucleating proteins that polymerize linear actin filaments.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23060957", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 651, 
          "offsetInEndSection": 703, 
          "text": "mDia1, a linear actin nucleator of the Formin family", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24563699", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 237, 
          "offsetInEndSection": 373, 
          "text": "the mammalian Diaphanous members of the formin family of proteins (mDia) are two key players in the formation of filopodia and neurites.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23740402", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 156, 
          "text": "mDia proteins are mammalian homologues of Drosophila diaphanous and belong to the formin family proteins that catalyze actin nucleation and polymerization. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18287523", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 204, 
          "offsetInEndSection": 232, 
          "text": " The mDia family of formins ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17682067", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 644, 
          "offsetInEndSection": 693, 
          "text": "interacts with the formin protein mDia1 (DIAPH1).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18230650", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 271, 
          "text": "Formin-family proteins, in the active state, form actin-based structures such as stress fibres. Their activation mechanisms, however, are largely unknown except that mDia and its closely related formins can be activated by direct binding of the small GTPase Rho or Cdc42.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18239683", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 229, 
          "text": "Mouse Diaphanous-related formins (mDias) are members of the formin protein family that nucleate actin polymerization and subsequently promote filamentous actin (F-actin) elongation by monomer addition to fast-growing barbed ends.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20869367", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 158, 
          "text": "Diaphanous related formins (DRFs) are part of the formin protein family that control morphogenesis, embryonic differentiation, cytokinesis, and cell polarity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12857739", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 208, 
          "text": "Diaphanous related formins (DRFs) are cytoskeleton remodeling proteins that mediate specific upstream GTPase signals to regulate cellular processes such as cytokinesis, cell polarity, and organelle motility. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16361249", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the major clinical Villefranche criteria for classic Ehlers-Danlos syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22696272"
      ], 
      "type": "list", 
      "id": "54e1252fae9738404b000003", 
      "snippets": [
        {
          "offsetInBeginSection": 790, 
          "offsetInEndSection": 995, 
          "text": "All type V collagen defects were identified within a group of 102 patients fulfilling all major clinical Villefranche criteria, that is, skin hyperextensibility, dystrophic scarring and joint hypermobility", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696272", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is insulin-like growth factor-I (IGF-I) able to affect tendon protein synthesis in classic Ehlers-Danlos syndrome patients?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25103963"
      ], 
      "type": "yesno", 
      "id": "54e12ae3ae9738404b000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Tendon protein synthesis rate in classic Ehlers-Danlos patients can be stimulated with insulin-like growth factor-I", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25103963", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1323, 
          "offsetInEndSection": 1411, 
          "text": "IGF-I injections significantly increased FSR values in cEDS patients but not in controls", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25103963", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1471, 
          "offsetInEndSection": 1668, 
          "text": "In conclusion, baseline protein synthesis rates in connective tissue appeared normal in cEDS patients, and the patients responded with an increased tendon protein synthesis rate to IGF-I injections", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25103963", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is COL5A2 gene associated to ischemic heart disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23574622"
      ], 
      "type": "yesno", 
      "id": "54e12c30ae9738404b000005", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "Analysis of a gene co-expression network establishes robust association between Col5a2 and ischemic heart disease", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23574622", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 937, 
          "offsetInEndSection": 1148, 
          "text": "Col5a2, a gene previously not specifically linked to MI response but responsible for the classic type of Ehlers-Danlos syndrome, was found to have many and strong co-expression associations within this community", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23574622", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1648, 
          "offsetInEndSection": 1816, 
          "text": "Col5a2 shows predictive potential in MI, and in principle may represent a novel candidate marker for the identification and treatment of ischemic cardiovascular disease", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23574622", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is generic name of drug Adempas?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25395817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25352393", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24524094", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24391396", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24218053"
      ], 
      "type": "factoid", 
      "id": "54e1bdacae9738404b000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25395817", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Riociguat (Adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25395817", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 289, 
          "text": "Riociguat (Adempas(\u00ae)), a soluble guanylate cyclase stimulator, is a new, first-in-class drug approved for the treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) [inoperable or persistent/recurrent following surgery] or pulmonary arterial hypertension (PAH). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25352393", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 408, 
          "offsetInEndSection": 516, 
          "text": "On October 8, 2013, riociguat (Adempas\u00ae) became the first medication approved for multiple etiologies of PH.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524094", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 153, 
          "text": "Duavee, an oral contraceptive; riociguat (Adempas) for two types of pulmonary hypertension; and macitentan (Opsumit) for pulmonary arterial hypertension.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24391396", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 372, 
          "text": "Riociguat (Adempas(\u00ae)), an oral first-in-class soluble guanylate cyclase (sGC) stimulator, is under global development by Bayer Healthcare Pharmaceuticals Inc. for the treatment of adult patients with inoperable or chronic/persistent chronic thromboembolic pulmonary hypertension (CTEPH) and for the treatment of adult patients with pulmonary arterial hypertension (PAH). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24218053", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the association between proBNP serum concentrations and stroke outcomes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25102374", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23701638", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16565563"
      ], 
      "type": "summary", 
      "id": "54e1c5d5ae9738404b00000b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "N-terminal probrain natriuretic peptide levels as a predictor of functional outcomes in patients with ischemic stroke.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25102374", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 968, 
          "offsetInEndSection": 1865, 
          "text": "There was a strong positive correlation between the plasma level of NT-proBNP and the National Institutes of Health Stroke Scale score (r=0.415, P=0.000). Plasma levels of NT-proBNP in patients with an unfavorable outcome were significantly higher than those in patients with a favorable outcome [3432 (interquartile range, 1100-54991) vs. 978 (interquartile range, 123-1705) pg/ml; P=0.000]. In multivariate analyses, after adjusting for all other significant outcome predictors, the NT-proBNP level that remained can be seen as an independent unfavorable outcome predictor, with an adjusted odds ratios of 4.14 (95% confidence interval, 2.72-7.99; P=0.000). Our results show that plasma NT-proBNP levels were significantly elevated in patients with an unfavorable outcome and might be of clinical importance as a supplementary tool for the assessment of functional outcomes in patients with AIS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25102374", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 820, 
          "offsetInEndSection": 1389, 
          "text": "Plasma levels of BNP, NT-proBNP, cortisol and copeptin were associated with stroke severity, as well as short-term functional outcomes. After adjusting for all other significant outcome predictors, NT-proBNP, cortisol and copeptin remained as independent outcome predictors. In the receiver operating characteristic curve analysis, the biomarker panel (including BNP, NT-proBNP, cortisol and copeptin) predicted functional outcome and death within 90 days significantly more efficiently than the National Institute of Health Stroke Scale (NIHSS) or the biomarker alone.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23701638", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 654, 
          "offsetInEndSection": 798, 
          "text": "The NT-proBNP levels were significantly higher at 4 intervals after ischemic stroke than in healthy and at-risk control subjects (all p<0.001). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16565563", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1186, 
          "offsetInEndSection": 1742, 
          "text": "Multivariate analysis demonstrated that age and NIH Stroke Scale were the 2 strongest independent predictors of increased NT-proBNP levels (all p<0.01). Furthermore, increased NT-proBNP (> or = 150 pg/ml) was the strongest independent predictor of long-term (mean follow-up: 24 months) UFCO (26 patients) (all p<0.05). CONCLUSIONS: The NT-proBNP level was markedly elevated after acute ischemic stroke and declined substantially thereafter. An increased NT-proBNP level was strongly and independently correlated with UFCO in patients after ischemic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16565563", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Describe the mechanism of action of aliskiren. ", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24003484", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21687346", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21285669", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20812878", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20380486", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20019472", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20019471", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19895758", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19183745", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19066408", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23355128", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18374681"
      ], 
      "type": "summary", 
      "id": "54e221f6ae9738404b000010", 
      "snippets": [
        {
          "offsetInBeginSection": 364, 
          "offsetInEndSection": 494, 
          "text": "Preliminary assignment a direct renin inhibitor aliskiren enhances the diuretic, natriuretic and kaliyuretic effects of the drug. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24003484", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 44, 
          "text": "Aliskiren: An orally active renin inhibitor.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21687346", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 583, 
          "offsetInEndSection": 748, 
          "text": "Optimization of this compound by Novartis led to the development of aliskiren - the only direct renin inhibitor which is clinically used as an antihypertensive drug.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21687346", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 815, 
          "offsetInEndSection": 979, 
          "text": "Aliskiren is a new renin inhibitor of a novel structural class that has recently been shown to be efficacious in hypertensive patients after once-daily oral dosing.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21687346", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 334, 
          "offsetInEndSection": 462, 
          "text": "Aliskiren is a direct renin inhibitor that interrupts the renin-angiotensin-aldosterone system (RAAS) at its rate-limiting step.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21285669", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 578, 
          "offsetInEndSection": 780, 
          "text": "THE READER WILL GAIN: Aliskiren, the first approved renin inhibitor to reach the market, is a low-molecular-weight, orally active, hydrophilic non-peptide molecule that blocks angiotensin I generation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20812878", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1414, 
          "offsetInEndSection": 1561, 
          "text": "TAKE HOME MESSAGE: The DRI aliskiren is an effective antihypertensive agent that preliminary data suggests has a beneficial effect in CVD and CKD. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20380486", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "Aliskiren is a novel molecule which blocks the renin-angiotensin-aldosterone system in its rate limiting step by renin inhibition.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20019472", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 291, 
          "text": "After discovery of the first direct renin inhibitor, aliskiren, which blocks the renin-angiotensin-aldosterone system in the first rate limiting step, in addition to angiotensin-converting enzymes (ACE) and angiotensin-receptor blockers (ARB), renin has become an important target nowadays. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20019471", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 262, 
          "text": "Aliskiren, the first orally effective direct renin inhibitor, is an effective antihypertensive agent with distinctive properties including placebo-like tolerability, pharmacologic effects that persist after drug discontinuation, and a unique mechanism of action.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19895758", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 579, 
          "offsetInEndSection": 873, 
          "text": "Aliskiren, the first direct renin inhibitor to reach the market, is a low-molecular-weight, orally active, hydrophilic nonpeptide. Aliskiren blocks Ang I generation, while plasma renin concentration increases because the drugs blocks the negative feed-back exerted by Ang II on renin synthesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19183745", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 83, 
          "text": "Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19066408", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 112, 
          "offsetInEndSection": 267, 
          "text": "One drug that emerged from this effort is aliskiren, a direct human renin inhibitor that blocks the conversion of angiotensinogen to angiotensin I (Ang I).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19066408", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which genes are associated with Ehlers-Danlos syndrome type I/II?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20847697", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12145749", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9425231", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8923000", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8752669"
      ], 
      "type": "list", 
      "id": "54e22b62ae9738404b000011", 
      "snippets": [
        {
          "offsetInBeginSection": 437, 
          "offsetInEndSection": 675, 
          "text": "It is currently estimated that approximately 50% of patients with a clinical diagnosis of classic Ehlers-Danlos syndrome harbor mutations in the COL5A1 and the COL5A2 gene, encoding the \u03b11 and the \u03b12-chain of type V collagen, respectively", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20847697", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 954, 
          "offsetInEndSection": 1176, 
          "text": "In the majority of patients with molecularly characterized classic Ehlers-Danlos syndrome, the disease is caused by a mutation leading to a nonfunctional COL5A1 allele and resulting in haploinsufficiency of type V collagen", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20847697", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1178, 
          "offsetInEndSection": 1335, 
          "text": "A smaller proportion of patients harbor a structural mutation in COL5A1 or COL5A2, causing the production of a functionally defective type V collagen protein", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20847697", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 209, 
          "text": "Order of intron removal influences multiple splice outcomes, including a two-exon skip, in a COL5A1 acceptor-site mutation that results in abnormal pro-alpha1(V) N-propeptides and Ehlers-Danlos syndrome type I", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12145749", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 366, 
          "text": "Ehlers-Danlos syndrome (EDS) type I (the classical variety) is a dominantly inherited, genetically heterogeneous connective-tissue disorder. Mutations in the COL5A1 and COL5A2 genes, which encode type V collagen, have been identified in several individuals. Most mutations affect either the triple-helical domain of the protein or the expression of one COL5A1 allele", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12145749", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 368, 
          "offsetInEndSection": 506, 
          "text": "We identified a novel splice-acceptor mutation (IVS4-2A-->G) in the N-propeptide-encoding region of COL5A1, in one patient with EDS type I", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12145749", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Mutations of the alpha2(V) chain of type V collagen impair matrix assembly and produce ehlers-danlos syndrome type I", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9425231", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 169, 
          "offsetInEndSection": 332, 
          "text": "We have identified mutations of the COL5A2 gene, which encodes the alpha2(V) chain of type V collagen, in two unrelated patients with the severe type I form of EDS", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9425231", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1082, 
          "offsetInEndSection": 1183, 
          "text": "Our findings show that heterozygous mutations of the COL5A2 gene can produce the EDS type I phenotype", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9425231", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 180, 
          "text": "A splice-junction mutation in the region of COL5A1 that codes for the carboxyl propeptide of pro alpha 1(V) chains results in the gravis form of the Ehlers-Danlos syndrome (type I)", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8923000", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 267, 
          "offsetInEndSection": 449, 
          "text": "We report that genomic polymorphisms at the pro alpha 1(V) gene (COL5A1) locus cosegregated with the gravis form of Ehlers-Danlos syndrome (EDS) (type I) in a three generation family", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8923000", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 730, 
          "offsetInEndSection": 965, 
          "text": "Since exon 65 encodes 78 residues of the carboxyl propeptide, the expected result of this mutation is reduced efficiency in incorporating mutant pro alpha 1(V) chains into type V collagen molecules and reduced type V collagen synthesis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8923000", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 967, 
          "offsetInEndSection": 1052, 
          "text": "These studies indicate that heterozygous mutations in COL5A1 can result in EDS type I", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8923000", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "The gene encoding collagen alpha1(V)(COL5A1) is linked to mixed Ehlers-Danlos syndrome type I/II", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8752669", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 386, 
          "offsetInEndSection": 552, 
          "text": "Recently, genetic linkage has been demonstrated between the COL5A1 gene, which encodes the alphal chain of type V collagen, and EDS type II in a large British kindred", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8752669", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 554, 
          "offsetInEndSection": 707, 
          "text": "Using a polymorphic intragenic simple sequence repeat at the COL5A1 locus, we now demonstrate tight linkage to EDS type I/II in a three-generation family", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8752669", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 791, 
          "offsetInEndSection": 974, 
          "text": "The variation in expression in this family suggests that EDS types I and II are allelic, and the linkage data support the hypothesis that mutation in COL5A1 can cause both phenotypes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8752669", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Describe the mechanism of action of the LINX system for treatment of gastroesophageal reflux disease.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25264655", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25062898", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25012804", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25000345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24778041", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24117632", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23814607", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23237251", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23155537", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22538694", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21037442", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19951799"
      ], 
      "type": "summary", 
      "id": "54e22ee4ae9738404b000013", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Magnetic sphincter augmentation with the LINX device for gastroesophageal reflux disease after U.S. Food and Drug Administration approval.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25264655", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 269, 
          "text": "Magnetic sphincter augmentation (MSA) of the gastroesophageal junction with the LINX Reflux Management System is an alternative to fundoplication for gastroesophageal reflux disease (GERD) that was approved by the U.S. Food and Drug Administration (FDA) in March 2012. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25264655", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "Is the LINX reflux management system an effective treatment for gastro-oesophageal reflux disease?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25062898", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "BACKGROUND: Laparoscopic magnetic sphincter augmentation (MSA) with the LINX device is a promising new therapy for the treatment of gastroesophageal reflux disease (GERD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25012804", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 511, 
          "offsetInEndSection": 664, 
          "text": "Other nonmedical therapies include, the Stretta procedure, transoral incisionless fundoplication, and the magnetic sphincter augmentation device (LINX). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25000345", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "LINX(\u00ae) Reflux Management System in chronic gastroesophageal reflux: a novel effective technology for restoring the natural barrier to reflux.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814607", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 927, 
          "offsetInEndSection": 1206, 
          "text": " The LINX(\u00ae) Reflux Management System (Torax Medical, St. Paul, MN, USA) is designed to provide a permanent solution to GERD by augmenting the sphincter barrier with a standardized, reproducible laparoscopic procedure that does not alter gastric anatomy and is easily reversible.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814607", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "LINX(\u2122) Reflux Management System: magnetic sphincter augmentation in the treatment of gastroesophageal reflux disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 968, 
          "offsetInEndSection": 1267, 
          "text": "The LINX(\u2122) Reflux Management System (Torax Medical) is designed to provide a permanent solution to GERD by augmenting the physiologic function of the sphincter barrier with a simple and reproducible laparoscopic procedure that does not alter gastric anatomy and can be easily reversed if necessary.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1275, 
          "offsetInEndSection": 1436, 
          "text": "The Linx sphincter augmentation device has been developed to address this gap with improvement of the barrier function of LES and reversible design if necessary.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23155537", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 299, 
          "offsetInEndSection": 575, 
          "text": " METHODS: A sphincter augmentation device (LINX Reflux Management System; Torax Medical, Shoreview, MN), designed to prevent reflux due to abnormal opening of the lower esophageal sphincter (LES), was laparoscopically implanted at the gastroesophageal junction in 44 patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21037442", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 73, 
          "offsetInEndSection": 357, 
          "text": "Specific topics include reviews of long-term outcomes after laparoscopic antireflux surgery, the use of surgically placed implantable device for LES augmentation (Linx), the use of mesh for hiatal hernioplasty, and prone and nonthoracic approaches to minimally invasive esophagectomy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19951799", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is the protein Papilin secreted?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21784067", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20805556", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19724244", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19297413", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15094122", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15094110", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12666201", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11076767", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7515725", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3320045"
      ], 
      "type": "yesno", 
      "id": "54e25eaaae9738404b000017", 
      "snippets": [
        {
          "offsetInBeginSection": 1085, 
          "offsetInEndSection": 1307, 
          "text": "Using expression analysis, we identify three genes that are transcriptionally regulated by HLH-2: the protocadherin cdh-3, and two genes encoding secreted extracellular matrix proteins, mig-6/papilin and him-4/hemicentin. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21784067", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 226, 
          "offsetInEndSection": 458, 
          "text": "We found that mig-6 encodes long (MIG-6L) and short (MIG-6S) isoforms of the extracellular matrix protein papilin, each required for distinct aspects of DTC migration. Both MIG-6 isoforms have a predicted N-terminal papilin cassette", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19297413", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 111, 
          "text": "apilins are homologous, secreted extracellular matrix proteins which share a common order of protein domains. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15094122", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 404, 
          "text": "The TSR superfamily is a diverse family of extracellular matrix and transmembrane proteins, many of which have functions related to regulating matrix organization, cell-cell interactions and cell guidance. This review samples some of the contemporary literature regarding TSR superfamily members (e.g. F-spondin, UNC-5, ADAMTS, papilin, and TRAP) where specific functions are assigned to the TSR domains.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15094110", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 43, 
          "text": "Papilins are extracellular matrix proteins ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12666201", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 48, 
          "text": "Papilin is an extracellular matrix glycoprotein ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11076767", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 731, 
          "offsetInEndSection": 882, 
          "text": " Collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins were made primarily by hemocytes and were secreted into the medium. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7515725", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "A sulfated glycoprotein was isolated from the culture media of Drosophila Kc cells and named papilin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3320045", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which cell type has the protein Chromogranin A as marker?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25294889", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25294372", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25220535", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25177680", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25532001", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25501094", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25394660", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25099181", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24888775", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24897131"
      ], 
      "type": "factoid", 
      "id": "54e262daae9738404b000018", 
      "snippets": [
        {
          "offsetInBeginSection": 562, 
          "offsetInEndSection": 642, 
          "text": "Neuroendocrine differentiation (chromogranin A and/or synaptophysin positivity) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25294889", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1029, 
          "offsetInEndSection": 1093, 
          "text": "All paragangliomas were universally positive for chromogranin A ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25294372", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 92, 
          "text": "chromogranin A (CGA) is a useful marker for pancreatic neuroendocrine tumors (pNET)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25220535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 151, 
          "text": "Together with Chromogranin B and Secretogranins, Chromogranin A (CGA) is stored in secretory (chromaffin) granules of the diffuse neuroendocrine system", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25177680", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 21, 
          "offsetInEndSection": 168, 
          "text": "Chromogranin A (CgA) is the most important general tumour marker used in the diagnosis and follow-up of patients with neuroendocrine tumours (NET).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25532001", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 197, 
          "text": "Chromogranin A (CgA) not only plays an important role in pathologic diagnosis, but is also used as a circulating biomarker in patients with gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25501094", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1206, 
          "offsetInEndSection": 1274, 
          "text": "numbers of chromogranin A (CHGA)-positive enteroendocrine cells (EEC", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25394660", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1761, 
          "offsetInEndSection": 1816, 
          "text": " CgA is a reliable serum diagnostic biomarker for PNETs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25099181", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 81, 
          "offsetInEndSection": 186, 
          "text": "Chromogranin A (CgA) was considered as the most practical and useful serum tumor marker in PNET patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25099181", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 401, 
          "offsetInEndSection": 461, 
          "text": "the neuroendocrine markers chromogranin A and synaptophysin;", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24888775", 
          "endSection": "abstract"
        }
      ]
    }
  ]
}